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Abstract 
The focal point of this work has been the development of new and expedient Brønsted 
acid–catalysed synthetic methods with alcohol pro–electrophiles to rapidly achieve 
molecular complexity. 
Chapter 1 provides insight into notable developments within the field of Brønsted 
acid–mediated transformations of alcohols as pro–electrophiles. 
Chapter 2 describes our efforts towards the realisation of a chiral Brønsted acid–
catalysed enantioselective 1,3–allylic alcohol isomerisation of 3–indolinols. 
Chapter 3 describes the synthesis of 1,2–dihydroquinolines via a Brønsted acid–
catalysed intramolecular allylic amination. 
Chapter 4 is an account of the Brønsted acid–catalysed cyclisation of b–amino–1,4–
enols to oxazol–2(3H)–ones and 5–alkenyloxazolidin–2–ones. 
Chapter 5 provides a summary of the works presented herein. 





AAI  Allylic alcohol isomerisation 
ACDC  Asymmetric counteranion–directed catalysis 
BA  Brønsted acid 
BINBAM  1,1′–Binaphthyl–2,2′–bis(sulphon)amide 
BINOL  1,1'–Bi–2–naphthol 
BINSA  1,1′–Binaphthyl 2,2′–disulphonic acid  
Boc  t–Butoxycarbonyl 
CBA  Chiral Brønsted acid 
COSY  Correlated spectroscopy 
CPA  Chiral phosphoric acid 
CPME  Cyclopentyl methyl ether 
DCE  1,2–Dichloroethane 
DCM  Dichloromethane 
DIPA  Diisopropylamine 
dr  Diastereomeric ratio 
ee  Enantiomeric excess 
ESI  Electron spray ionisation 
HPLC  High performance liquid chromatography 
HRMS  High resolution mass spectrometry 
HSQC  Heteronuclear single–quantum correlation spectroscopy 
LDA  Lithium diisopropylamide 
LUMO  Lowest unoccupied molecular orbital 
MS  Molecular sieves 
NMR  Nuclear magnetic resonance 
nr  No reaction 
o–QM  ortho–Quinone methide 
p–QM  para–Quinone methide 
Petrol  Petroleum ether (Tb 40–60 °C) 
ppm  Parts per million 
rcsm  Recovered starting material 
rr  Regioisomeric ratio 
RT  Room temperature 
SPINOL  1,1′-Spirobiindane-7,7′-diol 
TBD  Triazabicyclodecene 
TFA  Trifluoroacetic acid 
THF  Tetrahydrofuran 
TLC  Thin layer chromatography 
TRIP  2,4,6–Triisopropylphenyl 
TS  Transition state 
VANOL  3,3′–Diphenyl–2,2′–bi(1–naphthol) 










1.1 Chiral Brønsted Acid Catalysis 
The design of efficient synthetic protocols for the construction of chiral organic 
compounds with a high degree of enantiopurity is, and continues to be, an actively 
pursued area of exploration in contemporary organic chemistry. One synthetic strategy 
to induce product chirality in recent years is chiral organocatalysis, a method 
employing a small chiral compound as the reaction catalyst. As a result of their 
extensive chiral pool, low cost, and lack of toxicity, in addition to their resilience to 
air and moisture, this field has received considerable attention from both industry and 
academia towards highly enantioselective transformations.1–17  
Asymmetric Brønsted acids, in particular BINOL–based scaffolds, have been 
investigated extensively in the field of organocatalysis (Figure 1.1).18 The chiral 
induction obtained in these reactions relies heavily on the intimate active site of the 
C2–symmetry of the BINOL backbone. Further to this is the ability of the chiral pocket 
to remain intact as the acidic proton migrates during the mediation of a transformation. 
 
Figure 1.1: (a) Generic architecture of BINOL–based asymmetric Brønsted acid catalysts. (b) Select BINOL–
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Since their inception, the development of these catalysts has been continuously 
pursued. For example, the imidodiphosphoric acids were developed by List et al. to 
have a more sterically demanding active site with a view to enhanced enantiofacial 
discrimination towards substrates lacking spatially defined interactions (Figure 1.2).19  
 
Figure 1.2: BINOL–based imidodiphosphoric Brønsted acid catalyst developed by List et al. 
Both the (R) and (S) enantiomers of the BINOL–derived catalysts are commercially 
available or readily accessible via established synthetic procedures. This provides the 
ability to tailor the axially chiral backbone, with regards to both electronic properties 
and steric hindrance, to afford novel chiral Brønsted acids.  
The classical modes of action for transformations mediated by these Brønsted acids is 
through interactions with a pro–electrophile, either by protonation or H–bonding. In 
so doing, the energy of the LUMO is lowered to generate an ‘activated’ substrate. The 
capacity in which this catalyst–substrate interaction takes place can be defined by one 
of four modes of function; mono–, dual–, bifunctional–, or counteranion–activation 
(Figure 1.3).20 Mono–activation takes place when the substrate singularly takes part in 
either H–bonding or forms an ion pair with the Brønsted acid catalyst (Figure 1.3a). 
Dual–activation is defined by the reaction substrate making two distinct points of 
contact with the Brønsted acid catalyst (Figure 1.3b). The term bifunctional–activation 
involves a mechanism in which both an electrophilic substrate and a separate reaction 






























Figure 1.3: Modes of activation of chiral phosphoric acid catalysts. 
This mode of action is most often proposed and investigated in chiral phosphoric acid 
catalysis.21,22 Lastly, counteranion–activation, better known as asymmetric 
counteranion–directed catalysis (ACDC), a term coined by List et al., is described as 
the contact ion–pairing between a cationic substrate and a chiral phosphate anion 
(Figure 1.3d).23 
As a consequence of the versatility of these catalysts, their application to asymmetric 
transformations of a myriad of substrate classes that include imines, aziridines, 
epoxides, alcohols, and carbonyl compounds have been readily realised.24–29 This 
proficiency has enabled access to a plethora of enantiopure, synthetically valuable 
compounds, which could not easily be accomplished previously.30  
The focus of this Introduction is on the development of chiral Brønsted acid–mediated 



















































































plethora of works in this area of catalysis research, only examples that best exemplify 
the progress made in the field have been selected to clarify the concept. Illustrated in 
Figure 1.4 are the acid catalysts employed in the selected synthetic studies described 
in this Introduction and research work of the thesis. 
 
Figure 1.4: Asymmetric Brønsted acid catalysts employed in the reactions discussed heretofore. 
1.2 Alcohols as Pro–Electrophiles in Chiral Brønsted Acid 
Catalysis 
Pioneering works in the area of chiral Brønsted acid catalysis were realised in 2004 by 
the Akiyama and Terada groups who, independently, realised the asymmetric 















BA1, X = O, R = H 
BA2, X = O, R = SiPh3
BA3, X = O, R = 1-naphthyl
BA4, X = O, R = 9-anthracenyl65,78,98
BA5, X = O, R = 2-pyrenyl
BA6, X = O, R = 9-phenanthracenyl80,83
BA7, X = O, R = 2,3,4,5,6-(pentamethyl)phenyl64,96
BA8, X = O, R = 2-naphthyl77
BA9, X = O, R = 3,5-(trifluoromethyl)phenyl
BA10, X = NTf, R = 1-naphthyl
BA11, X = NTf, R = CH-diphenyl44
BA12, X = NTf, R = 9-anthracenyl
BA13, X = NTf, R = 2-pyrenyl
BA14, X = O, R = H
BA15, X = O, R = t-Bu
BA16, X = O, R = NO231
BA17, X = O, R = Ph
BA18, X = O, R = 2-naphthyl33
BA19, X = O, R = OMe76
BA20, X = O, R = Cl79,85
BA21, X = NTf, R = Ph46
BA22, X = NTf, R = t-Bu







BA24, X = O, R1 = R2 = i–Pr43,59,97
BA25, X = O, R1 = Me, R2 = t-Bu52,57
BA26, X = O, R1 = R2 = cyclohexyl49







BA28, X = O, R = 9-phenanthracenyl72,82,84,86
BA29, X = O, R = 2,4,6-(triisopropyl)phenyl60,74
BA30, X = O, R = 1-naphthyl72,81
BA31, X = O, R = Ph73
BA32, X = O, R = 9-anthracenyl55
BA33, X = O, R = 2,4,6-(trimethyl)phenyl
BA43, X = NTf, R = 1-naphthyl66
BA44, X = NTf, R = 2,4,6-(triisopropyl)phenyl87
BA34, X = NTf, R = Ph42,45







BA36, X = O, R = 9-phenanthracenyl56,58
BA37, X = O, R = 9-pyrenyl
BA38, X = O, R = 9-anthracenyl54,61,62
BA39, X = O, R = 1-pyrenyl63,88
BA40, X = O, R = 1-naphthyl47
BA41, X = O, R = 2-naphthyl75
BA45, X = O, R = 2,4,6-(triisopropyl)phenyl70




Scheme 1.1: (a) Asymmetric Mannich–type reaction of imine 1 with silyl ether 2 by Akiyama et al., i) BA16 
(10 mol%), toluene, –78 °C, 24 h. (b) Asymmetric direct Mannich reaction of imine 4 with 1,3–dicarbonyl 5 
by Terada and co–workers. ii) BA18 (2 mol%), 5 (1.1 eq), DCM, RT, 1 h. 
workers, the chiral phosphoric acid-catalysed reactions of imine 1 together with silyl 
enol ether 2 was found to furnish the corresponding enantioenriched amine adduct 3 
in 65–100% yield and with 81–96% ee (Scheme 1.1a). The Terada group reported the 
enantioselective reaction between Boc–protected–imines 4 and 1,3–dicarbonyl 
compounds 5 to afford the corresponding enantiopure amines 6 in 93–99% yield and 
with 93–98% ee (Scheme 1.1b). In the wake of this ground-breaking research, 
innumerable reports have described the use of BINOL-based chiral phosphoric acids 
as catalysts for a broad scope of asymmetric transformations.20 Included in this have 
been methods that target the enantioselective formation of products of synthetic value 
from alcohol pro–electrophiles. 
As alcohols are ubiquitous in nature, the compound class is often viewed as ideal 
reagents for the development of synthetic reactions. This is in addition to their ease of 
synthesis and the potential for the production of water as potentially the only by–
product.34,35 Alcohols also possess the potential to participate in H–bonding 
































































asymmetric reaction development.36,37 The functional group can exhibit the following 
reactivities: a) in oxidations to afford the corresponding aldehyde, ketone, or 
carboxylic acid; b) as the electrophile in nucleophilic substitution reactions, resulting 
in the loss of the hydroxyl motif, and c) as a nucleophile when the hydroxyl group 
attacks an electrophilic species (Scheme 1.2). 
 
Scheme 1.2: Potential Brønsted acid–catalysed reactivities of alcohols. 
The majority of reports exploring the transformations of alcohols in chiral Brønsted 
acid catalysis have focused on their nucleophilic nature. In comparison, alcohols as 
electrophiles have received relatively limited attention. This has been viewed as a more 
challenging due to the intrinsically poor asymmetric environment afforded by the 
carbocationic species created via dehydration of the alcohol. As a consequence, this 
results in low levels of stereoinduction as the asymmetric catalyst mediates the 
enantioselective step. 
1.2.1 Allylic Alcohols 
The field of allylic alcohol substitution has traditionally been dominated by Lewis acid 
and transition metal catalysis.38–41 Over the years, this synthetic strategy has been 
shown to provide one of the most powerful and efficient methods for the formation of 

























paid to Brønsted acid-mediated reactions of the compound class as a result of the 
hydroxyl moiety often being viewed as a poor leaving group. 
One of the first asymmetric allylic substitution reactions mediated by a chiral 
phosphoric acid was reported by Rueping et al. (Scheme 1.3).42 In the presence of 
BA34 (5–10 mol%), a variety of o–allylic alcohol–substituted phenols 7 were shown 
to efficiently cyclise to the corresponding 2H–chromenes 8 in 61–95% yield and with 
84–96% ee. The reaction mechanism was postulated to involve initial protonation of 
the substrate that resulted in its dehydration. Nucleophilic attack of the phenolic 
oxygen onto the allylic cation in this intimate ion–pair species was then surmised to 
provide the enantioenriched 2H-chromene 8. This proposed mechanism was further 
supported by control experiments that showed the products obtained from 
enantioenriched starting materials to relinquish all stereochemical information when 
exposed to an achiral Brønsted acid catalyst. The formation of transition state 9, 
comprised of the carbocationic species and the phosphoramidate anion along with the 
phenolic O–H hydrogen bonding with the catalyst, was subsequently proposed. 
 
Scheme 1.3: Asymmetric Brønsted acid–mediated contact ion pair allylic substitution of o–allylic alcohol–
substituted phenols 7 to 2H–chromenes 8. i) BA34 (5-10 mol%), toluene, –78 °C. 
Following this study, the Gong group reported the allylation of 1,3–dicarbonyl 
compounds 10 by allylic alcohols 11 (Scheme 1.4a).43 The corresponding substitution 
products 12 were furnished via the bifunctional–activation–type transition state 13 in 





























Scheme 1.4: (a) Asymmetric Brønsted acid–mediated allylic alkylation of alcohol 11 with 1,3–dicarbonyl 
10 to dicarbonyls 12. i) BA24 (10 mol%), DCE, –20 °C, 36 h. (b) Application of the former protocol to the 
metasequirins 15 and 16. Ar = 3,4–(OMe)2C6H5. 
two members of the metasequirin family (Scheme 1.4b). The first, 
hydroxymetasequirin A tetramethyl ether diacetate 15, was accessible in 9 steps from 
the alkene 14, a further two steps were shown to complete the synthesis of 
metasequirin B tetramethyl ether diacetate 16 in 10% yield over 11 steps. 
Concurrently, Du et al. showed that the enantioselective chiral phosphoric acid–
mediated allylic amination of allylic alcohols 17 could be achieved with TsNH2 to 
afford the allylic amines 19 and 20  (Scheme 1.5).44 In  this study,  the Brønsted acid  
 
Scheme 1.5: Asymmetric Brønsted acid–mediated intermolecular allylic amination of alcohol 17 with 

































































































BA11 was found to form the optimum ion pair species with the carbocationic 
intermediate for efficient enantio–induction in the proposed transition state 21. This 
furnished the allylic amines 19 and 20 in 16–88% yield with ee values of 13–94%. The 
regioselectivity of this transformation was found to be highly influenced by the 
electronic nature of aryl substituents present on the allylic alcohol 17. 
Building on this work, Xie and Zhou reported the synthesis of the 1,2–
dihydroquinolines 23 that relied on the chiral Brønsted acid-mediated allylic amination 
of allylic alcohols 22 (Scheme 1.6).45 In the presence of chiral N–phosphoramide 
BA34, this enantioselective method provided the 2H–quinolines in 43–90% yield and 
with 53–93% ee via the purported carbocation–catalyst ion pair transition state 24. 
 
Scheme 1.6: Asymmetric Brønsted acid–mediated intramolecular allylic amination of alcohol 21 to 2H–
quinolines 22. i) BA34 (10 mol%), DCM/PhH (1:1), –20 °C, MgSO4 (72 mg/0.1 mmol), 3–5 days. 
At about the same time, Chan and co–workers described the chiral Brønsted acid-
mediated enantioselective dehydrative Nazarov–type electrocyclisation of b–amino-
2-en-1-ols 25 (Scheme 1.7).46 With (S)–BA21 as the catalyst, this enantioselective 
method provided a facile synthetic route to 1H–indenes and 4H– 
cyclopenta[b]thiophenes in 76–99% yield and with ee values of 83–99%. Both 
experimental and computational studies supported the hypothesis that a contact ion 
pair species, in conjunction with H–bonding, to be operative in the proposed dual–




























Scheme 1.7: Asymmetric Brønsted acid–mediated Nazarov–type electrocyclization of allylic alcohol 25 to 
indene 26. i) (S )–BA21 (5 mol%), 4 Å MS, toluene, 0.05 M, at RT for 0.5 h, or at –60 °C for 36 h. 
information from the catalyst to the substrate was thought to occur simultaneously with 
the 4p –electrocyclization. 
In the same year, the groups of Yang and Kartika independently reported the 
enantioselective Brønsted acid–mediated synthesis of b–indolyl cyclopentenamides 
30 (Scheme 1.8).47,48 Yang et al. reported the SPINOL–derived phosphoric acid 
catalyst BA40 to provide the optimum combination of selectivity and reactivity for the 
asymmetric addition of indoles 29 to a–hydroxylcyclopentenamides 28. These 
reaction conditions provided the b–addition adducts 30 in 41–80% yield and with 50–
98% ee after separation of the a’–addition by–product 31. Kartika and co–workers 
found  the  optimum  conditions  to  involve  the  BINOL–derived  CPA  catalyst  BA6.  
 
Scheme 1.8: Enantioselective Brønsted acid–mediated synthesis of b–indolyl cyclopentenamides 28 
independently with indoles 29 reported by both Yang et al.  and Kartika et al. Yang’s optimised 
conditions, i) BA40 (10 mol%), 29 (1.5 eq.), toluene, 45 °C, 12 h. Kartika’s optimised conditions, ii) BA6 (10 























































Yang et al. 2018














These conditions furnished a mixture of both b– and a’–addition products 30 and 31 
in 16–92% combined yield and with regioisomeric ratios (rr) of 2.3:1–20:1 along with 
ee values of 30 of 32–98%. 
More recently, Yang and co–workers reported the Brønsted acid–mediated kinetic 
resolution of tertiary–substituted allylic alcohols 32 (Scheme 1.9).49 This protocol was 
found to provide access to enantioenriched 1,2–amino alcohols (S)–32 and the 
transesterification products (R)–33. In this study, the optimum reaction conditions for 
the kinetic resolution was achieved with BA26 as the catalyst, which provided the two 
enantioenriched compounds in 31–56% yield and with 74–98% ee. 
 
Scheme 1.9: Brønsted acid–mediated kinetic resolution of tertiary–substituted allylic alcohols 32. i) BA26 
(10 mol%), PhCl, 5 Å MS, 0 °C to 25 °C, 48 to 65 h. 
1.2.2 Benzylic Alcohols 
Within the field of chiral Brønsted acid catalysis, reactions that make use of o–
hydroxybenzyl alcohols 34 have gained an increasing amount of attention over recent 
years. The driver of this chemistry has been the ease in which the substrates can be 
converted to the highly reactive o–quinone methide (o–QM) resonance structure 35 as 
a result of dehydration in the presence of a chiral phosphoric acid catalyst (Scheme 
1.10). The shepherding of this postulated reactive species in functional group 
transformations such as nucleophilic addition and [n + m] cycloaddition involving the 





























Scheme 1.10: Generation and utilisation of o–QM mediated by Brønsted acid catalysis. (X = O,N) 
1.2.2.1 Nucleophilic Additions 
In 2014, the groups of Schneider and Rueping concurrently reported the 
enantioselective addition of 1,3–dicarbonyl compounds 39 and 44 to o–QM 38 
mediated by a chiral Brønsted acid catalyst (Scheme 1.11).52,53 These transformations 
afforded the 4H-chromene derivatives 41 and 46 in yields and ee values of up to 98%. 
In the case of the tricyclic adducts, dr values of up to 98:2 were also obtained. In both  
 
Scheme 1.11: Asymmetric addition of 1,3–dicarbonyl compounds 39 or 44 to o–hydroxybenzyl alcohols 
38 to O–heterocycles 41 and 46. a) (i) BA25 (5 mol%), CHCl3. (ii) p–TsOH, 40 °C, CHCl3. b) (i) BA24 (5 mol%), 
























































































b) Rueping et al.
a) Schneider et al.
 
 14 
works, the mechanism for the transformations were reasoned to begin with the 
protonation of the o-hydroxybenzyl alcohol 38 by the Brønsted acid catalyst. The 
reactive in situ generated o–QM species was proposed to undergo nucleophilic attack 
by the respective 1,3–dicarbonyl compounds 39 and 41 to afford the addition products 
40 and 45. The p–TsOH and FeCl3 co–catalysts employed in these works was proposed 
to promote cycloaddition of these respective adducts to provide the corresponding 4–
aryl–4H–chromin and tricyclic tetrahydroxanthene products. For the 4–aryl–4H–
chromin adduct, the proposed involvement of the intermediate 40 was supported by its 
isolation. The preservation of the enantiomeric excess value of this intermediate to the 
product also implied the enantio–determining step to be the initial nucleophilic attack 
by the 1,3–dicarbonyl compound onto the o–QM species. 
Following this study, the Sun group described an expedient method for the 
construction of indoles containing an all–carbon quaternary stereocentre from tertiary 
o–hydroxybenzyl alcohols 48 and indoles 29 mediated by chiral Brønsted acid 
catalysis (Scheme 1.12).54 The reaction mechanism was proposed to proceed via the 
transition state 50 in which the chiral Brønsted acid catalyst interacts simultaneously 
with the in situ generated o–QM species and H–bonding interactions with the indole 
derivative. Achieving product yields up to 99%  and ee values of up to 96%, control  
 
Scheme 1.12: Brønsted acid–mediated enantioselective addition of indoles 29 with o–hydroxybenzyl 


































experiments showed that the presence of the phenolic hydroxy group and an electron–
donating group para to the benzylic alcohol were crucial for both reactivity and 
selectivity. Removal of the electron–donating group or protection of the phenolic 
alcohol led to a significant decrease in both product yield and ee value. Furthermore, 
protection of the indole 29 as the N–methyl derivative was reported to lead to isolation 
of only the E1 reaction product. This supported the hypothesis of the involvement of 
the H–bonded transition state 50 directing the enantioselective nucleophilic attack onto 
the o–QM species. On the basis of this concept, a number of research groups have 
extensively explored the reaction chemistry of o–QM intermediates with other 
Brønsted acid–compatible nucleophiles that are able to partake in H–bonding (Table 
1.1). 
Table 1.1: Brønsted acid–mediated enantioselective substitutions of o–hydroxybenzyl alcohols 52. 
 


















































Table 1.1 continued 
entry nucleophile catalyst product details reference 

































55 / 53 62 
Akin to the o–hydroxybenzyl alcohols 38, the p–hydroxybenzyl alcohols 63 have also 
been reported to form the corresponding p–quinone methides (p–QM) species 64 via 
a dehydrative isomerisation process under acidic conditions. In an initial study by Sun 
and co–workers, the enantioselective reaction of pyrroles 68 with p–hydroxybenzyl 
alcohols 63 was found to provide a range of 1,6–conjugate addition products 67 in 42–
98% yield with ee values of 69–99% (Scheme 1.13).61 The transformation was 
proposed to proceed via a mode of activation in which both the p–QM species and the 
pyrrole compound simultaneously coordinated to the chiral Brønsted acid catalyst to 


























Scheme 1.13: Brønsted acid–mediated asymmetric addition of pyrroles 68 with p–hydroxybenzyl 
alcohols 63 to 67. (i) BA38 (5 mol%), CHCl3, 3 Å MS, 0 °C, 48 h. 
responsible for the stereoselective addition of the pyrrole to the p–QM adduct to 
deliver the enantioenriched product. 
Sun et al. extended the synthetic approach to include the chiral Brønsted acid–
mediated additions of naphthols 54 to p–hydroxybenzyl alcohols 69 (Scheme 1.14).62 
In the presence of the SPINOL–derived Brønsted acid (S)–BA38, the 1,6–conjugate 
addition of the naphthol to the in situ generated p–QM species furnished the 
triarylmethane product 70 in 43–99% yield and with 61–93% ee. In line with their 
previous reports, the transfer of stereochemical information was thought to derive from 
the formation of the bifunctional–activated transition state 71 in which both the p–QM 
species  and  the  naphthol were H–bonded to the chiral  Brønsted  acid  catalyst.  This 
 
Scheme 1.14: Brønsted acid–mediated asymmetric addition of naphthols 54 with p–hydroxybenzyl 



































































methodology was found to be limited to 2–naphthols as reactions with 1–naphthols 
were shown to give good to excellent product yields but with moderate ee values. 
Building on this study, the asymmetric 1,6–conjugate addition to an aza–p–QM 
species, generated in situ from the corresponding p-aminobenzyl alcohols 72, by 
substituted indoles 29 was reported by the Sun group.63 Employing the pyrenyl–
substituted chiral Brønsted acid (S)–BA39 as the catalyst, the method was shown to 
afford the N–alkylation product 73 in 47–99% yield with ee values of 71–99% 
(Scheme 1.15). It was found that the selection of the N–protecting group in 72 was 
essential for the selectivity at the new C–N bond. Added to this, the involvement of 
the reputed aza–p–QM intermediate was supported in a control experiment 
demonstrating that a N,N–disubstituted aza–p–QM species led to no reaction under the 
standard reaction conditions. The observed ee values obtained in this study were also 
proposed to be due to the transition state 74 in which the chiral Brønsted acid catalyst 
performs a bifunctional role, simultaneously activating the aza–p–QM species and the 
indole. 
 
Scheme 1.15: Brønsted acid–mediated asymmetric N–alkylation of indoles 29 through 1,6–conjugate 
addition with p–aminobenzyl alcohols 72 to 73. i) (S )–BA39 (10 mol%), PhMe, 5 Å MS, RT, 36 h. 
1.2.2.2 Cycloadditions 
Schneider and Saha documented one of the first examples of o–QM intermediates in 







































Scheme 1.16: Brønsted acid–mediated asymmetric addition of enamides 75 with o–hydroxybenzyl 
alcohols 38 to o–heterocycles 76. i) BA7 (5 mol%), DCM, 4 Å MS, RT. 
o–hydroxybenzyl alcohols 38 with enamides 75 (Scheme 1.16).64 A broad range of 
acetamidotetrahydroxanthenes 76 were furnished in 54–83% yield and with 76–98% 
ee and diastereomeric ratios of up to 98:2. The mechanism was thought toinvolve 
Brønsted acid–catalysed dehydration of the o–hydroxybenzyl alcohol 38 to give the 
o–QM species. Its involvement with the enamide and catalyst in the bifunctional 
transition state 77 was reported to be crucial in the enantioselective cycloaddition step. 
The versatility of the synthetic method was demonstrated by the conversion of a 
number of the o–heterocyclic products to the corresponding chromene derivatives 
through Brønsted acid–catalysed elimination of the acetamide with retention of optical 
purity. 
At about the same time, the asymmetric inverse–electron–demand oxa–Diels–Alder 
reaction of 3–methyl–2–vinylindoles 78 and o–QM species generated in situ from o–
hydroxybenzyl  alcohols  38,  was  reported by  the  Shi  group  (Scheme 1.17).65  This  
 
Scheme 1.17: Brønsted acid–mediated asymmetric oxa–Diels–Alder of o–hydroxybenzyl alcohols 38 with 






































































synthetic method furnished a range of enantioenriched chromans 79 featuring three 
neighbouring stereogenic centres in 50–99% yield and with ee values of 92–99% and 
good dr values of up to 95:5. Control experiments also confirmed the necessity to use 
C3–substituted indoles so as to prevent addition of the nucleophile at this position. The 
proposed reaction mechanism was thought to involve the chiral Brønsted acid catalyst 
BA4 playing a bifunctional role in the transition state 80 by H–bonding to both the o–
QM species and the dienophile during the enantio–determining step. In addition, (Z)–
vinylindoles were shown to isomerise to the (E)–alkene under the reaction conditions 
with no loss in stereoselectivity, albeit with a decrease in reactivity. 
In the same year, Rueping and co–workers detailed the chiral Brønsted acid–mediated 
cycloaddition of o–hydroxybenzyl alcohols 38 with unactivated alkenes 81 (Scheme 
1.18).66 The phosphoramide–based acid catalysts were found to be more suitable than 
their phosphoric acid counterparts for this transformation. In the presence of the 
catalyst BA30, the reaction furnished a range of chromanes 82 in 45–96% yield and 
with 83–99% ee and up to 98:2 dr. The hypothesised reaction mechanism was 
surmised to proceed with the chiral Brønsted acid catalyst acting as a dual–activator 
in the transition state 83 that interacted with the substrates through H–bonding and ion 
pairing.  As  a  consequence, this allowed the aryl alkene  to  initiate  cycloaddition  by  
 
Scheme 1.18: Brønsted acid–mediated asymmetric cycloaddition of o–hydroxybenzyl alcohols 38 with 































approaching the complex in an endo fashion to afford the corresponding o–heterocycle 
82. 
The Sun group reported the analogous chiral Brønsted acid–mediated [4 + 2] 
cycloaddition of o–hydroxybenzyl alcohols 38 and vinyl sulphides 84 (Scheme 
1.19).67 The asymmetric transformation was shown to proceed to afford a range of 
enantioenriched chromanes 85 in 48–91% yield with ee values of 73–96%. In a similar 
manner to the study by the Rueping group, the postulated mechanistic pathway was 
reasoned to involve both H–bonding and ion–pair interactions of the substrates with 
the chiral Brønsted acid catalyst. The utility of the newly installed sulphenyl group in 
the product was also demonstrated by its ease of removal to provide access to a range 
of substituted chromanes. 
 
Scheme 1.19: Brønsted acid–mediated asymmetric cycloaddition of o–hydroxybenzyl alcohol 38 and 
vinyl sulphide 84 to chromanes 85. i) BA28 (10 mol%), DCM (0.05 M), 4 Å MS, –20 °C, 96 h. 
In a subsequent study by Shi et al., it was demonstrated that the chiral Brønsted acid 
catalytic [4 + 2] cycloaddition of in situ generated o–QM species, formed in situ from 
o–aminobenzyl alcohol 87, and o–hydroxystyrenes 88 (Scheme 1.20).68 In the 
presence of the phosphoramide catalyst BA27, the corresponding enantioenriched 
tetrahydroquinolines 89 possessing two chiral centres were furnished in 45–82% yield 
and with 52–86% ee and with dr values of ³95:5. A limitation of the synthetic method, 





























Scheme 1.20: Brønsted acid–mediated asymmetric cycloaddition of o–aminobenzyl alcohol 87 and o–
hydroxystyrenes 88 to quinolines 89. i) BA27 (10 mol%), CHCl3, 5 Å MS, 25 °C, 48 h. 
found in a control experiment using a methyl–protected o–hydroxystyrene under the 
standard reaction conditions. Added to this, no reaction was reported for styrene 
substrates possessing either a hydroxyl or p–substituted motif while those without the 
functional group gave product yields of 40–43% and with 44–58% ee and dr values of 
³95:5. On the basis of these findings, it was suggested that whilst the o–hydroxy group 
did not influence reactivity, it played a pivotal role in the transition state 90. 
Tentatively, this could be due to H–bonding interactions between the substrate and the 
CPA so as to provide efficient transfer of stereochemical information. 
Zhu and co–workers developed a chiral Brønsted acid–mediated asymmetric Pinacol 
rearrangement of vinyl diols 91 as an efficient approach to b,g–unsaturated ketones 92 
(Scheme 1.21).69 In this work, the transformation  of 21 examples catalysed by the 
BINOL–derived N–triflyl phosphoramide BA27, was shown to deliver the ketone 
product  in  yields  of  64–99%  and  with  41–96%  ee.  The  reaction  mechanism  put  
 
Scheme 1.21: Brønsted acid–mediated asymmetric Pinacol rearrangement of vinyl alcohol 91 to ketones 
































































forward involved initial Brønsted acid–catalysed dehydration to provide the transition 
state 93. The hypothesised H–bonding and ion–pair interactions between the catalyst 
anion and the remaining hydroxyl group and allylic carbocationic motif of the 
substrate was proposed to form an intimate chiral environment for the enantioselective 
1,2–shift to occur. 
In a recent study, Zu and co–workers described the first chiral Brønsted acid–mediated 
enantioselective aza–Pinacol rearrangement (Scheme 1.22).70 The SPINOL–derived 
BA42–catalysed protocol was found to be an efficient approach to the indoline 
structure 98, affording yields of 64–99% and with ee values of 41–96%. 
Mechanistically, it was proposed that on the formation of the H–bonded species 95, 
Brønsted acid–assisted dehydration of the tertiary alcohol led to cationic dual–
activated species 96. An enantioselective 1,2–shift was proposed to produce the aza–
Pinacol rearrangement intermediate 97, which underwent cyclisation to furnish the 
fused indoline product 98. 
 
Scheme 1.22: Brønsted acid–mediated asymmetric aza–Pinacol rearrangement of alcohol 94 to indolines 







































1.2.3 Heteroaryl Alcohols 
Heteroaryl–substituted carbinols 99 have been shown in a number of studies to serve 
as electrophiles due to their ability to be readily activated by a chiral Brønsted acid 
(Scheme 1.23). This is thought to be a result of stabilisation of the positive charge by 
the  heteroaryl  motif  through  resonance  in  the  ensuing  carbocationic  intermediate  
 
Scheme 1.23: General Brønsted acid–mediated reactivities of heteroaryl alcohols 99. 
100.71 As a consequence, this stability enables an extended interaction between the 
cationic intermediate and the counteranion and, thus, the potential of enhancing 
enantioinduction in its following transformations. 
One of the seminal works exploiting this mode of reactivity was described by Antilla 
et al. in a study reporting the asymmetric Pinacol rearrangement of indolyl diols 101 
mediated by a chiral phosphoric acid (Scheme 1.24).72 The protocol was found to 
provide an expedient approach to a wide variety of a–indolyl ketones 102 in 83–99% 
yield and with 91–96% ee. A plausible reaction mechanism was described to initially 
involve  Brønsted  acid–mediated  dehydration  to  provide  the  dual–activation–type  
 
Scheme 1.24: Brønsted acid–mediated Pinacol rearrangement of indolyl diols 101 to a–indolyl ketones 













































transition state 103. A subsequent [1,2]–aryl shift was then reasoned to complete the 
Pinacol rearrangement to furnish the enantioenriched ketone product. 
At about the same time, the Gong group delineated the enantioselective alkylation of 
enamides 104 by indolyl alcohols 105 (Scheme 1.25).73 The asymmetric reaction was 
reported to afford a broad range of enantioenriched b–aryl–3–(3–indolyl)propanones 
106 in yields and with ee values of 70–91 and 88–96%. Mechanistically, it was 
proposed that an initial Brønsted acid–mediated dehydration of indole 105 and its 
subsequent interaction with enamide 104 generated the transition state 107. This was 
thought to involve H–bonding and ion–pair interactions of the cationic indolyl species 
with the conjugate base of the catalyst. As a result, it was proposed that this provided 
the chiral environment for the alkylation or conjugate addition to occur, which, on 
hydrolysis, furnished the desired enantioenriched b–indolyl ketone product. 
 
Scheme 1.25: Brønsted acid–mediated alkylation reaction of enamides 104 by indolyl alcohols 105 to b–
aryl–3–(3–indolyl)propanones 106. (i) BA31 (10 mol%), DCM, –30 °C. 
In recent work by Shi and co–workers, the enantioselective synthesis of axially chiral 
naphthyl–indoles 109 from CPA–mediated addition of naphthols 54 with indolyl 
methanols 108 was described (Scheme 1.26).74 Achieving product yields and ee values 
of 56–99 and 82–92%, respectively, the reaction mechanism was postulated to be 


































Scheme 1.26: Brønsted acid–mediated enantioselective synthesis of axially chiral naphthyl–indoles 109 
from indolyl methanols 108 and 2–naphthols 54. (i) (S )–BA29 (10 mol%), 3 Å MS, toluene, 0 °C. 
subsequent interaction with the naphthol 54 and catalyst was thought to give the dual–
activation–type transition state 110. Nucleophilic addition of the naphthol, followed 
by rearomatisation was proposed to afford the biaryl–product. The absence of reaction 
and the formation of the product in low yield and ee for the respective control 
experiments with methyl–protected 2–naphthol and N–methyl–1H–indole was put 
forward as support for the involvement of dual activation in the transition state. 
In 2016, the chiral Brønsted acid–mediated asymmetric [3 + 2] cycloaddition of C3–
unsubstituted 2–indolylmethanols 108 with 3–vinylindoles 111 was realised by the Shi 
group (Scheme 1.27).75 The synthetic method was shown to efficiently construct a 
variety of cyclopenta[b]indoles 112 in 46–99% yield and with 68–92% ee and dr of up 
to 95:5. In this work, protection of indole nitrogen in 108 or 111 was reported to either 
significantly  reduce  the enantioselective outcome of the transformation or  led  to  no  
 
Scheme 1.27: Brønsted acid–mediated asymmetric [3 + 2] cycloaddition of 2–indolylmethanols 108 with 


































































reaction. It was found that only tertiary 2–indolylmethanols would react under the 
standard conditions, which was reasoned to be due to stabilisation of the reputed 
carbocationic intermediate being insufficient with secondary alcohol substrates. 
Added to this, the reaction mechanism put forward was proposed to involve the chiral 
phosphoric acid catalyst  playing a bifunctional  role  by  H–bonding to the N–H 
groupof both substrates. This provided the requisite chiral environment for regio– and 
enantioselective cycloaddition to occur to afford the cyclopenta[b]indole product. 
The Peng group reported the chiral Brønsted acid–mediated direct alkylation of 
ketones 115 with 3–hydroxy–2–oxindoles 114 to furnish the a–alkylation products 
116 in 27–98% yield and with 74–97% ee and up to 99:1 dr (Scheme 1.28).76 With 
initial attempts to employ 3–indolylmethanols shown to be unsuccessful, it was 
reasoned that the more electrophilic alcohol analogue would be a better alkylating 
reagent. In a control experiment, the analogous reaction of a Bn–protected indole 
showing the delivery of the corresponding product in a lower yield and ee value was 
put forward as support for the involvement of the transition state 117. It was proposed 
that the Brønsted acid catalyst might preferentially engage in H–bonding interactions 
with the vinylogous indolyl species and the enol isomer of the ketone that results in 
the latter adding to the re face of the former to afford the alkylated (R)–adduct 116. 
 
Scheme 1.28: Brønsted acid–mediated asymmetric direct a–alkylation of 3–hydroxy–2–oxindole 114 









































In the same year, Gong and co–workers described the chiral phosphoric acid–mediated 
enantioselective nucleophilic substitution reaction of 3–hydroxyoxindoles 118 with 
enecarbamates 119 (Scheme 1.29).77 This method provided an expedient synthetic 
route to 3,3’–disubstituted oxindoles 120 with a range of substitution patterns in 70–
92% yield and with ee values of 90–96% ee. As part of this study, density functional 
theory calculations revealed that the reaction was likely to proceed via a sequential 
dehydration–Michael addition pathway. The chiral Brønsted acid was proposed to 
initiate the dehydration and H–bond to the resulting iminium species along with the 
enamine to form the transition state 121. Subsequent addition to the activated 
enecarbamate to the si face of the N–heterocycle followed by hydrolysis was described 
to  furnish the alkylated (S)–adduct 120. The utility of this protocol was also 
demonstrated by conversion of one example to the natural product (+)–folicanthine 
122 in 12 steps with an overall yield of 3.7%. 
 
Scheme 1.29: a) Brønsted acid–mediated substitution of 3–hydroxyoxindoles 118 with enamines 119 to 
alkylated adducts 120. (i) BA8 (10 mol%), Na2SO4, DCM. b) Application of the present protocol to the total 












































































Prompted by these seminal discoveries, the reactivities of 3–hydroxy–2–oxindoles 
have explored by a number of groups (Table 1.2). In these following studies, a broad 
range of nucleophiles were shown to perform well and furnish the corresponding 
indolyl products 130–137 in yields and ee values of up to 99%. The stereoselectivity 
obtained in all reaction examples represented in Table 1.2 were also proposed to 
exhibit a transition state featuring bifunctional activation. 
Table 1.2: Chiral Brønsted acid–mediated reactivities of 3–hydroxyoxindoles  
 































R3 = H, Me, Bn
118 130–137











































































Table 1.2 continued 























































In more recent work, Shi and co–workers reported the chiral Brønsted acid–catalysed 
asymmetric interrupted Nazarov–type cyclisation of C3–alkenyl–substituted 2–
indolylmethanols 138 with indoles 29 (Scheme 1.30).86 Accomplished under mild 






































































Scheme 1.30: Brønsted acid–mediated asymmetric Nazarov–type cyclisation of C3–alkenyl–substituted 
2–indolylmethanols 138 with indoles 29 to cyclopenta[b ]indoles 141. (i) BA28 (10 mol%), 3 Å MS, CHCl3, 
25 °C. 
88% yield and with 80–99% ee and ³95:5 dr. The reaction was proposed to proceed 
via initial Brønsted acid–mediated dehydration of the alcohol substrate. The 
participation  of  the  ensuing  carbocationic  species  with  the  conjugate  base  of  the 
catalyst to form the transition state 139 involving a contact ion pair interaction and H–
bonding was proposed to occur. The chiral environment provided by these interactions 
was reasoned to facilitate the enantioselective Nazarov cyclisation to form the cyclic 
carbocation 140. In the resultant TS, the catalyst anion was thought to form a contact 
ion pair with the tricyclic cation and H–bond with the indole nucleophile. It was 
surmised that such interactions promoted nucleophilic addition of the indole 129 to 
furnish the desired product in an enantio–inductive manner. 
In 2016, the research groups of Rueping and Sun, independently, recognised the 
potential of 2–furanols 142 as pro–electrophiles that can undergo aza–Piancatelli 


























































Scheme 1.31: a) Brønsted acid–mediated asymmetric Piancatelli rearrangement of 2–furanols 142 with 
aryl amines 147 to cyclopentanones 146. (i) BA44 (5 mol%), CHCl3, 5 °C, 24 h. (ii) (S )–BA39 (10 mol%), 
DCE, RT. b) Rueping’s enantioselective synthesis of a cyclopentane-based hNK1 antagonist analogue 148. 
corresponding 3–aminocyclopentenones  146  were  furnished  in  yields of up to 95% 
and with ee values of up to 96%. Mechanistically, the studies proposed the process to 
begin with the catalyst–mediated dehydration of the 2–furanol 142 to afford the chiral 
Brønsted acid anion–stabilised oxocarbenium intermediate and aryl amine–containing 
TS 143. Nucleophilic attack by the aryl amine to the oxononium species was surmised 
to give the hemiaminal–containing species 144. Its subsequent ring opening was 
surmised to provide the pentadienyl cationic species–containing TS 145. Intimate 
electrostatic interactions between the asymmetric Brønsted acid anion and this 















(i) Rueping (R2 = H, alkyl)

























































electrocyclic ring closure to furnish the desired chiral cyclopentenone adduct 146. 
Rueping and co–workers also demonstrated the synthetic utility of this protocol with 
the synthesis of the human NK1 inhibitor 148, in an overall yield of 83% and with 
88% ee over three steps from the Piancatelli rearrangement of 142a (Scheme 1.31b). 
1.2.4 Propargyl Alcohols 
The reactivities of them propargyl alcohol substrate class has been mainly focussed on 
the functionalisation of the sp–hybridised carbon–carbon triple bond moiety and the 
nucleophilic substitution of the hydroxyl group. In general, these transformations were 
reported to be achieved by employing transition metal–catalysed protocols.89–95 
Synthetic examples that are promoted by organocatalytic methods, by contrast, have 
remained rare. 
The Schneider group described one of the earliest examples, reporting the chiral 
phosphoric acid–catalysed substitution of the 1–(o–hydroxyphenyl)propargylic 
alcohols 149 with enamides 75 (Scheme 1.32).96 The method furnished, amongst other  
heterocycles,  an   array  of   benzo[c]xanthenes   150   featuring  three  adjacent 
stereogenic centres in 54–80% yield and with 88–98% ee and up to 97:3 dr. In this 
work, the in situ generated o–QM intermediate was proposed to serve as a directing 
group to facilitate the conjugate addition of the enamides as in the transition state 151. 
 
Scheme 1.32: Brønsted acid–mediated nucleophilic substitution of alcohols 149 with enamides 75 to 





























A series of control experiments supported this hypothesis as either the absence or 
protection of the o–hydroxy group was shown to result in no reaction. 
A later report by Sun and co–workers delineated the chiral Brønsted acid–mediated 
asymmetric reduction of propargylic alcohols 152 with the benzyl–substituted 
Hantzsch ester 53 (Scheme 1.33).97 This method generated the corresponding chiral 
diarylmethyl alkynes 154 in 83–99% yield and with 69–92% ee. A set of control 
experiments demonstrated the o–QM intermediate was generated from the alcohol 
substrate upon exposure to the Brønsted acid catalyst. Subsequent addition of the 
hydride source was thought to result in the rapid formation of the desired 
enantioenriched reduction product 154. During the optimisation of the reaction 
conditions, it was found that the addition of a boronic acid additive greatly improved 
product yield. Curiously, this was not the case when the reagents were added 
sequentially. This led to the deduction that the initial Brønsted acid–catalysed 
dehydration of the alcohol substrate was being hindered as a result of catalyst 
deactivation by the formation of the pyridine by–product. Thus, the addition of the 
boronic acid additive was to facilitate catalyst turnover by protonation of the catalyst 
anion. Mechanistically, it was postulated that Brønsted acid–catalysed dehydration of 
 
Scheme 1.33: Brønsted acid–mediated asymmetric reduction of propargylic alcohols 152 with benzyl–
substituted Hantzsch ester 153  to chiral diarylmethyl alkynes 154. (i) (S )–BA24 (10 mol%), 4 A MS, DCM, 







































the alcohol substrate gave the o–QM intermediate which interacts with the catalyst and 
the Hantzsch pyridine to form the intimate transition state 155. Transfer of the hydride 
anion in this TS was described to afford the desired chiral alkyne 154. 
In subsequent work, the Terada group reported the chiral Brønsted acid–catalysed 
enantioconvergent nucleophilic substitution reaction of alkyne–dicobalt complexes 
156 with thiols 53 (Scheme 1.34).98 An expedient route for the transformation of both 
enantiomers of the racemic alcohol 156 was reported to afford a range of 
enantioenriched thioethers in  83–99%  yield  and  with  69–92% ee. During the course 
of the study, the reactivities and enantioselectivities of reactions with enantioenriched 
and racemic starting materials was found to follow the order of (R)–156 > (±)–156 > 
(S)–156, to give (R)–159 as the major product in all cases. It was also showed that both 
 
Scheme 1.34: Brønsted acid–mediated nucleophilic substitution reaction of alkyne–dicobalt complexes 





















































concentration, temperature, and the number of equivalents of the thiol greatly 
influenced product selectivity. A lower concentration suppressed nucleophilic addition 
of the thiol which allowed racemisation to predominate and the effects of the 
asymmetric Brønsted acid catalyst to efficiently remove the disfavoured intermediate 
158’. Likewise, an increase in the number of equivalents of the thiol was shown to 
accelerate nucleophilic addition which favoured the retention of stereochemical 
information. Experimental results also revealed that an increase in temperature 
strongly favoured the racemisation process. This led to the proposal that the generation 
of the cationic intermediate takes place under the control of the chiral conjugate base 
of the Brønsted acid catalyst. As a consequence, its racemisation to the favoured (R)–
158 which can then undergo C–S bond formation to furnish the enantioenriched 
product (R)–159. 
At about the same time, the Sun group described the Brønsted acid–mediated 
asymmetric synthesis of tetrasubstituted allenes 162 and 163 (Scheme 1.35).99 In 
contrast  to  previous  studies   focussed  on  delivering  carbon–centre  chirality,  this  
 
Scheme 1.35: Brønsted acid–mediated synthesis of asymmetric synthesis tetrasubstituted allenes 162 and 














































manner, the ability of the propargyl alcohol to undergo C–C and C–S bond formation 
with 161 and 53a to give the corresponding chiral allenes in up to 98% yield and with 
98% ee and 21:1 dr was observed. The stereoinduction was postulated to result from 
the formation of the transition state 164 in which the chiral catalyst was H–bonding to 
the p–QM intermediate and the nucleophile to generate a chiral environment for the 
1,2–conjugate addition to occur. 
1.3 Proposed Work 
The studies presented in this thesis will centre on the discovery and development of 
new synthetic methods that can rapidly and enantioselectively increase molecular 
complexity from alcohol pro–electrophiles driven by chiral Brønsted acid catalysis. 
This will be accomplished by investigating the enantioselective nature of chiral 
Brønsted acid catalysts with achiral alcohol substrates under mild and operationally 
straightforward reaction conditions.  
 In Chapter 2 of this thesis, we propose to develop cycloisomerisation chemistry of 
propargyl alcohols 165 as an expedient route to 2–indolyl methanols 168 (Scheme 
1.36). In previous work by the Chan group, these propargyl alcohols were shown to 
undergo a Brønsted acid–mediated hydroamination/1,3–AAI cascade pathway to this 
member of the indole family.100 By providing the proposed carbocationic species, 
reasoned to be involved in the transformation, with an intimate chiral environment  due 
to the presence of a chiral Brønsted acid, a subsequent enantioselective 1,3–AAI of the 
ensuing TS 167 to give the indole product might be realised (Scheme 1.36a). In the 
event of an asymmetric hydroamination/1,3–AAI cascade being unfeasible, it was also 




Scheme 1.36: Proposed synthetic route towards 2–indolyl methanols 168 from 1–(2–aminoaryl)–1,3–
diphenylprop–2–yn–1–ols 165. 
undergoing the desired asymmetric 1,3–AAI via TS 167 would provide an alternative 
strategy for enantioselective 2–indolyl methanol synthesis. (Scheme 1.36b). 
In Chapter 3 of this thesis, we will aim to develop the synthesis of 1,2–
dihydroquinolines 171 via Brønsted acid–mediated allylic amination of 1–(2–
aminoaryl)prop–2–en–1–ols 169 (Scheme 1.37). This work will first explore the 
ability of this substrate class to undergo Brønsted acid–catalysed dehydration to form 
the proposed  carbocationic  intermediate  170  which,  upon  the  cyclisation step, will 
provide the racemic N–heterocyclic product 171. The proposed transient motif could 
also hold the potential to form an intimate transition state with a chiral Brønsted acid  
 






























































anion through a combination of H–bonding and counteranion interactions in order to 
transfer stereochemical information in the ensuing ring–forming hydroamination step 
to afford the enantioenriched quinoline product. 
In Chapter 4 of this thesis, our aim was to realise the synthesis of oxazol–2(3H)–ones 
174 and 5–alkenyloxazolidin–2–ones 175 from Brønsted acid–mediated cyclisation of 
N–Boc amino alcohols 172 (Scheme 1.38). This study will investigate the potential for 
these b–amino alcohols to form an allylic carbocation upon acid–catalysed 
dehydration in combination with the propensity of the t–butoxycarbonyl group to 
decompose under such reaction conditions. In doing so, it was envisioned that the 
trapping of the newly generated carbocationic intermediate motif by the carbonyl 
functional group in the resulting carbamic acid intermediate 173 would result in 
cyclisation to provide a wide range of the two O,N–heterocyclic compounds.  
 




































2.0 Towards the Realisation of a Chiral 
Brønsted Acid–Catalysed Enantioselective 
1,3–Allylic Alcohol Isomerisation of 3–
Indolinols to 2–Indolyl Methanols 
2.1 Introduction 
Heterocyclic molecules are of considerable importance in the arsenal of the organic 
chemist, both as targets and as facilitators.101,102 They are a prominent structural 
feature in many of the products used in our daily lives such as antioxidant, sanitiser, 
dye, agricultural, and pharmaceutical products.103–109 Of the nitrogen–based 
heterocyclic scaffolds, the indole ring system is one of the most wide spread and 
versatile found in the natural world. A key component in a wide variety of biologically 
active natural products and building blocks in functionalised materials,110 indole is a 
portmanteau derived from the constituents from which it was first isolated, indigo dye 
and oleium.  
The indole family possess the unique ability to structurally mimic peptides and 
reversibly bind, with high affinity, to a multitude of receptors.111–114 Their ability to 
bind reversibly to an array of enzymes has been powerful motivation for synthetic 
chemists to discover original modes of action and novel structures of value. In the 
human body, the proficiency to bind reversibly to receptors has earned this N–
heterocycle membership to an association of compounds introduced by Evans et al. 
known as “privileged scaffolds”.115 For example, the indole–containing biomolecules 
melatonin, serotonin, and tryptophan have been shown to regulate the sleep–wake 
cycle, contribute to the formation of neurons, and feature as an amino acid building 




Figure 2.1: a) Selected indole derivatives featured in animal biology. b) Selected pharmaceuticals 
containing the indole core structure. aUS sales in 2008.109 c) Marine alkaloids containing the indole 
structure. 
A wide variety of naturally occurring and synthetic compounds containing the N–
heterocycle have been found to exhibit a plethora of bioactivities such as antifungal, 
anticancer, antihypertensive, antiHIV, and antidiabetic activity.110 In the 
pharmaceutical industry, leading examples include taladafil 179 developed by 
ICOS/Lilly for the treatment of erectile dysfunction, sumatriptan 180 from GSK for 
the treatment of migraines, and fluvastatin 181 from Novartis for the treatment of high 
cholesterol (Figure 2.1b).110,118–126 
In the natural world, an increasing number of indole alkaloids isolated from a variety 






































































neurotransmitter compounds. As a consequence, it is postulated that many of these 
marine alkaloids may also possess or have hitherto unrealised neurological 
activity.119,127,128 For instance, the marine indole alkaloid methylaplysinopsin 182 
inhibits monoamine oxidase (Figure 2.1c).129 In addition, the alkaloids purpuroine J 
183 and plakohypaphorine D 184 have been shown to display significant 
antihistaminic activity.130  
For these reasons, the design, synthesis, and modification of indoles has and continues 
to be an actively pursued area of chemistry.102,131–136 While this has led to the 
development of a myriad of methods for indole synthesis over the years, little attention 
has been paid to the generation of 2–indolyl methanols. To our knowledge, there are 
also no examples for synthesis of the N–heterocycle featuring an asymmetric 1,3–
allylic alcohol isomerisation (1,3–AAI) strategy. Currently, synthetic methods 
available to access this member of the indole family have relied on Grignard reaction 
and reduction of 2–carbonyl–substituted indoles to give the corresponding secondary 
or tertiary alcohols (Scheme 2.1).137–143  
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Current synthetic methods that realise 1,3–AAIs have been limited to racemic 
methods, asymmetric transformations mediated by lipases, and Rh–oxo–catalysis with 
enantioenriched starting materials.144–147 An asymmetric catalytic 1,3–AAI leading to 
the enantioselective synthesis of indolyl methanols has remained unexplored. In this 
context, we were drawn to the potential cycloisomerisation chemistry of o–anilinyl–
tethered propargyl alcohols 165a (Scheme 2.2). In previous work, the substrate class 
was serendipitously discovered to undergo silica–gel–catalysed cycloisomerisation to 
give the corresponding 2–oxindoles 188 in 91% yield (Scheme 2.2a).100 The mildly 
acidic nature of SiO2 was responsible for the proposed hydroamination/semi–pinacol 
rearrangement of the propargyl alcohol. This process was likely initiated with SiO2 
activation of the alkyne moiety followed by a nucleophilic attack of the alkylamido 
group. Migration of the hydroxyl group, and subsequent oxidative 1,2–migration of 
the benzyl group from the C-2 to the C-3 position, then affords the oxindole 188. When 
the stronger Brønsted acid p–TsOH was employed, however, a different 
cycloisomerisation pathway was shown to occur to afford the (1H–indol–2–
yl)methanol 168a in 38% yield (Scheme 2.2b). One possible hypothesis for this latter 
process was the formation of an allylic cation resulting from a Brønsted acid–catalysed 
hydroamination/1,3–AAI cascade pathway. 
 
Scheme 2.2: Reported synthesis of 2–oxindoles and indolyl methanols from 1–(2–aminoaryl)–1,3–
diphenylprop–2–yn–1–ols. i) p–TsOH (5 mol%), n–hexane/EtOAc (20:1 v/v), RT, 38% yield. ii) SiO2 (100 




















With this in mind, we anticipated an asymmetric version of this functional group 
transformation could be accomplished through the application of chiral Brønsted acid 
catalysis. We envisioned the development of this approach to access 2–indolyl 
methanols in an asymmetric manner would be attractive in view of their potential 
applications in the agricultural, pharmaceutical, and materials–based industry, and as 
building blocks in organic synthesis.  
2.2 Results and Discussion 
2.2.1 Synthesis of the Starting Material 
All N–protected 1–(2–aminoaryl)–1,3–diphenylprop–2–yn–1–ols 165 examined in the 
present work were prepared from the corresponding 2–aminoacetophenones 189 in 
two steps following known procedures (Scheme 2.3).100,148 The synthesis of propargyl 
alcohols 165 involved an initial amination of 189 with either methyl iodide or tosyl 
chloride under basic conditions to afford o–aniline derivatives 190a and 190b in 48 
and 66% yield, respectively. Methylation of 189 under the described conditions 
afforded 21% yield of the dimethylation product that was easily separated employing 
column chromatography on silica–gel. For both compounds 190a and 190b, 
subsequent LDA–mediated propargylation with phenylacetylene provided access to 
the desired propargyl alcohol 165a and 165b in respective yields of 76 and 99%. 
 
Scheme 2.3: Synthesis of propargyl alcohols 165 from 2–aminoacetophenones 189. i) R = Me: MeI, K2CO3, 
80 °C, DMF, 48%. R = Ts: TsCl, pyridine, 66% yield. ii) R = Me: phenylacetylene, LDA, –78 °C to RT, THF, 99% 













189 190a (R = Me)
190b (R = Ts)
165a (R = Me)
165b (R = Ts)
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2.2.2 Chiral Brønsted Acid–Mediated Enantioselective 
Hydroamination/1,3–AAI of o–Anilinyl–Substituted 
Propargyl Alcohols 
Our studies began by examining the chiral Brønsted acid–catalysed cyclisations of 
propargyl alcohol 165a, which was initially chosen as the model substrate to establish 
the optimum reaction conditions. To confirm the reproducibility of the reported 
Brønsted acid–mediated rearrangement to give propargyl alcohol 165a, the reaction of 
the substrate in a solution of n–hexane and EtOAc (20:1) with 10 mol% of p–TsOH as 
the catalyst was first examined (Scheme 2.4).100 
 
Scheme 2.4: Initially attempted p–TsOH–catalysed cyclisation of 165a to indolyl methanol 168a. i) p–
TsOH (10 mol%), n–hexane/EtOAc (20:1), 75% yield of 168a, 25% yield of 188. 
Under these reaction conditions, it was found that a separable mixture of the desired 
indolyl methanol 168a and 2–oxindole 188 was generated in a ratio of 3:1 and 
respective yields of 75 and 25%. Recrystallisation of a sample of 168a allowed access 
to a single crystal suitable for the determination of its crystal structure by X–ray 
crystallography (Figure 2.2).  
An enantioselective version of the desired 5–endo–dig–type cyclisation was next 
explored, and the reaction conditions initially investigated are summarised in Table 
2.1. Chiral Brønsted acid catalyst BA1 was employed for all control experiments 
discussed in Table 2.1 where the effect of various solvents, reaction temperatures, and 





















Figure 2.2: ORTEP drawing of N–(2–benzoylphenyl)–4–methylbenzenesulfonamide 168a with thermal 
ellipsoids at 50% probability levels. 
selected  due  to its commercial availability and the possibility  to  readily  modify  the 
structure in further studies directed at establishing the reaction conditions to obtain 
optimum product enantioselectivity.  
In the first instance, the transformation of 165a to 168a was examined on a 0.1 mmol 
scale in anhydrous THF (1 mL) and with 50 mg of 4Å MS at room temperature (entry 
1).  These  reaction  conditions  produced  168a  in  23%  yield  after  96  h.  Similarly, 
repeating the reaction conditions with toluene instead of THF as the solvent resulted 
in a long reaction time of 86 h and a low product yield of 35% (entry 2). An 
examination of the reaction conditions without the exclusion of air or moisture 
demonstrated the transformation in THF at room temperature for 0.5 h to be robust, 
achieving a product yield of 80% (entry 3). Conversion of propargyl alcohol 165a to 
the desired indolyl methanol product 168a in 92% yield was also achieved by 
employing toluene as the solvent at room temperature for 0.25 h (entry 4). The 
analogous control experiment at 0 °C for 1 h led to a product yield of  92%  (entry 5). 
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Table 2.1: Summary of the initial screening of conditions of the Brønsted acid–catalysed cyclisation of 
165a to 168a. 
 
entrya solvent 4Å MS (mg) time (h) temp. (°C) yield (%)b ee (%)c 
1d THF 50 96 RT 23 0 
2d PhMe 50 84 RT 35 0 
3 THF 0 0.5 RT 80 0 
4 PhMe 0 0.25 RT 92 0 
5 PhMe 0 1 0 92 0 
6 PhMe 0 24 –78 17 0 
aAll reactions were conducted on a 0.1 mmol scale in solvent (1 mL) with catalyst (10 mol%) 
without the exclusion of air or moisture. 
b1H NMR yield determined with CH2Br2 as the internal standard.  
cEnantiomeric excess determined using HPLC, conditions: Daicel Chiralpak OD column, 10% 
IPA/n–hexane, 1.0 mL/min, 25 °C. 
dReaction conducted using anhydrous solvent and an N2 atmosphere. 
At –78 °C, however, poor reactivity towards the cycloisomerisation of 165a to 168a 
was observed after 24 h, with the cyclic product obtained in 17% yield (entry 6). 
Moreover, in all the reaction conditions examined in Table 2.1, no chiral induction 
was detected by HPLC analysis, with the product furnished as a racemate in each 
instance. 
In view of these initial findings, the BINOL–based disulfonimide acid catalyst BA46 
(BINBAM) was examined.149 This is a chiral acid catalyst of interest due the amino 
group being buried more deeply in the chiral pocket than in the equivalent phosphoric 
acid. The synthetic route employed to access this scaffold is described in Scheme 2.5. 
This involved initial generation of the bis(O–arylthiocarbamate) 192 in 60% yield 













The desired 2,2’–disulphur centres were then installed by thermally induced Newman–
Qwart rearrangement to afford the bis–(S–arylthiocarbamate) 193 in 59% yield. 
Subsequent oxidative cleavage to the bis–sulfonic acid followed by NCS–mediated 
activation afforded the disulfonyl chloride 194 in 51% yield. Passing gaseous 
ammonia through a  solution of 194 suspended in benzene promoted the final 
cyclisation which was then acidified after purification to afford the target Brønsted 
acid BA46 in 60% yield over six steps. 
 
Scheme 2.5: Synthetic route to the BINBAM acid catalyst BA46.150 i) NaH, DMF. ii) ClC(C=S)NMe2, 85 °C, 4 
h, 60% yield. iii) Microwave (300 Watt), 200 °C, 20 min, 59% yield. iv) H2O2/HCO2H, DCM, then HCl. v) NCS, 
HCl(aq), MeCN, 15 °C, 15 min, 51% yield. vi) NH3(g), C6H6, RT, 2 h, 68% yield. 
In tandem with a change of catalyst, attention was turned to the N–Ts propargyl alcohol 
substrate 165b (Table 2.2). It was reasoned that a substrate bearing a nitrogen centre 
that was less nucleophilic in character might contribute to the induction of product 
selectivity. This was based on the working hypothesis that a less reactive amine group 
might allow for the formation of a more intimate transition state between it and the 
chiral Brønsted acid through hydrogen–bonding interactions prior to the 
hydroamination step. However, we discovered that neither p–TsOH, BA1 (pKa = 3.4, 
DMSO),25 nor the more acidic BINBAM catalyst BA46 (pKa = 0.2, DMSO)25 were 




































experiments that were conducted in toluene at room temperature, 1H NMR analysis 
confirmed only the substrate 165b present in the crude reaction mixtures. Presumably, 
our attempts to promote strong hydrogen–bonding interactions by fine–tuning the 
nucleophilicity of the substrate may have unintentionally supressed its ability to 
undergo hydroamination.  
Table 2.2: Summary of the screening of conditions for the Brønsted acid–catalysed cyclisation to 168b. 
 
entrya catalyst yield (%)b 
1 p–TsOH –c 
2 BA1 –c 
3 BA46 –c 
aAll reactions were conducted on a 0.1 mmol scale in PhMe (1 mL) with catalyst (10 mol%) for 24 h 
without the exclusion of air or moisture. 
b1H NMR yield determined with CH2Br2 as the internal standard. 
cNo reaction based on 1H NMR analysis of the crude reaction mixture. 
2.2.3 Chiral Brønsted Acid–Mediated Enantioselective 1,3–AAI of 
3–Indolinols 
Concluding that the development of the chiral Brønsted acid–mediated 
hydroamination/1,3–AAI of 165b may not be achievable, we queried whether an 
asymmetric rearrangement of a preformed 3–indolinol to 168b might be a more viable 
strategy (Scheme 2.6). With this is mind, AgOAc–catalysed intramolecular amination 
of the sulphonamide 165b and subsequent protodemetalation afforded the indolinol 














Scheme 2.6: Synthetic route towards 2–indolyl methanol 168b in a step–wise method via indolinol 166b. 
i) AgOAc (5 mol%), MeCN, RT, 1 h, 99% yield. 
With the substrate in hand, its reactivity in the presence of the chiral phosphoric acid 
BA1 was examined and the results are summarised in Table 2.3. Initially, the 
transformation of 166b to 168b was examined at the 0.1 mmol scale at room 
temperature with toluene as the reaction solvent and 10 mol% of the catalyst at room 
temperature (entry 1). These conditions produced a product yield of >99% and an ee 
value of 8% over 12 h. At this stage in experimentation, a single crystal of 168b of 
suitable quality for X–ray analysis was produced to allow its structure to be determined 
(Figure 2.3). 
Table 2.3: Summary of the screening of conditions for the Brønsted acid–catalysed 1,3–AAI of 166b. 
 
entrya catalyst loading (mol%) time (h) temp (°C) yield (%)
b ee (%)c 
1 10 12 RT >99 8 
2 5 18 RT >99 8 
3 5 1 50 >99 8 
4 1 20 RT >99 9 
aAll reactions were conducted on a 0.1 mmol scale in PhMe (1 mL) at RT without the exclusion of 
air or moisture. 
b1H NMR yield determined with CH2Br2 as the internal standard. 
cEnantiomeric excess determined using HPLC, conditions: Daicel Chiralpak OD column, 10% 
IPA/n–hexane, 1.0 mL/min, 25 °C. 
Next, examining the reaction with 5 mol% of catalyst BA1 resulted in a reaction time 
































Similarly, repeating the reaction at an elevated temperature of 50 °C achieved a 
product yield of >99% and an ee value of 8% after 1h (entry 3). At room temperature, 
the cycloisomerisation of 166b to 168b at a catalyst loading of 1 mol% achieved a 
comparable product yield of >99% and 9% ee after 20 h (entry 4). 
 
Figure 2.3: ORTEP drawing of phenyl(3–phenyl–1–tosyl–1H–indol–2–yl)methanol 168b with thermal 
ellipsoids at 50% probability levels. 
2.2.4 Synthesis and Evaluation of Sterically Encumbered Chiral 
Phosphoric Acid Catalysts 
Encouraged by the moderate stereoinduction observed by the BA1–catalysed 1,3–AAI 
of 166b, efforts were channelled toward the synthesis of BINOL–based chiral 
phosphoric acids featuring bulky aryl substituents at the 3 and 3’ positions. In view of 
the many reported chiral transformations employing the TRIP–substituted Brønsted 
acid BA24, this was structure to be our first port of call (Scheme 2.7).20,151,152 The 




Scheme 2.7: i) MeI, K2CO3, acetone, RT, 99% yield; ii) I2, THF, n–BuLi, TMEDA, –78 °C–RT, 54% yield; iii) 
2,4,6–triisopropylphenylmagnesium bromide, Ni(PPh3)2Cl2, Et2O, 0 °C–RT, 24% yield; iv) BBr3, DCM, 99% 
yield; v) Pyridine, then POCl3, then H2O, RT–reflux, 68% yield. Ar = 2,4,6–triisopropylphenyl. 
involved the initial protection of the commercially available and optically pure (R)–
BINOL 191.153 In the presence of methyl iodide under basic conditions, this afforded 
the desired dimethoxy scaffold 195 in 99% yield. Subsequent methoxy–directed 
ortho–lithiation–halogenation generated the diiodo adduct 196 in 54% yield. This laid 
the path for the application of Ni–mediated cross–coupling chemistry with the 
appropriate Grignard coupling partner to achieve the installation of the desired 3,3’–
aryl substituents to afford 197 in 24% yield. Lastly, boron–mediated deprotection 
followed by phosphorylation with POCl3 and subsequent hydrolysis afforded the target 
phosphoric acid catalyst BA24 in 68% yield. 
The control experiments of the indolinol 166b with the newly acquired TRIP–
substituted catalyst BA24 was next examined and the results are summarised in Table 
2.4. This revealed exposing 5 mol% of BA24 to the substrate in toluene at room 
temperature required 120 h to achieve 168b in 73% yield and 10% ee (entry 1). 
Likewise, repeating the reaction at a catalyst loading of 10 mol%, a similar reaction 

































Table 2.4: Summary of the reaction conditions screened for the BA24–catalysed 1,3–AAI of 166b. 
 
entrya catalyst loading (mol%) time (h) yield (%)
b ee (%)c 
1 5 120 73 10 
2 10 138 74 10 
aAll reactions were conducted on a 0.1 mmol scale in PhMe (1 mL) at RT without the exclusion of 
air or moisture. 
b1H NMR yield determined with CH2Br2 as the internal standard. 
cEnantiomeric excess determined using HPLC, conditions: Daicel Chiralpak OD column, 10% 
IPA/n–hexane, 1.0 mL/min, 25 °C. 
product yield and ee value of 74 and 10%, respectively (entry 2). From these findings 
it can be seen that catalyst BA24 was unable to provide a significant increase in 
selectivity. In response to these results, and to address the current low level of 
enantioselectivity obtained with BA24, a second set of commercially available 
BINOL–based chiral phosphoric acids were examined (Figure 2.4). The reactions of 
166b mediated by the newly acquired chiral phosphoric acid catalysts were 
investigated (Table 2.5). In the presence of 5 mol% of BA2 in distilled toluene at room 
temperature for 120 h, a product yield of 5% along with an ee value of 5% was obtained 
(entry 1). Repeating the reaction conditions without the exclusion of air or moisture 
afforded similar results, with a 6% product yield and an enantiomeric excess of 7% 
found (entry 2). Next, examining the reaction at an elevated temperature of 50 °C for  
 



























Table 2.5: Summary of the chiral acids screened for the Brønsted acid–catalysed 1,3–AAI of 166b. 
 
entrya catalyst temp. (°C) time (h) 
anhydrous 
conditions yield (%)
b ee (%)c 
1 BA2 RT 120 ✔ 5 5 
2 BA2 RT 120 ✖ 6 7 
3 BA2 50 120 ✖ 62 4 
4 BA9 RT 120 ✔ >99 3 
5 BA9 RT 120 ✖ >99 4 
6 BA9 50 16 ✖ >99 5 
7 BA4 RT 120 ✔ 45 22 
8 BA4 RT 120 ✖ 56 25 
9 BA4 50 120 ✖ 97 7 
aAll reactions were conducted on a 0.1 mmol scale in PhMe (1 mL) with catalyst (5 mol%) without 
the exclusion of air or moisture. 
b1H NMR yield determined with CH2Br2 as the internal standard. 
cEnantiomeric excess determined using HPLC, conditions: Daicel Chiralpak OD column, 10% 
IPA/n–hexane, 1.0 mL/min, 25 °C. 
120 h afforded 168b in 62% yield along with an ee value of 4% (entry 3). Reactions 
with BA9 in place of BA10 as the catalyst were next examined (entry 4–6). At room 
temperature and over 120 h, the reaction afforded the product in quantitative yield and 
with 3 % ee (entry 4).    Repeating    the   reaction   conditions   without   the   use    of    
anhydrous  conditions  afforded similar results over 120 h, with a >99%  product  yield 
and an ee value of 4% (entry 5). Similarly, examining the effect of an elevated reaction 
temperature of 50 °C after 16 h produced a comparable product yield of 79% along 
with 5% ee (entry 6). Experiments employing the 9–anthracenyl substituted Brønsted 
acid catalyst BA4 revealed that in distilled toluene at room temperature, 
cycloisomerisation of 166b gave 168b in 45% yield and 22% ee over 120 h (entry 7). 
Similarly, the analogous reaction conditions without the exclusion of air and moisture 














at 50 °C afforded an improved product yield of 97%, a lower enantiomeric excess of 
7% was observed (entry 9). The marked difference in reactivity in experiments 
mediated by BA2 and BA9 containing the electron–withdrawing SiPh3 and 3,5–
(trifluoromethyl)phenyl motifs, respectively, led to the conclusion that such electronic 
factors may not be a significant contributing factor for determining selectivity in these 
reactions (entry 2 versus entry 5). Likewise, the difference in reactivity found for 
experiments catalysed by BA2 and BA4, where the steric bulk possessed by each 
catalyst might be considered to be relatively comparable, suggested this may also not 
be a significant contributor to the asymmetric outcome of the reaction (entry 2 versus 
entry 8). In this context, we reasoned that the shape occupied in space by the 
substituents at the 3 and 3’ positions of the Brønsted acid should be the major 
consideration in further optimisation studies and not their stereoelectronic nature.  
With this in mind, the reaction of 166b with the BINBAM catalyst BA46 and a 
VAPOL–based phosphoric acid BA48 was examined (Scheme 2.8). As a comparison 
of reactivity, the 1,3–AAI of the substrate mediated by the achiral Brønsted acid 
diphenyl phosphate BA47 was also investigated (Scheme 2.8a). Synthesis of BA48 in 
76% yield from its (R)–VAPOL diol 199 involved the one–pot phosphorylation with 
POCl3 under basic conditions and hydrolysis (Scheme 2.8b).  
 
Scheme 2.8: a) Further acids employed in future screening. b) Synthesis of B48 from corresponding diol. i) 

























The results obtained from the cycloisomerisation of 166b mediated by the newly 
acquired chiral phosphoric acid catalysts are summarised in Table 2.6. Initially, the 
presence of 5 mol% of BA48  in  distilled  toluene  at  room temperature was examined 
(entry 1). These conditions afforded a product yield of >99% and  20% ee over 120 h. 
Repeating the reaction conditions without the exclusion of air or moisture produced 
similar results, with a product yield and ee value of >99 and 10% being obtained (entry 
2). An increase in reaction temperature to 50 °C over 16 h revealed a comparable yield 
and, curiously, an increased enantiomeric excess value of 14% (entry 3). Next, the 
reactions mediated by the BINBAM catalyst BA46 were examined. Employing 
distilled toluene at room temperature over 16 h revealed a >99% product yield but with 
Table 2.6: Summary of the chiral acids screened for the Brønsted acid–catalysed 1,3–AAI of 166b. 
 
entrya catalyst (5 mol%) temp. (°C) time (h) 
anhydrous 
conditions yield (%)
b ee (%)c 
1 BA48 RT 120 ✔ >99 20 
2 BA48 RT 120 ✖ >99 10 
3 BA48 50 16 ✖ >99 14 
4 BA46 RT 16 ✔ >99 0 
5 BA46 RT 16 ✖ >99 6 
6 BA46 50 16 ✖ >99 0 
7 BA47 RT 2 ✔ >99 – 
8 BA47 RT 2 ✖ >99 – 
9 BA47 50 2 ✖ >99 – 
10d BA47 RT 24 ✖ >99 – 
aAll reactions were conducted on a 0.1 mmol scale in PhMe (1 mL) with catalyst (5 mol%) without 
the exclusion of air or moisture. 
b1H NMR yield determined with CH2Br2 as the internal standard. 
cEnantiomeric excess determined using HPLC, conditions: Daicel Chiralpak OD column, 10% 
IPA/n–hexane, 1.0 mL/min, 25 °C. 














no chiral induction (entry 4). Repeating the reaction conditions without the exclusion 
of air or moisture produced comparable yields along with 6% ee (entry 5). Increasing 
the reaction temperature to 50 °C was also shown to lead to a product yield of >99% 
but no enantioselectivity over 16 h (entry 6). This result is curious as a decrease in 
reaction time would have been reasonably expected (entry 5 versus entry 6). 
The reactivity of the substrate toward 1,3–AAI mediated by the achiral Brønsted acid 
diphenyl phosphate BA47 was next investigated. The results, summarised in entries 
7–9, illustrate that employing inert or atmospheric conditions, the reaction at room 
temperature or 50 °C for 2 h had no significant effect on reactivity, with >99% product 
yield afforded in all cases. An analogous control experiment conducted with BA47 at 
a catalyst loading of 1 mol% in toluene at room temperature for 24 h revealed a >99% 
product yield (entry 10). A catalyst loading of 1 mol% was not, however, considered 
reasonably feasible for the bulkier chiral Brønsted acids BA48, BA46, and BA47 due 
to the likelihood for the need for extended reaction times. 
A comparison of the reactivities found for the reactions of 166b promoted by Brønsted 
acids BA1, BA48, BA46, and BA47 under the conditions described in Table 2.3, entry 
2, and Table 2.6, entries 2, 5, and 8, respectively, revealed that an increase in acidity 
did not lead to an increase in reactivity (Figure 2.5). It was hypothesised that an 
increased acidity of the Brønsted acid catalyst would result in faster hydroxyl 
protonation, dehydration,  and  subsequent  formation  of  an allylic cation. As Brønsted 
acids BA47 and BA1 possess comparable pKa values, a comparable level of reactivity 
might be expected. However, diphenyl phosphate catalyst BA47 displays a reactivity 
9–times higher than that of BA1. This difference in reactivity could be attributed to 




Figure 2.5: Reactivity and selectivity comparison between acids BA47, BA1, BA48, and BA46. a) Calculated 
pKa value.154  
of the disulfonimide catalyst BA46 is reported to be more deeply buried in the chiral 
pocket than Brønsted acid BA1.149 As a result, and despite possessing an acidity of 
more than 3 pKa units  lower  than  that  of  BA1,  the  disulphonamide catalyst BA46 
exhibits comparable reactivity and selectivity. This further emphasises the role of 
steric interactions between the catalyst and the substrate on the reactivity of the latter. 
This hypothesis is further supported by the more sterically encumbered Brønsted acid 
BA48. In this control experiment, a reaction time of 120 h was required  to afford a 
comparable product yield of 99%. 
With regards to reactivity and selectivity, our studies have, thus far, shown the most 
effective BINOL–based phosphoric acids to be the bis(trifluoromethylphenyl) and 
anthracenyl–substituted catalysts BA4 and BA9 (Table 2.5, entries 5 and 8, 
respectively). With this is mind, the effect of solvent on the 1,3–AAI of alcohol 166b 
in conjunction with these catalysts was examined (Table 2.7). In a previous study with 
BA9 as the catalyst, the most effective conditions comprised of 5 mol% of the catalyst 









































Table 2.7: Summary of the solvents screened for the BA4 and BA9–catalysed 1,3–AAI of 166b. 
 
entrya catalyst (5 mol%)  solvent time (h) yield (%)
b ee (%)c 
1 BA9 p–xylene 120 37 3 
2 BA9 DCM 8 >99 7 
3 BA9 DCE 8 >99 11 
4d BA9 PhMe/dioxane 120 45 7 
5 BA4 p–xylene 120 52 28 
6 BA4 DCM 120 94 20 
7 BA4 DCE 120 77 19 
8d BA4 PhMe/dioxane 120 89 3 
aAll reactions were conducted on a 0.1 mmol scale in solvent (1 mL) with catalyst (5 mol%) at RT 
without the exclusion of air or moisture. 
b1H NMR yield determined with CH2Br2 as internal standard.  
cEnantiomeric excess determined using HPLC, conditions: Daicel Chiralpak OD column, 10% 
IPA/n–hexane, 1.0 mL/min, 25 °C. 
dSolvent ratio of 1:1. 
and with 4% ee (Table 2.5, entry 5). Repeating the reaction conditions with p–xylene 
instead of toluene  for 120 h generated a 37% yield of 168b and with an ee value of 
3%  (Table 2.7, entry 1).  A  survey  of  more  polar  solvents  revealed  the  analogous 
reaction with DCM as the solvent for 8 h afforded the product in >99% yield along 
with 7% ee (entry 2). Comparable results were recorded in a control experiment using 
1,2–dichloroethane as solvent (entry 3). Over 8 h, these conditions afforded a product 
yield of >99% and with an ee value of 11%. Employing a 1:1 mixture of toluene and 
dioxane as solvent produced 168b in 45% yield along with an enantiomeric excess 
value of 7% (entry 4). Next, solvent effects on the enantioselective outcome of the 
BA4–catalysed 1,3–AAI of 166b was examined. Our previous studies revealed that 
the most effective conditions were 5 mol% of the catalyst in toluene at room 














(Table 2.5, entry 8). Repeating these reaction conditions with p–xylene instead of 
toluene for 120 h generated 168b in 52% yield and with an ee value of 28% over 120 
h (Table 2.7, entry 5). The more polar solvents DCM was found to afford a product 
yield of 94% and with 20% ee (entry 6). A similar outcome was observed in a control 
experiment using 1,2–dichloroethane as the solvent (entry 7). Under these latter 
reaction conditions, a product yield of 77% along with an ee value of 19% was 
obtained. The analogous reaction employing a 1:1 mixture of toluene and dioxane as 
solvent produced 168b in 89% yield and with 3% ee (entry 8).  
The selectivity of these types of transformations could rely on the strength and 
proximity of cation–counteranion interactions and, therefore, the poor solubility has 
the potential to greatly affect this ion pairing. However, a balance needs to be struck 
between the solubility of the constituents of the reaction and the solubility of the ion 
pair. If the ions are sufficiently soluble then the solvent will interfere with the 
proximity of the two, resulting in a detrimental effect on selectivity.155  
2.2.5 Evaluating the Possibility of Product Racemisation 
Having achieved only moderate selectivity at this stage of our studies, we queried 
whether the benzylic carbon in the indolyl methanol product 168b could be promoting 
racemisation under the acidic conditions (Scheme 2.9). To test this hypothesis, the 
product obtained under the reaction conditions described in Table 2.5, entry 8, with an 
ee value of 25% was remeasured by HPLC analysis after 20 days at –20 °C (Scheme 
2.9). We speculated that it might be possible that protonation of the hydroxyl group 
and  subsequent   dehydration   would   form   cationic   species  II–168b.  As  a  result, 





Scheme 2.9: Graphical representation of potential product racemisation. 
The HPLC trace acquired from the reaction described in Table 2.5, entry 8, provided 
an enantiomeric excess reading of 17%. This result, showing an 8% decrease in ee 
value, indicated that product racemisation was to be a possible factor not previously 
taken into consideration. In an attempt to confirm this experimental result, two further 
reactions were conducted. Alcohol substrate 166b was exposed to 5 mol% of Brønsted 
acid catalyst BA4 in either p–xylene or DCM as the solvent at room temperature over 
14 h. An HPLC sample was taken at regular intervals and the enantiomeric excess 
value was recorded. A summary of these results is presented in Scheme 2.10. After 12 
h, the reaction in p–xylene revealed a product enantiomeric excess value of 36%. 
Subsequently, the ee value was determined to be 33%, representing a decrease of 3% 
after 84 h. After 12 h, the reaction in DCM showed a product ee value of 24%. The ee 
value of the product was shown to decrease by 5% to a final value of 19% over 84 h. 
 
Scheme 2.10: Enantiomeric excess values over time employing 5 mol% of BA4 in either p–xylene or DCM. 
Percentages represent enantiomeric excess values for 168b at each interval. 
The possibility of product racemisation led us to consider whether a carbon 
nucleophile could be employed to trap the carbocationic intermediate of the product 
involved in this process. To this end, we selected indole as the nucleophilic probe for 








































Table 2.8: Indole incorporation into 168b to test for racemisation. 
 
entrya catalyst  (5 mol%) time (h)  additive yield (%) ee (%)
e 
1 BA4 120 4 Å MSb –c – 
2 BA4 120 – –d – 
3 BA9 120 4 Å MSb –c – 
4 BA9 120 – –d – 
5 BA46 8 – –d – 
aAll reactions were conducted on a 0.1 mmol scale with indole (1.1 eq.) in DCM (1 mL) at RT 
without the exclusion of air or moisture. 
bReaction conducted with 50 mg of 4 Å MS. 
cNo reaction based 1H NMR analysis of the crude reaction mixture. 
dMinor detection of product by mass spectrometric analysis. 
eEnantiomeric excess determined using HPLC, conditions: Daicel Chiralpak OD column, 10% 
IPA/n–hexane, 1.0 mL/min, 25 °C. 
with non–polar aprotic solvents, DCM was employed for these investigations in 
conjunction with 5 mol%  of  the  Brønsted acid catalyst. Our studies commenced with 
0.1 mmol of a racemic sample of 168b, 50 mg of 4 Å MS, and BA4 as the catalyst at 
room temperature over 120 h (entry 1). These conditions afforded no reaction; only 
indolyl methanol 168b was detected by 1H NMR analysis of the crude reaction 
mixture. The exclusion of 4 Å MS under similar reaction conditions was found to lead 
to the trace detection of the indole–incorporated product 200 based on mass 
spectrometric analysis (entry 2). Repeating the reactions using Brønsted acid BA9 in 
place of BA4 as the catalyst afforded comparable results, where the inclusion of 4 Å 
MS resulted in no reaction, and their exclusion generated a trace amount of the product 
200 (entries 3 and 4). Likewise, the analogous BA46–catalysed reaction was found to 
promote the incorporation of indole into the indolyl methanol 168b after 8 h as 
















found only the trace detection of the diindole 200, they hint at the possibility that 
indolyl methanol 168b can dehydrate under the Brønsted acidic reaction conditions. 
In an attempt to provide further support for the mechanism proposed in Scheme 2.9, 
the trapping of the premised cationic intermediate II–168b generated from 166b by 
indole was next examined. The results of this investigation are summarised in Table 
2.9. When exposed to 0.1 mmol of 166b in DCM at room temperature for 120 h, 5 
mol% of Brønsted acid catalyst BA4 was found to promote only the trace incorporation 
of indole, as analysed by mass spectrometry (entry 1). Under similar reaction 
conditions, the BA9–mediated experiment was also shown to give only trace 
incorporation of indole (entry 2). In contrast, the analogous reaction catalysed by 
BA46 was found to lead to no indole incorporation being detected by mass 
spectrometry (entry 3).156 On the other hand, the BA4–catalysed reaction with p–
xylene as the solvent was found to give the indole–incorporated product 200 in 17% 
yield and with 20% ee (entry 4). The indolyl methanol 168b was additionally furnished  
Table 2.9: Indole incorporation into indolinol 166b to test for racemisation. 
 
entrya catalyst  (5 mol%) solvent 
yield (%) ee (%) 
168b 200 168b 200 
1 BA4 DCM –b – – – 
2 BA9 DCM –b – – – 
3 BA46 DCM –c – – – 
4 BA4 p–xylene 34 17 42 20 
aAll reactions were conducted on a 0.1 mmol scale with indole (1.1 eq.), catalyst (5 mol%) in DCM 
(1 mL) at RT for 120 h without the exclusion of air or moisture. 
bMinor detection by mass spectrometric analysis. 



















in 34% yield and with 42% ee. Prior to this discovery, the most effective conditions 
for the 1,3–AAI of 166b to 168b were 5 mol% of BA4 in p–xylene at room 
temperature for 120 h, which gave a yield of 56% along with 25% ee (Table 2.7, entry 
5). This latter result hinted at the possibility that indole could be interacting with either 
the substrate 168b, and/or the catalyst BA4, in a manner that leads to a more intimate 
chiral environment resulting in elevated selectivity. A similar rationale might explain 
the outcome of reactions with DCM as the solvent described in Table 2.9, entries 1–3. 
While this may also be in play, the ability of DCM to solvate such interactions might 
not only prevent the formation of an intimate chiral environment but also the 1,3–AAI 
or dehydration occurring. 
During the course of this study, Li, Shi et al. detailed the synthesis of an axially chiral 
naphthyl–indole motif 109 in 56–99% yield with 82–92% ee from indolyl methanols 
108 (Scheme 2.11).74 The mechanism was proposed to involve dehydration of the 
substrate to form the allylic cation, and reaction via the transition state 110 in the 
presence of BA32 as the catalyst. A feature of the work was the double–benzylic nature 
of the alcohol in 108 facilitating the ease of dehydration by providing a more stabilised 
carbocationic intermediate. We postulate that the indolyl methanol 168b in our studies 
could  also  undergo  dehydration in this manner to facilitate racemisation. In  view  of  
 


























the work by Li, Shi and co–works, further efforts to evaluate the potential of this line 
of investigation were not pursued. 
2.2.6 Counteranion Partners 
Various works have reported that employing catalytic salts of achiral amines, such as 
those shown in Figure 2.6, in conjunction with chiral BINOL–based phosphoric acid 
catalysts can result in the induction of high levels of enantioselectivity.23,157 Contact 
ion pair species, such as 203, do not experience solvent separation and, as a result, 
produce an intimate asymmetric environment. This ion pair species could potentially 
exist as a charged species such as 201, or as a hydrogen bonded complex such as 202. 
 
Figure 2.6: Reported achiral amine salts and phosphoric acid ion pairs. 
In view of these reports and our own findings, we next moved to examine the effect of 
a range of achiral amines on the chiral Brønsted acid–catalysed 1,3–AAI of 166b 
(Table 2.10). We hypothesised that an amine equivalent to indole that was unable to 
take part in nucleophilic addition could form an intimate transition state with the acid 
















































the product ee values obtained in the absence on the amine additive under the 
conditions detailed in Table 2.10, entries 1 to 12, are included. In this study the reaction 
mixtures were directly measured by chiral HPLC analysis without prior purification 
by column chromatography. Carbazole (5 mol%) was first investigated in the reaction 
of 166b subjected to 5 mol% of BA4 in p–xylene at room temperature (entry 1). It was 
not possible, however, to determine the enantiomeric excess value of the product as it 
and carbazole possessed identical Rf values which prevented their separation. 
Repeating the reaction conditions with either morpholine or diisopropylamine was 
found to give a similar outcome, leading to unattainable ee values (entries 2 and 3).  
Table 2.10: Investigation into achiral amines as a counteranion partners. 
 
entrya catalyst (5 mol%) 
amine 
(5 mol%) ee (%)


















































Table 2.10 continued 
entrya catalyst (5 mol%) 
amine 
(5 mol%) ee (%)



















aAll reactions were conducted on a 0.1 mmol scale with catalyst (5 mol%) in p–xylene (1 mL) at RT 
for 120 h without the exclusion of air or moisture. 
bEnantiomeric excess determined using HPLC, conditions: Daicel Chiralpak OD column, 10% 
IPA/n–hexane, 1.0 mL/min, 25 °C. 
cEnantiomeric excess value in the absence of the amine additive. 
Reactions with dibutylamine, imidazole, L–proline, and triazabicyclodecene as the 
amine additive all failed to enhance product selectivity, affording enantiomeric excess 
values in the range of 4–6% (entries 4–7). In comparison, an ee value of 28% was 
observed in the corresponding BA4–mediated reaction of 166b in the absence of the 
amine additive. The analogous reaction with diphenylamine as the amine additive was 
found to achieve an ee value of 29%, which is comparable to that found in the absence 
of the additive (entry 8). Repeating the reaction with BA1 instead of BA4 was found 
to give a product ee value of 8% that was comparable to that obtained in the absence 
of the additive (entry 9). On the basis of these finding, we speculated that 




















Two experiments employing a secondary amine with differing substituents were also 
examined (entries 10 and 11). However, these reactions employing N–benzylpropan–
2–amine and N–phenylphenanthen–9–amine were found to give low product ee values 
of 6 and 4%, respectively. Prompted by the works of Ishihara and co–workers on the 
effectiveness of 2,6–diphenylpyridine and a BINSA acid in asymmetric catalysis, the 
reaction of 166b in the presence of the aromatic heterocycle and BA46 in p–xylene at 
room temperature was attempted (entry 12).158 Under these reaction conditions, the 
indolyl methanol 168b, however, was afforded in a low ee value of 5%. 
With the strategy of employing various achiral amine salts shown to be unsuccessful, 
we next moved to introduce additives more akin to the indole structure such as 
benzotriazole, benzimidazole, and indazole (Scheme 2.12). In an initial experiment 
this revealed exposing 0.1 mmol of 166b to 5 mol% of BA4 in p–xylene to 1 equivalent 
of benzotriazole at room temperature over 120 h afforded 168b  in a 42% yield with 
an ee value of 25%. Repeating the reaction conditions with benzimidazole in place of 
benzotriazole generated indolyl methanol 168b in 51% yield and with 22% ee. 
Similarly, in the presence of 5 mol% of indazole as the additive, the analogous BA4–
mediated reaction was found to give a product yield and ee value of 53 and 23%, 
respectively. 
 
Scheme 2.12: Nitrogen heterocycles employed to induce enantioselectivity. i) BA4 (5 mol%), additive (1 

































2.2.7 Exploring the Use of Chiral Phosphoramide Catalysts 
With the low to moderate product ee values obtained from the reactions of 166b 
mediated by the phosphoric acid catalysts, attention was turned to exploring the more 
acidic BINOL–based phosphoramides (Scheme 2.13).  
The phosphoramide catalyst 208 was first introduced by Yamamoto et al. in studies 
directed toward realising the asymmetric Diels–Alder reaction of a,b-unsaturated 
ketones with siloxydienes to give the resulting Diels–Alder adduct in yields and ee 
values of >99 and ≤93%,  respectively.159 Its synthesis involved the initial boron–
mediated deprotection of 197 to afford the diol 198. Phosphorylation of 198 under 
basic conditions, followed by the addition of TfNH2 in anhydrous propionitrile 
afforded phosphoramide 208. Following flash column chromatography, 
phosphoramide 208 is washed with 6 M HCl to remove any potential metal impurities 
and isolated in 32% yield over three steps.153 The phosphoramides BA21, BA12, 
BA10, BA13,  BA15,  and  BA23  were  synthesised  following  this  procedure.  The   
 
Scheme 2.13: a) BINOL–based phosphoramide catalyst synthesis. i) BBr3 (7 eq.), DCM. ii) Anhydrous DCM, 
distilled Et3N, POCl3, DMAP. iii) TfNH2, anhydrous EtCN. Ar = phenyl, 32% product yield over three steps. b) 
































difficulty associated with this set of syntheses was significant; the sensitivity of the 
proposed PO3Cl intermediate to hydrolysis is considerable and poses a serious obstacle 
to obtaining these catalysts as the only adduct. If the distilled triethylamine or 
propionitrile were not sufficiently dry, the phosphoric acid was obtained. 
With the phosphoramide catalysts in hand, we commenced our investigation by 
examining their ability to asymmetrically catalyse the 1,3–AAI of 166b (Table 2.11). 
In the first instance, the t–butylphenyl–substituted phosphoramide catalyst BA15 was 
examined (entry 1). Treatment of 0.1 mmol of indolinol 166b with 5 mol% of this 
Brønsted acid in p–xylene at room temperature over a 120 h period afforded a 76% 
product yield along with an ee value of 11% (entry 1). Repeating the reaction 
conditions with the biphenyl–substituted catalyst BA21 for 20 h afforded a product 
yield  and  ee  value   of   >99%   and   13%,   respectively   (entry 2).   Similarly,  the  
Table 2.11: Summary of the chiral phosphoramide screen for the Brønsted acid–catalysed 1,3–AAI of 166b 
 
entrya catalyst (5 mol%) time (h) yield (%)b ee (%)c 
1 BA15 120 76 11 
2 BA21 20 >99 13 
3 BA12 1 >99 3 
4 BA23 0.25 >99 2 
5 BA10 0.25 >99 10 
6 BA13 0.25 >99 14 
7d BA13 3 >99 13 
aAll reactions were conducted on a 0.1 mmol scale with catalyst (5 mol%) in p–xylene (1 mL) at RT 
without the exclusion of air or moisture. 
b1H NMR yield CH2Br2 used as internal standard.  
cEnantiomeric excess determined using HPLC, conditions: Daicel Chiralpak OD column, 10% 
IPA/n–hexane, 1.0 mL/min, 25 °C. 














anthracenyl–substituted phosphoramide BA12–mediated reaction after 1 h produced 
168b in >99% yield and 3% ee (entry 3). Changing the catalyst to the phenyl–
substituted BA23 after 0.25 h gave a product yield of >99% along with 2% ee (entry 
4). The naphthyl–substituted Brønsted acid BA10–catalysed reaction provided 
generated 168b in >99% yield and with an ee value of 10% (entry 5). With the 
pyrenyl–substituted phosphoramide BA13 as the catalyst, a product yield and 
enantiomeric excess value of >99 and 14%, respectively, was obtained (entry 6). As 
the BA13–catalysed 1,3–AAI of 166b were found to be the most effective out of this 
set of experiments,  the reaction  conditions were  performed once more in toluene at 
–40 °C (entry 7). The experiment was carried out to determine if a greater degree of 
enantioselectivity could be achieved at a lower  reaction  temperature.  The  switch to 
toluene at this point was necessary as the melting point of p–xylene is ca. 13 °C. 
However, under these latter reaction conditions, a similar outcome was observed, with 
the product being afforded in near quantitative yield and with an ee value of 13%. 
In view of the low product ee values obtained from the BINOL–based Brønsted acids, 
attention was turned to the VANOL– and menthol–based Brønsted acids BA49 and 
BA50 (Figure 2.7). BA49 was prepared in 31% yield over these steps from its diol 209 
involving phosphorylation with POCl3, addition of TfNH2, and acidification (Figure 
2.7a). Cyclopentadieneyl catalyst BA50 was synthesised in three steps following 
reported procedures (Figure 2.7b).160,161 This involved the addition of 
dimethylmalonate to dimethylacetylene dicarboxylate in acidified pyridine and 
subsequent treatment with potassium  acetate to afford the cyclic adduct 212 in 45% 
yield over two steps. Subsequent treatment with an excess of (–)–menthol in the 
presence of N–methylimidazole in toluene at reflux furnished the desired chiral 




Figure 2.7: a) Synthesis of VANOL–based phosphoramide catalyst BA49. i) Anhydrous DCM, distilled Et3N, 
POCl3, DMAP. ii) TfNH2, anhydrous EtCN, 31% yield. b) Synthesis of menthol–based acid catalyst BA50. i) 
Pyridine, AcOH. ii) KOAc; HCl, 45% yield over two steps. iii) (–)–Menthol, NMI, PhMe, reflux, 48 h, 90% yield. 
its reported ability to outperform chiral phosphoric acids in organocatalysis, with 
catalyst loadings as low as 0.01 mol%.33,161 It was envisioned that a Brønsted acid 
containing  a  different  sterically   and space–occupying  backbone  to  that  of  BINOL 
might provide the opportunity to realise a more intimate chiral environment for 
asymmetric induction. 
We moved to investigate the effect of these catalysts on the 1,3–AAI of 166b to indolyl 
methanol 168b (Table 2.12). This revealed that subjecting 0.1 mmol of indolinol 
substrate 166b to 5 mol% of BA49 in p–xylene at room temperature for 120 h 
furnished 168b in 47% yield and 2% ee (entry 1). Repeating the reaction conditions 
with BA49 in DCM was able to reduce the reaction time to 20 h to deliver a product 
yield of >99% and with a 13% ee value (entry 2). The analogous reaction with the 




















































to lead to a product yield of 64% along with an ee value of 4% (entry 3). Similarly, 
changing to solvent to DCM was observed to give a similar outcome, with 168b 
furnished in 60% yield and with 3% ee (entry 4). 
Table 2.12: Summary of the VANOL– and (–)–menthol–based Brønsted acid–catalysed 1,3–AAI of 166b. 
2.2.8 Evaluating the Migrating Group 
With an asymmetric 1,3–AAI of 166b remaining elusive, we speculated whether a 
larger alkoxy migrating group in place of the hydroxyl motif might lead to an increase 
in product enantioselectivity. We postulated that a larger and more sterically 
demanding alkoxy motif might migrate more slowly and, in the process, participate in 
stronger hydrogen–bonding interactions with the catalyst. The alkoxyindole product 
might also be anticipated to be less prone to undergo racemisation under the acidic 
reaction conditions. With this in mind, the 3–indolyl methyl ether 166b–Me was 
prepared in 72% yield by treating the alcohol substrate 166b to MeI under basic 
conditions in THF (Scheme 2.14). Likewise, the indole benzyl ether 166b–Bn was 
synthesised in 81% yield by exposing indole alcohol 166b to BnBr under basic 
conditions  in  THF. Treating the 3–indolyl methyl ether 166b–Me to 5  mol%  of  the  
 
entrya catalyst (5 mol%) solvent time (h) yield (%)b ee (%)c 
1 BA49 p–xylene 120 47 2 
2 BA49 DCM 20 >99 13 
3 BA50 p–xylene 120 64 4 
4 BA50 DCM 120 60 3 
aAll reactions were conducted on a 0.1 mmol scale in solvent (1 mL) with catalyst (5 mol%) at RT 
without the exclusion of air or moisture. 
b1H NMR yield CH2Br2 used as internal standard. 
cEnantiomeric excess determined using HPLC, conditions: Daicel Chiralpak OD column, 10% 















Scheme 2.14: Investigations into the effect of a larger migrating group on enantioselectivity. a) (i) MeI (1.1 
eq.), NaH (1.1 eq.), THF, 72% yield. (ii) BA4 (5 mol%), p–xylene, RT, 120 h, 12% yield, 12% ee, 88% yield 
rcsm. b) (iii) BnBr (1.1 eq.), NaH (1.1 eq.), THF, 81% yield. (iv) BA4 (5 mol%), p–xylene, RT, 120 h, 65% yield, 
0% ee. 
Bronsted acid BA4 in p–xylene at room temperature for 120 h revealed the 
isomerisation product 168b–Me was furnished in 12% yield along with an 
enantiomeric excess of 12%.  The  starting  material  166b–Me  was recovered in 88% 
yield after column chromatography. Under similar reaction conditions, the BA4–
catalysed isomerisation of the 3–indolyl benzyl ether 166b–Bn was found to give the 
corresponding 2–benzyloxy–1H–indole adduct 168b–Bn as a racemate in 65% yield. 
2.3 Conclusion 
In summary, a wide variety of chiral Brønsted acid catalysts, shown in Figure 2.8, and 
reaction conditions were  investigated  to  identify  the  optimum conditions to mediate 
the first asymmetric 1,3–AAI of 3–indolinols to 2–indolyl methanols. Although 
excellent yields and short reaction times were achieved, the asymmetric 1,3–allylic 
alcohol isomerisation to provide indolyl methanols in a highly enantioselective manner 
remained unrealised. Our studies showed the best result obtained was accomplished 





























Figure 2.8: Chiral Brønsted acid catalysts employed during this cycloisomerisation/1,3–AAI study. 
conditions afforded the 1,3-AAI product 168b in 92% yield with an ee value of 20% 
(Scheme 2.15a). During the course of this work, Ramasastry and co–workers also 
reported a one–pot procedure involving AgOAc–catalysed 5–exo–dig cyclisation of 
165c to 166c and subsequent Brønsted acid–mediated 1,3–AAI to indolyl methanol 
168c (Scheme 2.15b).162 The conditions employed in this latter study involved the use 
of 10 mol% of the VAPOL–based Brønsted acid BA48 in 1,2–dichloroethane for 48 h 
which gave 168c in 22% yield with an ee value of 92%. Thus, our findings, and that 
of the Ramasastry group, have shown that the asymmetric 1,3–AAI reaction remains 




















































































Scheme 2.15: a) Optimised conditions for the 1,3-AAI of 166b to 168b. (i) BA4 (5 mol%), DCM, RT, 120 h. b) 
Works reported by Ramasastry et al. towards an asymmetric 1,3–AAI. (i) AgOAc (2 mol%), DCE, 60 °C, 3 h, 







































3.0 Brønsted Acid–Catalysed Allylic Amination 
of 1–(2–Aminoaryl)prop–2–en–1–ols to 
1,2–Dihydroquinolines 
3.1 Introduction 
The quinoline heterocycle features prominently in a myriad bioactive natural products 
and functional materials (Figure 3.1).163–165 For example, natural products containing 
the quinoline motif include the alkaloid virantmycin 213, an antiviral agent active 
against various viral strains,166,167 martinellic acid 214,168 found in the root of the 
tropical  plant  Martinella   iquitosensis,  and  angustureine  215,169  isolated  from  the  
 
Figure 3.1: a) Selected quinoline derivatives featured in natural products. b) Selected pharmacologically 




















































































South American Galipea officinalis tree bark (Figure 3.1a). The activity of 
pharmacologically relevant quinolines include the antibacterial agent 216, shown to 
be effect against various strains including E. coli and S. aureus (Figure 3.1b). 
Antitumour agent 217 has displayed activity against breast cancer cell lines, and the 
hormone inhibitor 218 functions as a cholesteryl ester transfer protein inhibitor.170–175 
Quinolines have also been found to be an important component in dye–sensitized solar 
cells such as 219, and the monoazo dye 220 (Figure 3.1c). In addition to this is their 
application as a ligand such as the chiral phosphine–phosphoramidate used for  
asymmetric metal–catalysed hydrogenations of olefins.176–179 The N–heterocyclic 
motif, both fully and partially hydrogenated, is also a versatile building block in 
various strategies to synthetically valuable products.180–187 As a result, the discovery 
of efficient synthetic methods using mild conditions to produce this member of the N–
heterocyclic family continues to be actively pursued.45,180a 
Recent reports have demonstrated both Brønsted and Lewis acid–catalysed reactions 
of allylic and homoallylic alcohols to be powerful synthetic tools to rapidly increase 
molecular complexity.45,188a For instance, we recently described a method for the 
synthesis of 1,2–dihydroquinolines in 42–91% yield that relied on Au(III)–catalysed 
allylic amination of 1–(2–aminoaryl)prop–2–en–1–ols (Scheme 3.1a).187 Following 
this work, Rueping et al. reported an asymmetric approach to 2H–chromenes in 61–
95% yield and 86–96% ee from the chiral Brønsted acid–catalysed intramolecular 
allylic substitution of 2–(1–hydroxy–3–arylallyl)phenols (Scheme 3.1b).196 The 
prospect of scale–up strategies for the Au(III)–mediated protocol for 1,2–
dihydroquinolines synthesis were deemed low, however, due to the need for high 
catalyst  loadings  and  cost  of  the  metal  salts. In  this  context,  it was  proposed  




Scheme 3.1: a) Au(III)–catalysed allylic amination. i) AuCl3 (5 mol%), AgSbF6 (15 mol%), PhMe, RT, 1 h. 18 
examples, 42–91% yield. b) Brønsted acid–catalysed allylic substitution. ii) H8–BA23 (5–10 mol%), PhMe, –
78 °C, 24 h. 14 examples 61–95% yield, 84–96% ee.  
the development of the Brønsted acid–mediated version of this N–heterocyclic–
forming transformation could form the basis for readdressing these limitations. Low–
cost, commercially available, and highly tolerant to air and moisture, Brønsted acids 
have been demonstrated to be versatile for catalysing a broad range of functional group 
transformations.197 We were also encouraged by the outcome of an experiment in an 
earlier study that revealed the p–TsOH–mediated reaction of the 1,2–amino alcohol 
169 provided the expected N–heterocycle 171a in 13 % yield (Scheme 3.2a). Added 
to this was a recent report detailing a thiourea–HBr co–catalytic procedure, although 
restricted to aryl–substituted starting materials, that allowed access to the N–
heterocycle.45,183 In this chapter, we describe the Brønsted acid–mediated allylic 
amination of a variety of 1–(2–aminoaryl)prop–2–en–1–ols (Scheme 3.2b). Achieved 
at  a  low  catalyst  loading  of  0.01  mol%,  a  series  of  1,2–dihydroquinolines  were  
 
Scheme 3.2: Brønsted–mediated allylic amination of 1–(2–aminoaryl)prop–2–en–1–ols 169. (i) p–TsOH (5 
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obtained in good to excellent yields without the need for the exclusion of air or 
moisture. 
3.2 Results and Discussion 
3.2.1 The Synthesis of the Starting Materials 
All 1–(2–aminoaryl)prop–2–en–1–ols presented in this study were prepared from the 
appropriate o–anilinyl methyl ketones in three steps using known methods (Scheme 
3.3).198 This involved  an  initial  base–catalysed  aldol  condensation  of  ketone 224 
with the appropriate aldehyde to give the enone 225. This is followed by sulfonylation 
with 4-toluenesulfonyl chloride and pyridine to afford a range of N–sulfonyl chalcones 
226. Subsequent NaBH4–mediated reduction of the aryl ketone allowed access to the 
secondary allylic alcohol substrate 169 (R3 = H) in 53–90% yield over three steps. 
Alternatively, reaction of 226 with the appropriate Grignard reagent provided the 
tertiary allylic alcohol substrates 169 (R3 = aryl, alkyl) in 51–90% yield over three 
steps. 
 
Scheme 3.3: Synthesis of 1–(2–aminoaryl)prop–2–en–1–ols 169 from o–anilinyl methyl ketones 224. i) 
R2CHO, NaOH, EtOH, 56–87% yield. ii) R4SO2Cl, Pyridine, 86–98% yield. iii) R3 = H: NaBH4 (5 eq.), MeOH, 53–
90% yield, or R3 = aryl/alkyl: R3MgBr (5 eq.), THF, 51–76% yield. 
3.2.2 Optimisation of the Reaction Conditions 
With allylic alcohol 169b as the model substrate, we commenced our study to identify 
the optimum Brønsted acid-catalysed dehydrative cyclisation conditions (Table 3.1). 
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Table 3.1: Optimisation of the reaction conditions for the Brønsted acid–mediated cyclisation of allylic 
alcohol 169b to 2H–quinoline 171b. 
 
entrya catalyst loading (%) solvent time (h) yield (%)b 
1 p–TsOH 10 PhMe 72 32 
2 12 M HCl 10 PhMe 16 33 
3 (PhO)2PO2H 10 PhMe 16 20 
4 TfOH 10 PhMe 0.25 79 
5 TfOH 10 DCM 3 47c 
6 TfOH 10 THF 4 52c 
7 TfOH 10 EtOAc 3 38c 
8 TfOH 10 MeCN 2 41c 
9 TfOH 10 EtOH 3 46c 
10 TfOH 1 PhMe 1 65 
11 TfOH 0.1 PhMe 2 76 
12 TfOH 0.01 PhMe 3 78 
13 TfOH 0.01 DCM 6 45 
aAll reactions were conducted on a 0.2 mmol scale in solvent (2 mL) without the exclusion of air or 
moisture. 
bIsolated yield.  
c1H NMR yield determined using CH2Br2 as the internal standard. 
temperature for 72 h produced 171b in 32% yield (entry 1). Conducting the reaction 
with 12 M HCl or diphenylphosphinic acid as the catalyst in place of p–TsOH afforded 
product yields of 33% and 20%, respectively (entries 2 and 3). To explore the effects 
of a more acidic catalyst, when TfOH in place of p-TsOH was employed, the desired 
quinoline was afforded in 79% yield after 0.25 h (entry 4). Subsequent 
experimentation focussing on the effect of solvent on the desired transformation with 
TfOH as the catalyst revealed employing dichloromethane gave the desired N–











with either THF or EtOAc as the solvent, affording product yields of 52 and 38% after 
4 and 3 h, respectively (entries 6 and 7). No improvement in product yield was found 
on repeating the reaction in more polar solvents such as MeCN and EtOH (entries 8 
and 9). In these experiments, product yields of 41 and 46% were obtained after 2 and 
3 h. With toluene found to be the best solvent, the reaction at different catalyst loadings 
was next explored (entries 10–13). This found that decreasing the catalyst loading from 
10 to 1 to 0.1 to 0.01 mol% showed no significant loss in conversion, with 171b 
obtained in 65–78% yield (entries 10–12). In each experiment, however, a ten–fold 
decrease in catalyst loading did require an additional hour of reaction time. However, 
the analogous reaction at a catalyst loading of 0.01 mol% with DCM in place of toluene 
was shown to give a lower product yield of 45% after 6 h (entry 13). Based on the 
above results, the optimum reaction conditions for the transformation of 169b to 171b 
was found to be 0.01 mol% of TfOH in toluene at room temperature for 3 h (entry 12).  
3.2.3 Determining the Scope of the Catalytic Method 
To assess the generality of the present optimised procedure, our attention next turned 
to the reactions of a number of 1–(2–aminoaryl)prop–2–en–1–ols 169a and 169c–o 
(Scheme 3.4). In general, these studies demonstrated that the TfOH–mediated 
experimental conditions were wide in scope and an array of substituted 1,2–
dihydroquinolines 171c–o could be afforded in good to excellent yields. Reactions of 
substrates with an electron–withdrawing or –donating group featured at the para–
position of the styryl group 169c–e were found to be well tolerated and furnished the 
corresponding products 171c–e in good to excellent yields of 64–93%. Similarly, 
substrates with an electron–withdrawing group at the para–position of the anilinyl 




Scheme 3.4: TfOH–catalysed allylic amination of 1–(2–aminoaryl)prop–2–en–1–ols 169. i) All reactions 
were conducted on a 0.2 mmol scale with TfOH (0.01 mol%) in toluene (3 mL) at room temperature for 
2–10 h. Values in parentheses denote isolated product yields. 
dihydroquinolines 171f and 171g in yields of 63 and 81%, respectively. The reaction 
of a starting alcohol featuring an ortho–nosyl–protected group (169h) cyclised 
smoothly, giving 171h in a product yield of 65%. Substrates with a pendant alkyl 
(169i,j) or cycloalkyl (169k,l) group at the tertiary carbinol carbon centre were also 
found to provide the corresponding 1,2–dihydroquinolines 171i–l in 45–80% yield, 
with the structure of 171j determined by X–ray crystallographic analysis (Figure 3.2). 
The reactions of tertiary alcohol substrates featuring an aryl (169m and 169n) or 
thiophenyl (169o) moiety were revealed to proceed well. These experiments delivered 





















171c, R = Cl (88%)
171d, R = Br (93%)
171e, R = OMe (71%)
171f, R = Br (63%)
171g, R = F (81%)
171h (65%)



































171m and 171n were also confirmed by X–ray crystallographic analysis (Figure 3.3). 
However, the present protocol was discovered to be restricted to substrates comprising 
an aryl–substituted alkene motif. The TfOH–mediated experiment of 169a, containing 
a terminal alkene moiety, was found to produce a mixture of decomposition products 
that could not be identified by 1H NMR analysis.  
On the other hand, the present Brønsted acid–meditated allylic aminations revealed 
that the nitrogen ring–forming reaction was highly selective, with the 1,2–
dihydroquinolines being obtained as a single product. The potential for the formation 
of side–products as a consequence of competitive hydroamination, Friedel–Crafts or 
dehydration reactions were not observed by 1H NMR measurements of the crude 
reaction mixtures. With these results in hand, we next examined whether the analogous 
asymmetric reaction of the newly designed Brønsted acid–catalysed process could be 
realised. 
  
Figure 3.2: ORTEP drawing of 4–phenethyl–2–phenyl–1–tosyl–1,2–dihydroquinoline 171j with thermal 





Figure 3.3: a) ORTEP drawings of 4–(2–methoxyphenyl)–2–phenyl–1–tosyl–1,2–dihydroquinoline 171n 






3.2.4 Development of the Chiral Brønsted Acid–Catalysed 
Asymmetric Allylic Amination of 1–(2–Amino)prop–2–en–
1–ols 
To evaluate whether an asymmetric version of the present 1,2–dihydroquinoline 
formation reaction could be realised, the cyclisation of allylic alcohol 169b mediated 
by a variety of chiral Brønsted acids were investigated (Table 3.2). Our study 
commenced with the treatment of the substrate 169b with 5 mol% of the biphenyl–
substituted phosphoramide catalyst BA1 in toluene at room temperature for 0.3 h 
(entry 1). The reaction proceeded smoothly, giving a product yield of 74% and an 
enantiomeric excess value of 27%. Decreasing the reaction temperature to 0 °C for 2 
h was found to improve the product yield and ee value to 89 and 35%, respectively 
(entry 2). The  introduction  of 4 Å MS to these latter reaction conditions gave a lower  
 


















































product yield of 50% and an ee value of 37% (entry 3). Unfortunately, the anthracenyl–
substituted phosphoramide catalyst BA12 was unable to catalyse the desired 
cyclisation and no reaction was observed (entry 4). In contrast, the anthracenyl–
substituted phosphoric acid variant BA4 was found to catalyse the reaction at room 
temperature for 30 h, affording the desired product 171b in 70% yield and with 17% 
ee (entry 5). The 1–naphthyl–substituted phosphoramide catalyst BA10 was next 
examined at 0 °C for 2 h and was shown to catalyse the desired transformation to give 
a product yield of 49% along with 2% ee (entry 6). Under similar reaction conditions,  
Table 3.2: Optimisation of the asymmetric allylic amination of 1–(2–aminoaryl)prop–2–en–1–ol 171b. 
 
entrya catalyst time (h) temp. (°C) yield (%)b ee (%)c 
1 BA21 0.3 RT 74 27 
2 BA21 2 0 89 35 
3d BA21 2 0 50 37 
4 BA12 2 0 0 – 
5 BA4 30 RT 70 17 
6 BA10 2 0 49 2 
7 BA13 2 0 40 6 
8 BA15 24 0 0 – 
9 BA48 27 RT 58 25 
10e BA50 27 RT 0 – 
aAll reactions were conducted on a 0.2 mmol scale at RT in toluene (2 mL) with catalyst (5 mol%) 
without the exclusion of air or moisture. 
bIsolated yield. 
cEnantiomeric excess determined using HPLC, conditions: Daicel Chiralpak IC column, 15% IPA/n–
hexane, 1.0 mL/min, 25 °C. 
dReaction conducted with crushed 4 Å MS (100 mg). 













the pyrenyl–substituted Brønsted acid BA49 produced the 1,2–dihydroquinoline in 
40% yield and with 6% ee (entry 7). As with BA12, the t–butylphenyl–substituted 
catalyst BA15 was unable to promote allylic amination, leading to no reaction being 
detected by either TLC analysis or 1H NMR measurements (entry 8). Next, the 
VAPOL–based phosphoric acid BA48–catalysed reaction of 169b at room 
temperature for 27 h was found to give the product 171b in 58% yield and with 25% 
ee (entry 9). On the other hand, conducting the reaction with 10 mol% of the menthol–
based cyclopentadienyl acid catalyst BA50 was shown to lead to no product formation 
and the starting material being recovered in near quantitative yield (entry 10). 
With the best results, thus far, comprising the use of the Brønsted acid BA21 under 
the conditions described in Table 3.2, entry 2, the effect of temperature on this 
transformation was next explored (Table 3.3). This revealed treatment of the substrate 
169b to 5 mol% of BA21 in toluene at –40 °C for 4 h led to 171b being obtained in 
62% yield and with  37%  ee  (entry 1).  Repeating  the  transformation  at –78 °C, by  
Table 3.3: Examination of the effect of temperature on the asymmetric allylic amination of 1–(2–
aminoaryl)prop–2–en–1–ol 169b. 
 
entrya time (h) temp. (°C) yield (%)b ee (%)c 
1 4 –40 62 37 
2 10 –78 0 – 
3 2 –60 – RT 74 37 
4 2 –78 – RT 74 37 
aAll reactions were conducted on a 0.2 mmol scale with BA21 (5 mol%) at RT in solvent (2 mL) 
without the exclusion of air or moisture. 
bIsolated yield. 
cEnantiomeric excess determined using HPLC, conditions: Daicel Chiralpak IC column, 15% IPA/n–












contrast, resulted in no reaction with only starting material being recovered in near 
quantitative yield (entry 2). The analogous reaction initiated at –60 °C and allowed to 
warm up to room temperature over 2 h was found to give 171b in 74% yield and 37% 
ee (entry 3). Under similar reaction conditions initiated at –78 °C and allowed to warm 
up to room temperature, gave a similar product yield of 74% and 37% ee (entry 4). 
Overall, the results shown in Table 3.2 and Table 3.3 revealed that the cyclisation of 
1–(2–aminoaryl)prop–2–en–1–ol 169b in the presence of 5 mol% of the biphenyl–
substituted phosphoramide catalyst BA21 at 0 °C in toluene was deemed to provide 
the optimum reaction  conditions. Under  these reaction  conditions, the 1,2–
dihydroquinoline 171b was furnished in 89% yield an ee value of 35%. 
3.2.5 Further Functional Group Transformations 
To demonstrate the versatility of the racemic 1,2–dihydroquinolines obtained from the 
present Brønsted acid–mediated cyclisation protocol, their further functional group 
transformations were investigated (Scheme 3.5). As a first example, treatment of the 
N–heterocycle 171c in DCM to m–CPBA under basic conditions for 6 h was shown to 
afford the epoxide product 227 in 85% yield. In a second example to illustrate the 
potential versatility of the compound class, hydrogenation of the 1,2–dihydroquinoline 
171c in the presence of a catalytic amount of Pd/C (10 wt%) and an atmosphere of 
hydrogen at room temperature for 2 h gave the tetrahydrogenated product 228 in 95% 
yield. 
 
Scheme 3.5: Modification of 171c. a) Epoxidation of 171c to 227. (i) m–CPBA, NaHCO3, DCM, 0 °C, 85% 


















3.2.6 Proposed Reaction Mechanism 
A tentative reaction mechanism for the Brønsted acid–catalysed transformation of 1–
(2–aminoaryl)prop–2–en–ols to 1,2–dihydroquinolines is shown in Scheme 3.6. It is 
proposed to proceed in a similar manner to that for the analogous Au(III)–mediated 
allylic amination reactions.200 This process could begin with the protonation of the 
allylic alcohol 169b, as a representative example, by the Brønsted acid catalyst to form 
the oxonium species I–169b. Subsequent dehydration would afford the allylic 
carbocation species II–169b. Nucleophilic attack of the pendant sulphonamide group 
onto the allylic cation in II–169b would result in cyclisation and formation of the 
quinolinium intermediate III–169b. Deprotonation of this newly formed carbocationic 
species by the triflate conjugate base would then deliver the desired 1,2–
dihydroquinoline product. 
 
Scheme 3.6: Proposed reaction mechanism for the Brønsted acid–mediated conversion of 1–(2–





























We surmise the moderate product enantioselectivity obtained could be due to the 
carbocationic intermediate II–169b associating with the conjugate base of the chiral 
Brønsted acid catalyst (Scheme 3.7).181 This gives the chiral contact ion pair species 
IV–169b. This is further assisted by the possibility of IV–169b sitting in a 
conformation that also allows favourable p-p  stacking interactions and potential 
hydrogen–bonding interactions between the nitrogen–containing functional group and 
the chiral conjugate base. The moderate enantioselectivity, however, might be due to 
the formation of an insufficiently intimate ion pair species and/or weakness of the 
aforementioned stereoelectronic interactions.196  
 
Scheme 3.7: Representation of a contact–ion pair between the Brønsted acid catalyst and a dehydrated 
cationic intermediate. i) BA21 (5 mol%), PhMe, 0 °C, 2 h, 89% yield, 35% ee. Enantiomeric excess 
determined using HPLC, conditions: Daicel Chiralpak IC column, 15% IPA/n–hexane, 1.0 mL/min, 25 °C. 
3.3 Conclusion 
In summary, an efficient protocol to access 1,2–dihydroquinolines from 1–(2–
aminoaryl)prop–2–en–1–ols that relies on a Brønsted acid–catalysed allylic amination 
has been presented (Scheme 3.8). The reaction was found to be robust, tolerating a 
wide variety of substrate substitution patterns, and complimenting the metal–catalysed 
version of this transformation. The effectiveness of the present operationally simple 






















with a low catalyst loading of 0.01 mol%. The protocol was also shown to be selective 
with no evidence of products arising from Friedel–Crafts reactions, dehydration 
processes, or competitive hydroaminations observed. This is notable given the need 
for more expedient and direct atom–economical method that can utilise low–cost and 
readily available reagents and catalysts. 
 
Scheme 3.8: A Brønsted acid-mediated cyclisation protocol as an efficient approach to 1,2–
dihydroquinoline 171 derivatives from 1–(2–aminoaryl)prop–2–en–1–ols 169. (i) TfOH (0.01 mol%), PhMe, 
























4.0 Brønsted Acid–Catalysed Cyclisation of b–
Amino–1,4–enols to Oxazol–2(3H) –ones 
and 5–Alkenyloxazolidin–2–ones 
4.1 Introduction 
Oxazolidinone–containing compounds are immensely important targets in organic 
chemistry and have, over the years, received a significant amount of attention due to 
their biological significance and versatility in organic synthesis as a ligand and 
intermediate (Figure 4.1).201–215 A prominent example is the development of the 
oxazolidinone–containing linezolid 229 marketed as Zyvox®, one of only three new 
antibiotic  drug classes  approved  by  the  Food  and  Drug Administration  in  the  last 
 
Figure 4.1: a) Selected pharmacologically relevant oxazolidinones. b) Selected functional molecules 



















































































thirty years.216 Linezolid is an antibiotic treatment for drug–resistant, gram–positive 
bacterial infections in strains such as Streptococci and Enterococci, for use particularly 
when other antibiotics have failed to perform.217,218 Other pharmaceutical compounds 
include tedizolid 230, a bacterial protein synthesis inhibitor, and the pyridyl–
substituted antifungal oxazolidinone 231.204 Oxazolidinones such as the benzyl–
substituted adduct 232 developed by Evans and co–worker have also been shown to 
be versatile chiral auxiliaries in a range of asymmetric reactions.219,220 The O,N–
heterocyclic ring system features heavily in polymerised materials such as the poly–
2–oxazolidinone varnish 233 as well as in various other applications from tablet 
coatings, lubricant additives, dye assistants, to rust inhibitors.221,222 Natural products 
containing the oxazolidinone structure include LL–BM123g2 234, a gram–negative 
antibacterial agent,223 cytoxazone 235, a bacterial cytokine synthesis inhibitor,204 and 
(+)–streptazolin 236, a natural product isolated from the bacterium Streptomyces 
viridochromogenes.224 This versatility of the oxazolidinone ring system has led to a 
plethora of methods for their construction (Scheme 4.1).  
Typically, access to this compound class has employed phosgene or chloroformate as 
carbonyl precursors (Scheme 4.1a).225–228 In addition, the cyclisation of propargylic 
carbamates 239 have been extensively explored and shown to proceed with a range of 
catalysts such as Au,229 Ag,230,231 Brønsted base,232,237 Cu,238 NHCs,239 and Pd 
(Scheme 4.1b).240,241 As a carbonyl surrogate, CO2 has been utilised with propargyl 
alcohols 241 in conjunction with amines to afford oxazolidinones in the presence of 
Cu,242,243 ionic liquids,242,244 Ag,245 and phosphines (Scheme 4.1c).246,247 The utility of 
CO2 to generate the heterocycle from amino alcohols 240 has also been demonstrated 




Scheme 4.1: Reported methods for the generation of the 2–oxazolidinone ring. 
(Scheme 4.1d).248 Added to this have been Pd–mediated synthetic methods that make 
use of amino alcohols with CO to produce the oxazolidinone adduct (Scheme 4.1e).249–
252 All these synthetic methods, however, often require the presence of metal salts and 
the use of high reaction temperatures and pressures. Other limitations include poor 
solubility of the reagents, high catalyst loadings, long reaction times, and expensive 
and/or toxic catalysts. For these reasons, the development of novel, efficient, and low–
cost synthetic protocols continue to be pursued in organic chemistry.239a  
In this regard, we queried whether a Brønsted acid–catalysed synthetic method could 
be realised to assemble the O,N–heterocyclic ring system. In recent years, a growing 
number of reports have shown the utility of a broad range of p –rich alcohols as starting 
materials in Brønsted acid–mediated C–C bond formation protocols.253 This has 
included synthetic methods that direct the intermediate carbocationic species, 
produced under such acidic reaction conditions, to engage in cyclisation pathways to 
furnish cyclic compounds of potential synthetic value.254 An example of this is the 
enantioselective asymmetric N–triflyl phosphoramide–mediated dehydrative 
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from electron–rich aryl and 2–thienyl vinyl b–amino alcohols (Scheme 4.2a).256 
Building on these developments, we queried the potential for intercepting the expected 
carbocationic intermediate I–242 by a pendant t–butyl carbamate group (N–Boc) 
rather than a dehydrative electrocyclization (Scheme 4.2b). We envisioned that, by 
fine–tuning the reaction conditions, we could achieve this aim by promoting the 
simultaneous decomposition of the N–protecting group and the dehydration of the 
carbinol alcohol to provide the reputed carbonic acid species II–242. This ensuing 
carbocationic species could subsequently participate in a cyclisation pathway 
commencing with addition of the carbonyl oxygen centre to the allylic carbocation to 
deliver either the oxazol–2(3H)–one 174, or the 5–alkenyloxazolidin–2–one 175 when 
R1, R2 ¹ H. In this chapter, we describe our development of this chemistry that provides 
a practical synthetic method to access these two members of the O,N–heterocyclic 
compound class from electron–rich secondary and tertiary aryl vinyl b–amino alcohols 
under mild atmospheric conditions. 
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4.2 Results and Discussion 
4.2.1 The Synthesis of the Starting Materials 
All N–Boc amino alcohols 172 examined in the present work were prepared following 
known experimental procedures (Scheme 4.3).269 The synthetic route involved initial 
a–bromination of acetophenone 244 to afford the a–bromoketone 245. After 
recrystallisation, this substrate was subjected to amination conditions with 
hexamethylenetetramine followed by acid–mediated hydrolysis to afford the 
ammonium salt 246. For compounds where R1 = p–OMe, treatment of the ammonium 
salt with di–t–butyl dicarbonate under basic conditions gave the N–Boc ketone 247 in 
68% yield. Subjecting the acetamide 247 to aldol condensation with the appropriate 
aldehyde afforded the desired a,b–unsaturated ketone 248. Subsequent NaBH4–
mediated reduction of the carbonyl compound provided access to the secondary allylic 
alcohol substrate 172 in 62% yield over two steps. Alternatively, Grignard addition of 
p–methoxyphenylmagnesium bromide to 248 produced the tertiary allylic alcohol 
substrate in 71% yield over two steps. 
 
Scheme 4.3: Synthesis of N–Boc amino alcohols 172 from the appropriate acetophenones. R1, R2 = H, R3 = 
H or Me. i) NBS (1.15 eq.), p–TsOH (10 mol%), MeCN; or Br2 (1 eq.), DCM, <3 °C. ii) 
Hexamethylenetetramine (1.1 eq.), CHCl3, 60 °C, then conc. HCl, EtOH. iii) Boc2O (1.5 eq.), Na2CO3 (1.5 eq.), 
DCM, 68% yield over three steps. iv) RCHO (1.2 eq.), piperidine (10 mol%), propionic acid (20 mol%), 
PhMe. v) NaBH4 (3 eq.), EtOH, 0 °C–RT, 62% yield over two steps; or R3MgX (4.5 eq.), THF, –78 °C–RT, 71% 



























The synthetic route outlined in Scheme 4.3, however, was found to be incompatible 
for the preparation of certain substrates (Scheme 4.4). When treated with 1.1 
equivalents of hexamethylenetetramine in chloroform, the a–bromoketones 245w and 
245x failed to afford the desired ammonium salts 246w and 246x. Similarly, the 
analogous reactions with heteroaryl a–bromoketones 245a–g were also unable to 
furnish the corresponding ammonium hydrochloride salts 246a–g. It was also found 
that the ketone precursors to the desired b–amino–1,4–enols 172y and 172z were 
unable to withstand the reducing conditions outlined in Scheme 4.4. As a result, only 
a mixture of unidentifiable decomposition products was produced as determined by 1H 
NMR measurements of the crude reaction mixtures. 
 
Scheme 4.4: Synthesis of secondary b–amino–1,4–enols 172. i) Hexamine (1.1 eq.), CHCl3, 60 °C, then 
conc. HCl, EtOH. ii) Boc2O (1.5 eq.), Na2CO3 (1.5 eq.), DCM. iii) RCHO (1.2 eq.), piperidine (10 mol%), 
propionic acid (20 mol%), PhMe. iv) NaBH4 (3 eq.), EtOH, 0 °C–RT. 
The synthesis of a further set of substrates 248d–i derived from the aldol condensation 
of the N–Boc–protected ketone 247a with the appropriate aldehydes was found to be 
unsuccessful (Scheme 4.5). In each case, only a mixture of the starting materials or 
unidentifiable decomposition products were produced as determined by 1H NMR 











245w (R = cyclopropyl)
245x (R = cyclohexyl)
245y (R = 2-furyl)
245z (R = 2-thienyl)
245α (R = 3-methylphenyl)
245β (R = 4-ethylphenyl)
245γ (R = 5-benzo[d][1,3]dioxole)
246w (R = cyclopropyl, 0%)
246x (R = cyclohexyl, 0%)
246y (R = 2-furyl, 86%)
246z (R = 2-thienyl, 79%)
246α (R = 3-methylphenyl, 0%)
246β (R = 4-ethylphenyl, 0%)
246γ (R = 5-benzo[d][1,3]dioxole, 0%)
172y (R = 2-furyl, 0%)




Scheme 4.5: Unsuccessful synthesis of N–Boc a,b–unsaturated ketones 248. (i) RCHO (1.2 eq.), piperidine 
(10 mol%), propionic acid (20 mol%), PhMe. 
4.2.2 Preliminary Studies 
To test the feasibility of our hypothesis, the Brønsted acid–catalysed cyclisations of 
alcohol 172v, selected as the model substrate, were investigated to determine the 
optimum reaction conditions (Table 4.1). Subjecting the substrate to 5 mol%  of  TfOH  
in  DCE   at   room   temperature   for   1   h   gave   the   two   oxazolidinone  positional 
Table 4.1: Summary of the initial screening of conditions of the Brønsted acid–catalysed cyclisation of 
172v. 
 
entrya temp. (°C) 
yield (%)b 
175v 175v’ 243v 
1 RT 29 21 19 
2 –40 –c – – 
3 –78 –c – – 
4 70 38 28 5 
aAll reactions were conducted on a 0.2 mmol scale in DCE (2 mL) with TfOH (5 mol%) for 1 h 
without the exclusion of air or moisture. 
bIsolated yield. 










































isomers 175v and 175v’, and the indene 243v in respective yields of 29, 21, and 20% 
yield (entry 1). The structure of the O,N–heterocycle 175v was unambiguously 
determined by X–ray crystallographic analysis (Figure 4.2). To explore whether 
reaction temperature might provide a greater degree of chemoselective control, the 
experiment was next conducted at –40 °C, –78 °C, and 70 °C (entries 2–4). At –40 °C 
and –78 °C, this gave a mixture of unknown decomposition products in both cases, as 
determined by 1H NMR analysis of the crude reaction mixtures. The analogous 
reaction at 70 °C, on the other hand, afforded the three products 175v, 175v’, and 243v 
in 38, 28, and 5% yield, respectively. We postulate that the furnished oxazolidinones 
175v and 175v’ could be due to competitive C–C bond formation at C1 and C3 in the 
premised carbocation intermediate. Indene 243v could result from an alternative 
competitive pathway involving 4p–electrocyclization on formation of the same 
proposed  carbocationic  intermediate.46  Deducing  that  the  high  degree  of  resonance  
 
Figure 4.2: ORTEP drawing of 4–(cyclohexylmethylene)–5,5–diphenyloxazolidin–2–one 175v with 
thermal ellipsoids at 50% probability levels.271 
 
 104 
stabilisation of the carbocation species to be a possible cause for the poor product 
selectivity, we surmised that substrates where these electronic interactions were less 
pronounced might provide a solution to improve chemoselectivity. With this in mind, 
the cyclohexyl–substituted alcohol 172r was chosen and subjected to 5 mol% of TfOH 
in DCE at room temperature for 1h (Scheme 4.6). Under these reaction conditions, a 
4:1 inseparable mixture of the oxazolidin–2–one positional isomers 175r’ and 175r in 
30% yield was obtained. It additionally provided the indene 243r in 54% yield. 
 
Scheme 4.6: Brønsted acid–catalysed reaction of alcohol 172r. i) TfOH (5 mol%), DCE, RT, 1 h. 
Attention was next turned to the TfOH–mediated reaction of secondary b–amino–1,4–
enol substrates 172l–m in which resonance stabilisation might be further reduced due 
to the presence of only one aromatic group (Table 4.2). Exposing 0.2 mmol of the p–
tolyl–substituted substrate 172l to TfOH (5 mol%) in DCE at room temperature for 1 
h afforded the oxazol–2(3H)–ones 174l and 174l’ in 66 and 13% yield, respectively 
(entry 1). The indene adduct was not detected by 1H NMR spectroscopic 
measurements. Repeating the reaction with the p–anisyl–substituted alcohol 172b 
gave a similar outcome, providing 174b and 174b’ in 51 and 23% yield, respectively 
(entry 2). The analogous reaction with the phenyl–substituted substrate 172m was 






















Table 4.2: Summary of the Brønsted acid–catalysed cyclisation of secondary alcohol substrates 172. 
 
entrya substrate R1 
yield (%)b 
174 174’ 
1 l Me 66 13 
2 b OMe 51 23 
3 m H 42 – 
aAll reactions were conducted on a 0.2 mmol scale in DCE (2 mL) with TfOH (5 mol%) at RT for 1 h 
without the exclusion of air or moisture. 
b1H NMR yield determined with CH2Br2 as the internal standard. 
4.2.3 Optimisation of the Reaction Conditions 
With these preliminary results in hand, a determination of the optimum reaction 
conditions for the Brønsted acid–catalysed cyclisation was conducted with the 
secondary b–amino–1,4–enol 172a as the model substrate (Table 4.3). This study 
initially revealed that exposing alcohol 172a to p–TsOH (5 mol%) in EtOAc at room 
temperature under atmospheric conditions for 48 h provided the oxazol–2(3H)–one 
174a and oxazolidine–2–one 175a in 22 and 25% yield, respectively (entry 1). 
Repeating the reaction in EtOH afforded the two O,N– heterocyclic  products  in  yields  
of 13 and 21% (entry 2). In contrast, treating the N–Boc protected alcohol 172a with 
TFA or benzoic acid in place of TfOH was found to result in no reaction observed by 
either TLC analysis or 1H NMR measurements of the crude reaction mixtures (entries 
3 and 4). Our subsequent studies found that the reaction mediated by TfOH in DCM 
furnished 174a and 175a in yields of 59 and 12%, respectively (entry 5). The 



















and 175a in yields of 12 and 33%, respectively (entry 6). Similarly, employing THF 
as the reaction solvent was shown to give 174a and 175a in respective yields of 38 and 
39% (entry 7). Changing the reaction medium to EtOAc as solvent was found to give 
a similar outcome, providing 174a and 175a in yields of 35 and 22%, respectively 
(entry 8). With 1,2–dichloroethane as the solvent, the oxazol–2(3H)–one and 
oxazolidin–2–one adducts were furnished in respective yields of 46 and 9% (entry 9).  
Table 4.3: Optimisation of the reaction conditions for the Brønsted acid–catalysed cyclisation of 172a. 
 
entrya catalyst solvent 
yield (%)b 
174a 175a 
1 p–TsOH EtOAc 22 25 
2 p–TsOH EtOH 13 21 
3 TFA –c –d – 
4 PhCO2H –c –d – 
5 TfOH DCM 59 12 
6 TfOH Et2O 12 33 
7 TfOH THF 38d 39d 
8 TfOH EtOAc 35 22 
9 TfOH DCE 46 9 
10 TfOH (CH3)2CO 27 30 
11 TfOH EtOH 60e – 
12f TfOH EtOH 59e – 
aAll reactions were conducted on a 0.1 mmol scale in solvent (1 mL) with catalyst (5 mol%) at RT 
for 48 h without the exclusion of air or moisture. 
b1H NMR yield determined with CH2Br2 as the internal standard.  
cReaction conducted in DCM, Et2O, THF, EtOAc, DCE, (CH3)2O, and EtOH. 
dNo reaction observed with TLC analysis or 1H NMR measurements of the crude reaction mixtures. 
eIsolated yield. 



















Likewise,  the  analogous  reaction  in  acetone  was  found  to  lead  to 174a  and 175a 
being attained in 27 and 30% yield, respectively (entry 10). In a final set of control 
reactions with EtOH as the solvent, the oxazol–2(3H)–one 174a was obtained as the 
only product in 60% yield (entry 11). A comparable product yield of 59% was afforded 
when the experiment was conducted for a second time at reflux temperature for 1 h, 
which was then deemed to provide the optimum reaction conditions (entry 12).  
4.2.4 Determining the Scope of the Catalytic Method 
To assess the scope of the present synthetic approach, our attention first turned to the 
reactions of a series of secondary b-amino-1,4-enols (Scheme 4.7). In general, the 
cyclisation of starting alcohols 172b–f and 172i–n revealed the Brønsted acid–
catalysed reaction conditions to be wide–ranging, affording the corresponding oxazol–
2(3H)–ones in 42–99% yield. Experiments with diaryl–containing starting materials 
featuring either electron–withdrawing or –donating moieties in the para–position of 
the aromatic rings (172b–d and 172f) were demonstrated to cyclise to give 174b–d 
and 174f in 60–99% yield. The conversion of the five–membered heterocycle 174b to 
the N–tosyl–protected derivative N–Ts–174b enabled the structure of the O,N–
heterocycle to be unambiguously determined by X–ray crystallographic analysis 
(Figure 4.3). Starting materials featuring an alkyl (172i,j) or cyclohexyl (172k) motif 
instead of an aryl group at the enamine carbon centre were found to afford the cyclic 
adducts 174i–k in 86–97% yield. A comparable outcome was found for b–amino–1,4–
enols featuring a para–tolyl and benzyl (172l) or phenyl and benzyl (172m) or 
cyclohexyl (172n) motifs at the carbinol– and enamine–carbon centres, respectively. 
In these transformations, the corresponding oxazol–2(3H)–ones 174l–m were 
furnished in 42–65% yield with 174l also afforded as an inseparable mixture of 




Scheme 4.7: Brønsted acid–catalysed cyclisations of various secondary b–amino–1,4–enols. i) TfOH (5 
mol%), EtOH, reflux, 0.25–1 h. aReaction conducted in 1,2–dichloroethane as the solvent. bProduct was 
obtained as a separable mixture of 174e and 175e in an overall yield of 68% and a ratio = 2.2:1 with 
compound 175e isolated in 21% yield. cProduct was obtained as an inseparable mixture of positional 
isomers in a ratio = 10:1. 
anisyl–containing  starting materials with a p–bromophenyl (172e), 2–benzofuranyl 
(172g), or 2–furanyl (172h) moiety at the enamine carbon centre were revealed to be 
the exception. In the case of the latter two substrates, the oxazolidine–2–ones 175g 
and 175h furnished as were the only products with respective yields of 68 and 51%. 
For the cyclisation of 172e, a separable mixture of both the oxazolidine–2–one 175e 


































174b, R = H (62%)
174c, R = CF3 (98%)a
174d, R = NO2 (60%)a
174e, R = Br (47%)b
174f (99%)






174l, R = Me (65%)c



















Figure 4.3: ORTEP drawing of 4–benzylidene–5–(4–methoxyphenyl)–3–tosyloxazolidin–2–one N–Ts–
174b  with thermal ellipsoids at 50% probability levels.271 
To further assess the generality of the present Brønsted acid–mediated procedure, the 
cyclisation of various tertiary b–amino–1,4–enols was next examined (Scheme 4.8). 
This initially revealed that substrates possessing geminal di–p–anisyl motifs at the 
carbinol carbon centre in conjunction with a p–(trifluoromethyl)phenyl (172o) or 
cycloalkyl (172p and 172q) motif gave the appropriate five–membered heterocycle 
175o–q in yields of 70–99%. Under the optimised TfOH–mediated reaction 
conditions, the cyclisation of 172r, featuring geminal diphenyl motifs and a cyclohexyl 
group at the respective carbinol carbon and enamine carbon centres, provided the 
corresponding oxazolidin–2–one 175r in 87% yield. The structure of the O,N–
heterocycle was unambiguously confirmed by X–ray crystallographic analysis (Figure 
4.4). Likewise, starting alcohols containing gem–dimethyl groups at the carbinol 
carbon centre and a phenyl (172s), 2–furyl (172t), or 2–benzofuryl (172u) at the 
enamine carbon centre afforded the appropriate five–membered heterocyclic adducts 




Scheme 4.8: Brønsted acid–catalysed cyclisations of various tertiary b–amino–1,4–enols 172. i) TfOH (5 
mol%), EtOH, reflux, 0.25–1 h. 
 
 
Figure 4.4: ORTEP drawing of 4–benzylidene–5,5–diphenyloxazolidin–2–one 175r with thermal ellipsoids 
















































175o, (70%) 175p, n = 1 (99%)
175q, n = 4 (99%)
175r, (87%)




4.2.5 Proposed Reaction Mechanism 
In view of the results obtained and previous work, a postulated Brønsted acid–
catalysed reaction mechanism is illustrated in Figure 4.5.46 This process might begin 
with Brønsted acid–mediated protonation of the carbinol oxygen centre of the amino 
alcohol 172 to generate the protonated species I–172. This intermediate may then 
undergo dehydration to generate the carbocationic species II–172. Subsequent 
cyclisation through addition of the carbonyl oxygen centre to the allylic carbocation 
motif in II–172 to deliver the five–membered oxonium adduct III–172. Elimination 
of the tert–butyl motif in the form of isoprene via deprotonation of one of the methyl 
groups would then produce the oxazolidin–2–one 175. For substrates where R2 = H,  a  
further  step  involving  isomerisation  of  the  O,N–heterocycle  would  afford  the 
more stable oxazol–2(3H)–one 174. Although the reason for the generation of both 
174d and 175d remains unclear, the favoured formation of 175f and 175g could be 
due  to  the  potential for H–bonding between the amino group of  the  cyclic  carbamate  
 


















































and the oxygen centre of the O–heterocycle in these compounds. This H–bonding has 
the potential to hinder the isomerisation of these adducts to their corresponding 
oxazol–2(3H)–ones 174f and 174g. 
4.3 Conclusion 
In summary, a Brønsted acid–mediated method for the efficient cyclisation of 
secondary b–amino–1,4–enols to oxazol–2(3H)–ones 174 has been developed 
(Scheme 4.9). The synthetic protocol was also shown to be applicable to the cyclisation 
of tertiary alcohols to give the corresponding 5–alkenyloxazolidin–2–ones 175. This 
transformation has been achieved without the need to exclude air or moisture and was 
demonstrated to be applicable to substrates containing a wide variety of substitution 
patterns. The synthetic approach compliments the analogous transition metal–
catalysed transformations to these two members of the five–membered O,N–
heterocyclic family of compounds.  
 
Scheme 4.9: A Brønsted acid–mediated cyclisation protocol as an efficient approach to oxazol–2(3H)–one 
174 and 5–alkenyloxazolidin–2–one 175 derivatives from the respective secondary and tertiary b–amino–
































5.0 Concluding Remarks 
In summary, this thesis has explored new reactivities of alcohols as pro–electrophiles 
in the field of Brønsted acid catalysis. In Chapter 2, the efforts towards realising the 
first asymmetric 1,3–allylic alcohol isomerisation of 3–indolinols to 2–indolyl 
methanols was discussed (Scheme 5.1). A broad selection of chiral Brønsted acid 
catalysts were screened during the investigation into defining the optimum 
enantioselective reactions conditions, and although excellent yields and short reaction 
times were achieved, the asymmetric 1,3–AAI was unable to provide indolyl 
methanols in a highly enantioselective manner. It was proposed that the asymmetric 
Brønsted acid catalysts employed in this study were unable to form a sufficiently 
intimate contact ion pair transition state for the transfer of stereochemical information 
from the catalyst anion to the substrate carbocation. 
 
Scheme 5.1: Chiral Brønsted acid–mediated 1,3–AAI of 3–indolinols 166b to 2–indolyl methanols 168b. 
In Chapter 3, the development of a Brønsted acid–mediated allylic amination to access 
1,2–dihydroquinolines from 1–(2–aminoaryl)prop–2–en–1–ols was discussed 
(Scheme 5.2). This was achieved with an operationally simple and efficient synthetic 
protocol that employed TfOH at a low catalyst loading of 0.01 mol% under ambient 
conditions. This method was shown to be robust, tolerating a variety of substrate 






















Scheme 5.2: A Brønsted acid-mediated cyclisation protocol as an efficient approach to 1,2–
dihydroquinoline 171 derivatives from 1–(2–aminoaryl)prop–2–en–1–ols 169. (i) TfOH (0.01 mol%), PhMe, 
air, RT. 
In Chapter 4, the Brønsted acid–catalysed cyclisation of b–amino–1,4–enols 172 as a 
new synthetic strategy to the oxazol–2(3H)–ones 174 and 5–alkenyloxazolidin–2–
ones 175 was discussed (Scheme 5.3). This dehydrative process was accomplished 
without the need to exclude air or moisture and was shown to tolerate a variety of 
substrate substitution patterns to provide these O,N–heterocycles in good to excellent 
yields. 
 
Scheme 5.3: A Brønsted acid–mediated cyclisation protocol as an efficient approach to oxazol–2(3H)–one 
174 and 5–alkenyloxazolidin–2–one 175 derivatives from the respective secondary and tertiary b–amino–
















































6.1 General Information 
1H, 13C, 31P, and 19F NMR spectra were measured on a Bruker Avance 300, 400, 500, 
or 600 MHz spectrometers at room temperature (298 K). Chemical shifts (d ) are 
recorded in parts per million (ppm) relative to solvent residual peaks (CDCl3 ∂H: 7.26, 
d C: 77.16; CD2Cl2 d H: 5.32, d C: 53.84; d6-acetone d H: 2.05, d C: 206.26, 29.84; 
d6-DMSO d H: 2.50, d C: 39.52). Couplings constants (J) are recorded in Hertz and 
are reported to the nearest 0.5 Hz. 1H and 13C assignments are based on the assessment 
of COSY, APT, HSQC, and HMBC correlations. Multiplicities are given as: multiplet 
(m), singlet (s), broad singlet (brs), doublet (d), triplet (t), quartet (q), quintet (quint.), 
sextet (sext.), heptet (hept.), or the appropriate combination, e.g: dt = doublet of 
triplets. 
Low resolution mass spectra were determined on an Agilent Technologies 6130 
Quadrupole LC-MS mass spectrometer. HRMS were obtained on a Bruker MaXis 
Impact mass spectrometer and were obtained from Dr. Lijiang Song, Philip Aston, or 
James Morrey at the University of Warwick. All mass spectra are reported in units of 
mass to charge ratio (m/z). Melting points were recorded with a Gallenkamp MDP350 
instrument and are reported as observed. Infrared spectra were recorded on a Perkin 
Elmer Spectrum 100 FT–IR spectrometer. Optical rotations, [a]DT, were recorded 
using an Optical Activity Ltd. AA-1000 millidegree polarimeter and are reported as 
observed. Analytical thin layer chromatography was performed using Merck 60 F254 
pre-coated silica gel plates. Visualisation was achieved by UV light (254 nm). Column 
chromatography was performed using Apollo Scientific Ltd. 60 40-63 µM silica gel. 
All reactions were performed under atmospheric conditions unless otherwise stated.  
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1H NMR Assignments 
CHx (non-aromatic hydrogen), HAr (aromatic hydrogen), xHx (hydrogen attached to 
heteroatom). 
13C NMR Assignments 
CHx (non-aromatic carbon, bonded to hydrogen), C (non-aromatic carbon, not bonded 
to hydrogens), CAr (aromatic carbon, not bonded to hydrogen), CArH (aromatic carbon, 
bonded to hydrogen). 
6.2 Asymmetric Catalyst Synthesis Procedures 
All Brønsted acid catalysts synthesised are known compounds and were generated 
according to reported procedures, the analytical data obtained from which matched the 
reported literature data. The methods for the synthesis of the Brønsted acid catalysts 
protocols are outlined below. 
Methylation of BINOL8 
 
(R)–(+)–2,2’–Dihydroxy–1,1’–dinaphthyl (1 eq.) was added to acetone (4 mL/mmol). 
The mixture was stirred until homogeneous before anhydrous K2CO3 (4 eq.) was 
added. The heterogeneous mixture was then refluxed under nitrogen atmosphere. 
Methyl iodide (6 eq.) was then added to the reaction mixture and refluxed for a 
minimum of 4 h before a second portion of methyl iodide (3 eq.) was added to ensure 
complete protection. After 18 h the volatile components were removed by rotary 









This heterogeneous mixture was stirred for 8 h to ensure maximum K2CO3 removal. 
The resulting white solid was then filtered and dried under vacuum for 12 h to give 
(R)–2,2'–dimethoxy–1,1'–binaphthalene as a white solid (99%). 
Iodination of BINOL6 
 
To a vessel under nitrogen was added anhydrous diethyl ether (10 mL/mmol), n–
butyllithium (3 eq.), and TMEDA (1.4 eq.). The resulting mixture was then stirred at 
room temperature for 20 mins. (R)–2,2'–Dimethoxy–1,1'–binaphthalene (1 eq.) was 
then added and stirred overnight. The flask was then cooled down to –78 °C before a 
solution of iodine (2.5 eq.) in anhydrous THF (1.25 mL/mmol) was added drop-wise 
to the reaction mixture. The reaction mixture was stirred for 1 h at –78 °C and then 
brought to room temperature. After stirring for 10 h, water (8 mL/mmol) was added 
slowly, followed by THF (5 mL/mmol). The resulting colourless solution was then 
stirred for 2 h. The organic layer was then extracted with Et2O/THF (1:1, 3 x 3 
mL/mmol). The combined organics were then washed with Na2CO3 (10% aq., 3 x 30 
mL) and then water (4 mL/mmol), dried over MgSO4, filtered, and concentrated under 
reduced pressure. To the resulting crude solution was added Et2O (4 mL/mmol) and 
stirred for 1 h to afford (R)–3,3'–diiodo–2,2'–dimethoxy–1,1'–binaphthalene as an off–
















To an oven dried two-neck round bottom flask with stirrer bar and condenser was 
added (R)–3,3'–diiodo–2,2'–dimethoxy–1,1'–binaphthalene (1 eq.), the appropriate 
aryl boronic acid (2.4 eq.), Pd(PPh3)4 (0.15 eq.), and Ba(OH)2 (5 eq.) were added and 
the reaction flask put under vacuum and back filled to purge with nitrogen. A mixture 
of 3:1 dioxane/water (12 mL/mmol) was then added via syringe and the reaction 
brought up to 80 °C for 12 h. Upon completion the reaction mixture was cooled to 
room temperature and diluted with 1 M AcOH and EtOAc to achieve a biphasic 
solution. The aqueous layer was then extracted three times with EtOAc and the 
combined organics washed with H2O, followed by brine, then drying with MgSO4 and 




An oven-dried, 100-mL, two-necked, round-bottomed flask under nitrogen 
atmosphere is charged with (R)–3,3'–diiodo–2,2'–dimethoxy–1,1'–binaphthalene (1 
eq.), and Ni(PPh3)2Cl2 (0.1 eq.) in anhydrous Et2O (12 mL/mmol). To this flask was 
added freshly prepared Grignard reagent in Et2O (4 mL/mmol, prepared from 



























suspension was stirred at room temperature for 10 min and then refluxed for 24 h. The 
reaction was then cooled to 0 °C and quenched slowly with 1.0 M HCl solution (7 
mL/mmol). The two layers were then separated, and the aqueous layer was washed 
with Et2O (3 x 7 mL/mmol). The organic layer was then dried with MgSO4 and 
concentrated under reduced pressure to afford the desired product as a crude mixture.  
Methoxy BINOL deprotection8 
 
To a solution of the appropriate crude 3,3’–disubtitued BINOL derivative (1 eq.) in 
DCM (30 mL/mmol) was slowly added 1.0 M solution of boron tribromide (7 eq.) in 
DCM (7 mL/mmol) at 0 °C. The reaction mixture was warmed up to room temperature 
and stirred overnight. The mixture was then cooled to 0 °C and slowly quenched with 
water (9 mL/mmol). The mixture was then separated, and the aqueous layer was 
extracted with DCM (3 x 15 mL/mmol). The combined organic layer was then dried 
over MgSO4, filtered and concentrated under reduced pressure. 
BINOL phosphorylation6 
 
A binaphthol derivative (1 eq.) was dissolved in pyridine (2 mL/mmol) under N2 
atmosphere. To the resulting solution was added POCl3 (2 eq.) at RT and the reaction 
mixture was stirred and monitored by TLC until completion. Water (2 mL/mmol) was 


























complete hydrolysis. DCM was then added, and pyridine removed via reverse 
extraction with 1 M HCl. The organic phase was then dried with MgSO4 and 
concentrated under reduced pressure. The resultant residue was then purified by 
column chromatography on silica gel to afford the desired product. 
BINOL phosphoramidation7 
 
To a solution of the appropriate BINOL derivative (1 eq.) in anhydrous DCM (5 
mL/mmol) at 0 °C were added distilled Et3N (7 eq.), POCl3 (1.2 eq.), and DMAP (2 
eq.). The mixture was then brought to room temperature and stirred for 2 h, followed 
the by addition of EtCN (5 mL/mmol) and then TfNH2 (2 eq.). The reaction was then 
brought to 100 °C for 24 h. Upon completion the reaction was quenched with water 
and extracted twice with Et2O. The combined organics were then washed with sat. aq. 
NaHCO3 once, and 6 M HCl twice. The resultant organics were then dried over MgSO4 
and concentrated under reduced pressure. The obtained crude product was then 
purified by column chromatography on silica gel (eluent: n–hexane–DCM–Et2O) 
providing the phosphoramide, potentially as a salt. The product was then washed with 
6 M HCl a second time, dried over MgSO4, and concentrated to afford the desired 
product.  
6.3 Experimental Data for Chapter 2 
All molecules generated throughout this study are known compounds. The protocols 
for the synthesis of the model allyl– and propargyl–alcohol substrates, and data for the 
subsequent rearrangement product, are shown below. 
OH
OH














 (2–(Methylamino)phenyl)(phenyl)methanone 190a1 
Yellow solid (0.18 g, 48%). To a solution of 2–aminobenzophenone (592 
mg, 3 mmol) in DMF (7.5 mL) was added K2CO3 (0.829 g, 6 mmol) and 
methyl iodide (0.37 mL, 6 mmol). The reaction was stirred at 80 °C and monitored by 
TLC analysis until completion and subsequently quenched with water (10 mL). The 
product was extracted with ethyl acetate (3 x 15 mL) and the combined organics 
washed with water (3 x 15 mL), brine (15 mL), dried over MgSO4, and concentrated 
under reduced pressure. The crude mixture was purified by column chromatography 
on silica gel to give the title compound. Acquired analytical data matches that reported 
in the literature. 1H NMR (CDCl3, 500 MHz): d 8.54 (brs, 1H, J = 8.0 Hz, HAr), 7.62–
7.59 (2H, m, HAr), 7.54–7.30 (5H, m, HAr), 6.77 (d, 1H, J = 8.5 Hz, HAr), 6.57 (t, 1H, 
J = 7.0 Hz, , HAr), 3.01 (s, 3H, CH3). 13C NMR (CDCl3, 125 MHz): d 199.7, 153.1, 
140.4, 134.4, 134.8, 131.0, 129.6, 127.7, 116.9, 113.9, 111.7, 30.1. MS (ESI): m/z 
(C14H13NO + Na+) found: 234.1. 
N–(2–Benzoylphenyl)–4–methylbenzenesulfonamide 190b2 
White solid (2.33 g, 66%). To a solution of the 2-aminobenzophenone 
(1.97 g, 10 mmol) in pyridine (5 mL) was added p–TsCl (2.3 g, 12 mmol) 
at room temperature. The resulting solution was stirred for 4 h. On completion, the 
reaction mixture was quenched with water (5 mL), filtered, and dried. The red/pink 
solid was then dissolved in DCM and activated charcoal added; hot filtration and 
subsequent concentration under reduced pressure gave the title compound as a white 
solid. Acquired analytical data matches that reported in the literature. 1H NMR 
(CDCl3, 500 MHz): d  10.05 (s, 1H, NH), 7.85 (d, 1H, J = 8.5 Hz, HAr), 7.60–7.51 (m, 
4H, HAr), 7.46–7.39 (m, 5H, HAr), 7.14 (t, 1H, J = 8.5, 7.0 Hz, HAr), 7.06 (d, 2H J = 









137.9, 135.5, 133.8, 133.1, 132.3, 129.5, 129.1, 128.2, 127.6, 126.7, 123.2, 21.2. MS 
(ESI): m/z (C20H17NO3S + Na+) found: 374.1. 
1–(2–(Methylamino)phenyl)–1,3–diphenylprop–2–yn–1–ol 165a1 
To a stirred solution of diisopropylamine (0.21 mL 1.5 mmol) in 
anhydrous THF at −78 °C was added n–butyllithium (2.0 M, 0.75 mL, 
1.5 mmol) dropwise, and the resulting solution was stirred for 10 min. Phenylacetylene 
(0.1 mL, 1 mmol) was added in a dropwise manner. The resulting mixture was stirred 
for 1 h. In a separate flask, (2–(methylamino)phenyl)(phenyl)methanone (106 mg, 0.5 
mmol) was dissolved in THF (2 mL) and added to the LDA mixture dropwise and the 
resulting solution allowed to stir for 1 h. The reaction mixture was then warmed to 
room temperature and stirred for 1 h. Upon completion, the reaction mixture was 
quenched by adding saturated NH4Cl (10 mL) and extracted with EtOAc (3 × 10 mL). 
The combined organic layers were washed with brine (20 mL), dried over MgSO4, and 
concentrated under reduced pressure. The resulting product was then used without 
further purification.  
N–(2–(1–hydroxy–1,3–diphenylprop–2–yn–1–yl)phenyl)–4–
methylbenzenesulfonamide 165b 3 
White solid (0.17 g, 76%). To a stirred solution of diisopropylamine 
(0.21 mL 1.5 mmol) in anhydrous THF at −78 °C was added n–
butyllithium (2.0 M, 0.75 mL, 1.5 mmol) dropwise, and the resulting solution was 
stirred for 10 min. Phenylacetylene (0.1 mL, 1 mmol) was added in a dropwise manner. 
The resulting mixture was stirred for 1 h. In a separate flask, N–(2–benzoylphenyl)–
4–methylbenzenesulfonamide (175 mg, 0.5 mmol) was dissolved in THF (2 mL) and 
added to the LDA mixture dropwise and the resulting solution allowed to stir for 1 h. 









completion, the reaction mixture was quenched by adding saturated NH4Cl (10 mL) 
and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed 
with brine (20 mL), dried over MgSO4, and concentrated under reduced pressure. 
Purification by column chromatography on silica gel afforded the title compound. 
Acquired analytical data matches that reported in the literature. 1H NMR (CDCl3, 500 
MHz): d 8.81 (brs, 1H, NH), 7.52 (d, 1H, J = 8.0 Hz, HAr), 7.47 (d, 1H, J = 8.0 Hz, 
HAr), 7.36−7.43 (m, 4H, HAr), 7.33 (d, 2H, J = 8.0 Hz, HAr), 7.21−7.29 (m, 6H, HAr), 
7.10−7.16 (m, 1H, HAr), 6.88−6.94 (m, 3H, HAr), 4.19 (brs, 1H), 2.18 (s, 3H). 13C 
NMR (CDCl3, 125 MHz): d  143.5, 143.0, 136.6, 131.6, 130.4, 129.9, 129.2, 128.9, 
128.6, 128.3, 128.0, 127.6, 127.3, 126.2, 122.3, 121.8, 118.4, 89.8, 89.0, 74.9, 21.2. 
MS (ESI): m/z (C28H23N3OS + Na+) found: 476.2. 
Optimisation of Propargyl Alcohol Cyclisation 
 
To a small pop-cap vial was added the appropriate solvent (1mL), catalyst (5 mol%) 
and alcohol substrate 190 (0.5 mmol). The reaction was stirred at the appropriate 
temperature and monitored by TLC (eluent: 15% EtOAc–n–hexane) until completion.  
(1–Methyl–3–phenyl–1H–indol–2–yl)(phenyl)methanol 168a1 
Yellow oil. Acquired analytical data matches that reported in the 
literature. 1H NMR (CDCl3, 400 MHz): d 7.68 (d, 1H, J = 8.0 Hz, 
ArH), 7.51 (d, 2H, J = 7.0Hz, ArH), 7.45 (t, 2H, J = 8.0 Hz, ArH), 7.21–7.36 (m, 8H, 
ArH), 7.15 (t, 1H, J = 7.5 Hz, ArH), 6.37 (s, 1H, HOCH), 4.21 (brs, 1H, OH), 3.48 (s, 
3H, NCH3). 13C NMR (CDCl3, 100 MHz): d 141.2 (CAr), 137.9 (CAr), 135.5 (CAr), 












125.7 (CAr), 122.3 (CArH), 120.2 (CArH), 119.7 (CArH), 117.1 (CAH), 109.8 (CArH), 
67.7 (CH), 31.8 (CH). MS (ESI): m/z (C22H19NO + Na+) found: 336.1. 
3–Benzyl–1–methyl–3–phenylindolin–2–one 1881 
White solid. Acquired analytical data matches that reported in the 
literature. 1H NMR (CDCl3, 400 MHz): d 7.49 (d, 2H, J = 7.5 Hz, HAr), 
7.34 (t, 2H, J = 7.0 Hz, HAr), 7.28 (d, 1H, J = 7.0 Hz, HAr), 7.19–7.23 (m, 2H, HAr), 
6.98–7.09 (m, 4H, HAr), 6.82 (d, 2H, J = 6.5 Hz, HAr), 6.60 (d, 1H, J = 8.0 Hz, HAr), 
3.69 (d, 1H, J = 13.0 Hz, CH2), 3.44 (d, 1H, J =13.0 Hz, CH2), 2.94 (s, 3H, NCH3). 
13C NMR (CDCl3, 100 MHz): d 177.5 (C=O), 143.1 (CAr),  139.4 (CAr), 135.4 (CAr), 
131.5 (CAr), 130.2 (CArH), 128.8 (CArH), 128.1 (CArH),  127.4 (CArH), 127.1 (CArH), 
126.3 (CAr), 125.1 (CArH), 122.5 (CArH), 108.6 (CArH), 58.8 (C), 44.6 (CH), 26.9 (CH). 
MS (ESI): m/z (C22H19NO + Na+) found: 336.1. 
Optimisation of the 1,3–Allylic Alcohol Isomerisation of Alcohol 166b 
 
To a small pop-cap vial was added the appropriate solvent (1 mL), catalyst (5 mol%) 
and alcohol substrate 166b (0.5 mmol). The reaction was stirred at the appropriate 
temperature and monitored by TLC (15% EtOAc–n–hexane) until completion, or for 
up to a maximum of five days. The crude reaction mixture was then analysed using 
NMR. Yields were obtained from the NMR data using CH2Br2 as internal standard. 




















White solid (224 mg, 99%). To a tinfoil covered round bottomed flask 
containing a solution of N–(2–(1–hydroxy–1,3–diphenylprop–2–yn–1–
yl)phenyl)–4–methylbenzenesulfonamide (226 mg, 0.2 mmol) in MeCN (2 mL) was 
added AgOAc (0.01 mmol). The reaction was stirred at room temperature and 
monitored by TLC analysis. Upon completion, the reaction mixture was filtered 
through Celite, washed with DCM (10 mL), and concentrated under reduced pressure. 
Purification by column chromatography on silica gel afford the title compound. 
Acquired analytical data matches that reported in the literature. 1H NMR (CDCl3, 500 
MHz): d 7.93 (d, 1H, J = 8.0 Hz, HAr), 7.67 (d, 2H, J = 7.5 Hz, HAr), 7.43-7.46 (m, 
1H, HAr), 7.38 (d, 2H, J = 8.0 Hz, HAr), 7.34 (t, 2H, J = 7.5 Hz, HAr), 7.17-7.24 (m, 
7H, HAr), 7.06 (d, 2H, J = 8.0 Hz, HAr), 6.99 (d, 1H, J =  7.0 Hz, HAr), 6.26 (s, 1H, 
CH), 2.33 (s, 3H, CH3). 13C NMR (CDCl3, 125 MHz): d 145.4 (CAr), 145.0 (CAr), 
142.6 (C), 142.0 (CAr), 138.4 (CAr), 135.7 (CAr), 133.1 (CArH), 130.1 (CArH), 129.7 
(CArH), 129.5 (CAr), 128.5 (CArH), 128.0 (CArH), 128.0 (CArH), 127.9 (CArH), 127.5 
(CArH), 127.0 (CArH), 126.8 (CArH), 125.5 (CArH), 125.1 (CArH), 119.7 (CH), 81.9 
(C), 21.7 (CH). MS (ESI): m/z (C28H23NO3S - H+) found: 452.1. 
2–Benzylidene–3–methoxy–3–phenyl–1–tosylindoline 166b–Me 
 
To a stirred solution of 2-benzylidene-3-phenyl-1-tosylindolin-3-ol (0.5 mmol) in 
anhydrous THF (5 mL) at 0 °C was added portion–wise NaH (0.55 mmol). MeI (0.55 
mmol) was then added dropwise over 10 min and brought up to room temperature, 














extracted with ethyl acetate (3 x 15 mL) and the combined organics washed with water 
(3 x 15 mL), brine (15 mL), dried over MgSO4, and concentrated under reduced 
pressure. The crude mixture was purified by column chromatography on silica gel to 
give the title compound. White solid (166 mg, 71% yield). 1H NMR (d6-acetone, 500 
MHz): d  7.91 (d, 1H, J = 8.0 Hz, HAr), 7.68 (d, 2H, J = 7.5 Hz, HAr), 7.45-7.47 (m, 
1H, HAr), 7.39 (d, 2H, J = 8.0 Hz, HAr), 7.32 (t, 2H, J = 7.5 Hz, HAr), 7.19-7.25 (m, 
7H, HAr), 7.01 (d, 2H, J = 8.0 Hz, HAr), 6.94 (d, 1H, J =  7.0 Hz, HAr), 5.87 (s, 1H, 
=CH), 3.45 (s, 3H, CH), 2.28 (s, 3H, CH3). 13C NMR (d6-acetone, 125 MHz): d  
145.6 (CAr), 144.7 (CAr), 140.3 (C), 142.5 (CAr), 139.0 (CAr), 135.5 (CAr), 133.3 (CArH), 
130.0 (CArH), 129.8 (CArH), 129.2 (CAr), 128.8 (CArH), 128.2 (CArH), 128.2 (CArH), 
127.7 (CArH), 127.2 (CArH), 126.8 (CArH), 126.4 (CArH), 126.0 (CArH), 125.3 (CArH), 
123.1 (CH), 92.3 (C), 55.6 (CH), 21.9 (CH). IR (neat, νmax, cm-1): 2965, 2858, 1729, 
1604, 1388, 1160, 1067,  801. MS (ESI) m/z calcd. (C29H25NO3S + Na+): 490.1453, 
found: 490.1469 (M + Na+). 
2–Benzylidene–3–ethoxy–3–phenyl–1–tosylindoline 166b–Bn 
 
To a stirred solution of 2-benzylidene-3-phenyl-1-tosylindolin-3-ol (0.5 mmol) in 
anhydrous THF (5 mL) at 0 °C was added portion–wise NaH (0.55 mmol). BnBr (0.55 
mmol) was then added dropwise over 10 min and brought up to room temperature, 
allowed to stir for 1 h, and subsequently quenched with water. The product was 
extracted with ethyl acetate (3 x 15 mL) and the combined organics washed with water 
(3 x 15 mL), brine (15 mL), dried over MgSO4, and concentrated under reduced 






Ph OBnBnBr, NaH, THF
 
 129 
give the title compound. White solid (220 mg, 81% yield). 1H NMR (d6-acetone, 500 
MHz): d 7.93 (d, 1H, J = 8.0 Hz, HAr), 7.74 (d, 2H, J = 7.5 Hz, HAr), 7.46-7.49 (m, 
1H, HAr), 7.43 (d, 2H, J = 8.0 Hz, HAr), 7.29–7.37 (m, 7H, HAr), 7.14-7.27 (m, 7H, 
HAr), 7.08 (d, 2H, J = 8.0 Hz, HAr), 6.87 (d, 1H, J =  7.0 Hz, HAr), 5.39 (s, 1H, C=CH), 
4.87 (s, 2H, OCH2), 2.35 (s, 3H, CH3). 13C NMR (d6-acetone, 125 MHz): d 145.5 
(CAr), 144.8 (CAr), 140.1 (C), 142.7 (CAr), 139.5 (CAr), 136.2 (CAr), 135.7 (CAr), 133.2 
(CArH), 130.8 (CArH), 129.9 (CArH), 129.5 (CAr), 129.0 (CArH), 128.5 (CArH), 128.3 
(CArH), 128.1 (CArH), 127.7 (CArH), 127.6 (CArH), 127.3 (CArH), 127.1 (CArH), 126.6 
(CArH), 126.3 (CArH), 126.1 (CArH), 125.1 (CArH), 123.0 (CH), 110.9 (C), 75.3 (CH), 
22.6 (CH). IR (neat, νmax, cm-1): 2894, 1591, 1372,  1124,  1038,  832. MS (ESI) m/z 
calcd. (C35H29NO3S + Na+): 566.1766, found: 566.1751 (M + Na+). 
2–Benzylidene–3–phenyl–1–tosylindolin–3–ol 168b3 
Yellow oil. Acquired analytical data matches that reported in the 
literature. 1H NMR (CDCl3, 400 MHz): d 8.08 (d, 1H, J = 8.5 Hz, 
HAr), 7.51 (d, 2H, J = 7.0 Hz, HAr), 7.47 (t, 3H, J = 8.0 Hz, HAr), 7.36-7.42 (m, 4H, 
HAr), 7.25−7.30 (m, 7H, HAr), 7.09 (d, 2H, J = 8.0 Hz, HAr), 6.34 (d, 1H,  J = 12.0 Hz, 
CH), 4.75 (d, 1H,  J = 12.0 Hz, OH), 2.35 (s, 3H, CH3). 13C NMR (CDCl3, 100 MHz): 
d 144.1 (CAr), 143.7 (CAr), 136.3 (CAr), 135.5 (CAr), 134.4 (CAr), 131.4 (CAr), 129.1 
(CArH), 128.8 (CArH), 128.0 (CArH), 128.0 (CArH), 127.3 (CArH), 127.3 (CArH), 126.3 
(CArH), 126.0 (CArH), 124.8 (CArH), 124.7 (CArH), 124.0 (CArH), 119.6 (CArH), 113.8 
(CAr), 67.7 (CH), 20.7 (CH). MS (ESI): m/z (C28H23NO3S - H+) found: 452.1. 
2–(Methoxy(phenyl)methyl)–3–phenyl–1–tosyl–1H–indole 168b–Me 
 Yellow oil (5.5 mg, 12% yield). 1H NMR (d6-acetone, 500 MHz): 












3H, J = 8.0 Hz, HAr), 7.37-7.44 (m, 4H, HAr), 7.22−7.29 (m, 7H, HAr), 7.12 (d, 2H, J 
= 8.0 Hz, HAr), 5.94 (s, 1H, =CH), 3.50 (s, 3H, CH), 2.33 (s, 3H, CH3). 13C NMR (d6-
acetone, 125 MHz): d 144.6 (CAr), 144.1 (CAr), 136.8 (CAr), 135.4 (CAr), 134.9 (CAr), 
132.1 (CAr), 129.5 (CArH), 128.9 (CArH), 128.2 (CArH), 128.0 (CArH), 127.7 (CArH), 
127.5 (CArH), 127.2 (CArH), 126.8 (CArH), 125.5 (CArH), 124.9 (CArH), 124.5 (CArH), 
119.8 (CArH), 114.3 (CAr), 78.1 (CH), 69.8 (CH), 21.2 (CH). IR (neat, νmax, cm-1): 
3072, 2525, 1390, 1154, 956. MS (ESI) m/z calcd. (C29H25NO3S + Na+): 490.1453, 
found: 490.1469 (M + Na+). 
2–((Benzyloxy)(phenyl)methyl)–3–phenyl–1–tosyl–1H–indole 168b–Bn 
 Colourless oil (35.5 mg, 65% yield). 1H NMR (d6-acetone, 500 
MHz): d  8.05 (d, 1H, J = 8.5 Hz, HAr), 7.59 (d, 2H, J = 7.0 Hz, HAr), 
7.45 (t, 3H, J = 8.0 Hz, HAr), 7.35-7.41 (m, 5H, HAr), 7.31–7.35 (m, 4H, HAr), 
7.22−7.31 (m, 7H, HAr), 7.02 (d, 2H, J = 8.0 Hz, HAr), 5.91 (s, 1H, CH), 4.52 (s, 2H, 
OCH2), 2.37 (s, 3H, CH3). 13C NMR (d6-acetone, 125 MHz): d  143.9 (CAr), 143.6 
(CAr), 138.8 (CAr), 136.5 (CAr), 135.7 (CAr), 135.2 (CAr), 134.8 (CAr), 132.1 (CAr), 129.6 
(CArH), 128.7 (CArH), 128.1 (CArH), 127.9 (CArH), 127.7 (CArH), 127.6 (CArH), 127.3 
(CArH), 127.1 (CArH), 127.0 (CArH), 126.7 (CArH), 125.9 (CArH), 125.0 (CArH), 124.4 
(CArH), 124.2 (CArH), 119.8 (CArH), 115.2 (CAr), 78.5 (CH), 72.1  (CH), 21.1 (CH). 
IR (neat, νmax, cm-1): 3020, 2499, 1367, 1117, 921. MS (ESI) m/z calcd. 










6.4 Experimental Data for Chapter 3 
6.4.1 General Procedures4 
Construction of the N–tosyl a,b–unsaturated ketone scaffold 226 
 
To an EtOH (10 mL/mmol) solution containing the 2’–aminoacetophenone (1 mmol), 
aldehyde (1 eq.), at room temperature was added 2.5 M NaOH (0.6 mL/mmol) and the 
resulting reaction mixture was allowed to stir for 4 h. On completion, the reaction 
mixture was quenched by the addition of 1 M HCl (10 mL/mmol) and the solvent was 
removed under reduced pressure. The crude 2’–aminochalcone was taken up in 
pyridine (0.4 mL/mmol) and p–TsCl (1.6 eq.) was added in one portion at room 
temperature under a nitrogen atmosphere. The resulting reaction mixture was then 
stirred at room temperature for 4 h. After which, the solvent was removed under 
reduced pressure and the crude mixture was purified by column chromatography on 
silica gel with DCM as eluent. At this stage, one of two methods were employed: 
Procedure 1: Sodium borohydride reduction to 169 
 
The N–tosyl 2’–aminochalcone (3.0 mmol) was dissolved in methanol (30 mL/mmol) 
and cooled to 0 °C. Sodium borohydride (1.3 eq.) was added in one portion and the 
reaction mixture was allowed to stir for 3 h. Upon completion, the reaction mixture 
was quenched by the addition of water (1 mL/mmol) and the solvent was removed 
under reduced pressure. The crude mixture was dissolved in DCM (10 mL/mmol), 
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concentrated under reduced pressure. The crude mixture was purified by column 
chromatography on silica gel (eluent: 2:1 PhMe–DCM) to afford the secondary alcohol 
substrate.  
Procedure 2: Grignard addition to 169 
 
The tosyl–protected 2’–aminochalcone (3.0 mmol) was dissolved in THF (60 
mL/mmol) and a solution of alkyl or aryl magnesium bromide (1 M in THF solution, 
4.5 mmol) was added at 0 °C and subsequently allowed to slowly return to room 
temperature. The reaction mixture was allowed to stir at room temperature for 24 h 
and the progress of the reaction was followed by TLC analysis and mass spectrometry. 
Upon completion, the reaction mixture was quenched with saturated NH4Cl (60 
mL/mmol). After additional stirring at room temperature for 10 min, EtOAc (90 
mL/mmol) was added and the organic phase was separated. The aqueous phase was 
further extracted with EtOAc (3 x 30 mL/mmol) and the combined organic layers were 
washed with brine (60 mL), dried over anhydrous magnesium sulphate and 
concentrated under reduced pressure. The crude mixture was purified by column 
chromatography on silica gel (eluent: 2:1 PhMe–DCM) to afford the tertiary alcohol 
substrate. 
6.4.2 Compound Data 
N-(2-(2-Hydroxybut-3-en-2-yl)phenyl)-4-methylbenzenesulfonamide 169a4a 
 White solid (0.85 g, 90% yield); Tm = 140–144 °C. Acquired analytical 
data matches that reported in the literature. 1H NMR (d6-acetone, 500 














HAr), 7.31 (d, 2H, J = 8.0 Hz, HAr), 7.19 (ddd, 2H, J = 15.5, 7.5, 1.5 Hz, HAr), 6.96 (td, 
1H, J = 7.5, 1.5 Hz, HAr), 5.94 (dd, 1H, J = 17.0, 10.5 Hz, CH), 5.17 (dd, 1H, J = 17.5, 
1.0 Hz, CH), 5.00 (dd, 1H, J = 10.5, 1.0 Hz, CH), 2.35 (s, 3H, CH3), 1.61 (s, 3H, CH3). 
13C NMR (d6-acetone, 125 MHz): δ 143.4 (CH), 143.3 (CAr), 137.3 (CAr), 136.8 
(CAr), 132.7 (CAr), 129.2 (CArH), 127.8 (CArH), 127.2 (CArH), 126.8 (CArH), 122.6 
(CArH), 118.4 (CArH), 111.9 (CH), 76.0 (C), 27.9 (CH), 20.3 (CH). MS (ESI): m/z 
(C17H19NO3S - H+) found: 316.1. 
 N-(2-(1-Hydroxy-3-phenylallyl)phenyl)-4-methylbenzenesulfonamide 169b4a 
 White solid (1.02 g, 90% yield); Tm = 84–86 °C. Acquired analytical 
data matches that reported in the literature. 1H NMR (d6-acetone, 400 
MHz): δ 7.70–7.63 (m, 2H, HAr), 7.52 (d, 1H, J = 8.0 Hz, HAr), 7.40–7.31 (m, 4H, 
HAr), 7.21 (td, 6H, J = 12.0, 8.0 Hz, HAr), 7.06 (t, 1H, J = 7.5 Hz, HAr), 6.59 (dd, 1H, 
J = 16.0, 2.0 Hz, CH), 6.20 (dd, 1H, J = 16.0, 5.5 Hz, CH), 5.47 (d, 1H, J = 5.5 Hz, 
CH), 2.29 (s, 3H, CH3). 13C NMR (d6-acetone, 100 MHz): δ 143.5 (CAr), 137.3 (CAr), 
136.7 (CAr), 136.2 (CAr), 132.8 (CAr), 130.5 (CH), 129.7 (CArH), 129.4 (CArH), 128.5 
(CArH), 128.4 (CArH), 128.1 (CArH), 127.6 (CArH), 127.1 (CArH), 126.5 (CH), 124.2 
(CArH), 120.7 (CArH), 73.7 (CH), 20.5 (CH). MS (ESI): m/z (C22H20NO3S - H+) 
found: 378.1. 
N-(2-(3-(4-Chlorophenyl)-1-hydroxyallyl)phenyl)-4-methylbenzenesulfonamide 169c4a 
 Colourless oil (1.04 g, 84% yield). Acquired analytical data 
matches that reported in the literature. 1H NMR (d6-acetone, 
500 MHz): δ 7.69–7.65 (m, 2H, HAr), 7.51 (d, 1H, J = 8.0 Hz, HAr), 7.38 (s, 4H, HAr), 
7.28–7.19 (m, 4H, HAr), 7.09 (dd, 1H, J = 8.0, 7.0 Hz, HAr), 6.60 (dd, 1H, J = 16.0, 2.0 









(s, 3H, CH3). 13C NMR (d6-acetone, 125 MHz): δ 143.6 (CAr), 137.4 (CAr), 136.1 
(CAr), 135.6 (CAr), 132.9 (CAr), 132.7 (CAr), 131.6 (CArH), 129.5 (CH), 128.6 (CH), 
128.4 (CArH), 128.2 (CArH), 128.1 (CArH), 127.1 (CArH), 124.4 (CArH), 121.1 (CArH), 
73.4 (CH), 20.5 (CH3). MS (ESI): m/z (C22H19NClO3S - H+) found: 412.1 and 414.1.  
N-(2-(3-(4-Bromophenyl)-1-hydroxyallyl)phenyl)-4-methylbenzenesulfonamide 169d 4a 
Colourless oil (1.12 g, 82% yield). Acquired analytical data 
matches that reported in the literature. 1H NMR (d6-acetone, 
500 MHz): δ 7.69–7.62 (m, 2H, HAr), 7.55–7.48 (m, 3H, HAr), 7.34–7.28 (m, 3H, HAr), 
7.28–7.15 (m, 5H, HAr), 7.07 (td, 1H, J = 7.5, 1.0 Hz, HAr), 6.57 (dd, 1H, J = 16.0, 1.5 
Hz, CH), 6.25 (dd, 1H, J = 16.0 and 5.5 Hz, CH), 5.49 (dd, 1H, J = 5.5 and 1.5 Hz, 
CH), 2.30 (s, 3H, CH3). 13C NMR (d6-acetone, 125 MHz): δ 143.6 (CAr), 137.4 (CAr), 
136.1 (CAr), 136.0 (CAr), 132.9 (CAr), 131.7 (CArH), 131.6 (CArH), 129.5 (CH), 128.5 
(CArH), 128.4 (CArH), 128.3 (CArH), 128.2 (CArH), 127.2 (CH), 124.4 (CArH), 121.1 
(CArH), 120.8 (CAr), 73.4 (CH), 20.6 (CH3). MS (ESI): m/z (C22H19NBrO3S - H+) 
found: 456.0 and 458.0. 
N-(2-(1-Hydroxy-3-(4-methoxyphenyl)allyl)phenyl)-4-methylbenzenesulfonamide 
169e4b 
 Yellow oil (1.04 g, 85% yield). Acquired analytical data 
matches that reported in the literature. 1H NMR (d6-acetone, 
500 MHz): δ 8.39 (d, 1H, J = 5.5 Hz, HAr), 7.67–7.61 (m, 2H, HAr), 7.26–7.05 (m, 
12H, HAr), 6.87–6.80 (m, 3H, HAr), 6.44 (dd, 1H, J = 16.0, 1.5 Hz, CH), 6.04 (dd, 1H, 
J = 16.0 and 6.5 Hz CH), 5.25 (d, 1H, J = 6.0 Hz, CH), 3.80 (s, 3H, CH3), 2.31 (s, 3H, 
CH3). 13C NMR (d6-acetone, 125 MHz): δ 131.2 (CAr), 129.6 (CAr), 129.6 (CAr), 
129.3 (CAr), 129.1 (CAr), 129.1 (CH), 128.9  (CAr), 128.8 (CArH), 128.3 (CArH), 128.2 









(CArH), 124.5 (CArH), 121.6 (CArH), 114.0 (CArH), 113.9 (CArH), 113.8 (CArH), 74.9 
(CH), 55.3 (CH), 21.6 (CH). MS (ESI): m/z (C23H24NO4S - H+) found: 408.1. 
N-(4-Bromo-2-(1-hydroxy-3-phenylallyl)phenyl)-4-methylbenzenesulfonamide 169e 
 Yellow oil (1.03 g, 88% yield). 1H NMR (d6-acetone, 500 MHz): 
δ 9.07 (brs, 1H, NH), 7.62 (d, 2H, J = 8.5 Hz, HAr), 7.43 (d, 1H, J 
= 8.5 Hz, HAr), 7.28–7.37 (m 7H, HAr), 7.08 (d, 2H, J = 8.0 Hz, HAr), 6.53 (d, 1H, J = 
16.0 Hz, CH), 6.11 (dd, 1H, J = 16.0, 6.0 Hz, CH), 5.62 (brs, 1H, OH) 5.24 (d, 1H, J 
= 5.5 Hz, CH), 2.32 (3H, s). 13C NMR (d6-acetone, 125 MHz): δ 162.5 (CAr), 144.1 
(CAr), 135.9 (CAr), 135.2 (CAr), 133.6 (CAr), 132.3 (CArH), 131.9 (CArH), 131.3 (CArH), 
129.8 (CH), 128.8 (CArH), 128.5 (CArH), 128.1 (CArH), 127.4 (CArH), 126.9 (CH), 
123.4 (CArH), 117.7 (CAr), 74.3 (CH), 21.7 (CH). IR (neat, νmax, cm-1): 3471, 3232, 
2925, 2855, 1597, 1487, 1384, 1330, 1161, 1091, 905, 729, 650.  MS (ESI) m/z calcd. 
(C22H20BrNO3S + Na+): 480.0239 & 482.0221, found: 480.0240 & 482.0222 (M + 
Na+). 
N-(4-Fluoro-2-(1-hydroxy-3-phenylallyl)phenyl)-4-methylbenzenesulfonamide 169g 
 Pale yellow oil (0.86 g, 72% yield). 1H NMR (CDCl3, 500 MHz): 
δ 7.78 (s, 1H, NH), 7.61 (d, 2H, J = 8.0 Hz, HAr), 7.39–7.42 (m, 1H, 
HAr), 7.28–7.37 (m, 5H, HAr), 7.15 (d, 2H, J = 8.0 Hz, HAr), 6.93 (d, 2H, J = 8.0 Hz, 
HAr), 6.54 (d, 1H, J = 16.0 Hz, CH), 6.13 (dd, 1H, J = 16.0, 6.5 Hz, CH), 5.16–5.28 
(m, 1H, CH), 2.41 (d, 1H, J = 3.5 Hz), 2.36 (s, 3H). 13C NMR (CDCl3, 125 MHz): δ 
160.2 (d, J = 246 Hz, CArF), 144.0 (CAr), 136.7 (CAr), 135.9 (CAr), 135.8 (d, J = 7 Hz, 
CAr), 132.5 (CH), 131.4 (d, J = 3.0 Hz, CAr), 129.8 (CArH), 128.8 (CArH), 128.5 (CArH), 
128.2 (CArH), 127.4 (CArH), 126.9 (CH), 125.5 (d, J = 8.0 Hz, CArH), 115.7 (d, J = 
23.0 Hz, CArH), 115.2 (d, J = 24.0 Hz, CArH), 73.5 (CH), 21.7 (CH). 19F NMR (CDCl3, 











1393, 1330, 1159, 1091, 908, 796, 693, 664, 549. MS (ESI) m/z calcd. (C22H20FNO3S 
+ Na+): 420.1040, found: 420.1036 (M + Na+). 
N-(2-(1-Hydroxy-3-phenylallyl)phenyl)-2-nitrobenzenesulfonamide 169h 
Light orange oil (0.65 g, 53% yield). 1H NMR (d6-acetone, 500 
MHz): δ 9.62 (brs, 1H, NH), 7.93–7.95 (m, 1H, HAr), 7.73–7.75 (m, 
1H, HAr), 7.58–7.67 (m, 4H, HAr), 7.47–7.52 (m, 2H, HAr), 7.28–7.31 (m, 5H, HAr), 
7.18 (d, 1H, J = 7.5 Hz, HAr), 6.48 (d, 1H, J = 16.0 Hz, CH), 6.35 (dd, 1H, J = 16.0, 
6.0 Hz, CH), 5.62 (s, 1H, OH), 5.56 (d, 1H, J = 6.0 Hz. CH). 13C NMR (d6-acetone, 
125 MHz): δ 136.1 (CAr), 134.8 (CAr), 134.5 (CAr), 133.8 (CAr), 132.7 (CArH), 131.8 
(CAr), 131.2 (CArH), 129.3 (CArH), 129.1 (CH), 129.1 (CArH), 128.9 (CArH), 128.7 
(CArH), 128.4 (CArH), 128.2 (CArH), 126.8 (CH), 126.3 (CArH), 125.4 (CArH), 123.8 
(CArH), 73.3 (CH). IR (neat, νmax, cm-1): 3482, 3217, 2926, 1693, 1586, 1538, 1493, 
1303, 1163, 1124, 966, 853, 752, 732, 693, 584, 559. MS (ESI) m/z calcd. 
(C21H18N2O5S + Na+): 433.0834, found: 433.0831 (M + Na+). 
N-(2-(2-Hydroxy-4-phenylbut-3-en-2-yl)phenyl)-4-methylbenzenesulfonamide 169i 4b 
Pale yellow oil (0.89 g, 76% yield). Acquired analytical data matches 
that reported in the literature. 1H NMR (d6-acetone, 500 MHz): δ 
10.03 (s, 1H, NH), 7.64 (t, 3H, J = 9.0 Hz, HAr), 7.40–7.32 (m, 4H, HAr), 7.28 (dd, 2H, 
J = 7.5, 1.5 Hz, HAr), 7.20 (td, 1H, J = 8.0, 1.5 Hz, HAr), 7.05 (d, 2H, J = 8.0 Hz, HAr), 
6.98 (td, 1H, J = 7.51, 1.5 Hz, HAr), 6.61 (d, 1H, J = 16.0 Hz, CH), 6.36 (d, 1H, J = 
16.0 Hz, CH), 5.77 (s, 1H, OH), 2.24 (s, 3H, CH3), 1.75 (s, 3H, CH3). 13C NMR (d6-
acetone, 125 MHz): δ 143.3 (CAr), 137.1 (CAr), 136.9 (CAr), 136.7 (CAr), 135.0 (CArH), 
133.0 (CAr), 129.2 (CH), 128.5 (CArH), 128.0 (CArH), 127.5 (CArH), 127.2 (CArH), 
127.0 (CArH), 126.5 (CH), 122.8 (CArH), 118.3 (CArH), 76.0 (C), 28.6 (CH), 20.4 (CH). 












Colourless oil (0.74 g, 51% yield). 1H NMR (d6-acetone, 500 MHz): 
δ 11.41 (s, 1H, NH), 8.02 (dd, 1H, J = 8.0, 1.5 Hz, HAr), 7.66 (d, 1H, J 
= 8.5 Hz, HAr), 7.60 (d, 2H, J = 8.0 Hz, HAr), 7.55–7.49 (m, 1H, HAr), 7.32 (d, 4H, J = 
4.4 Hz), 7.29–7.18 (m, 6H, HAr), 7.18–7.08 (m, 4H, HAr), 3.41 (d, 2H, J = 6.0 Hz, CH), 
3.33 (td, 1H, J = 8.5, 7.5, 3.5 Hz, CH), 2.48 (td, 2H, J = 9.5, 6.0 Hz, CH), 2.28 (s, 3H, 
CH3). 13C NMR (d6-acetone, 125 MHz): δ 144.4 (CAr), 144.0 (CAr), 142.1 (CAr), 
139.7 (CAr), 136.5 (CAr), 134.6 (CArH), 131.7 (CArH), 129.7 (CH), 128.4 (CArH), 128.2 
(CArH), 127.8 (CArH), 127.1 (CH), 126.3 (CArH), 125.7 (CArH), 122.9 (CArH), 122.7 
(CAr), 118.9 (CArH), 46.2 (C), 38.0 (CH2), 33.4 (CH2), 20.4 (CH3). IR (neat, νmax, cm-
1): 3479, 3171, 3061, 3027, 2926, 1651, 1601, 1578, 1494, 1452, 1334, 1159, 1119, 
752, 700, 565. MS (ESI) m/z calcd. (C30H29NO3S + Na+): 506.1760, found: 
506.1763 (M + Na+). 
N-(2-(1-Cyclopropyl-1-hydroxy-3-phenylallyl)phenyl)-4-methylbenzenesulfonamide 
169k 
Off-white oil (0.80 g, 63% yield). 1H NMR (d6-acetone, 500 MHz): 
δ 9.18 (s, 1H, NH), 7.63 (dd, 2H, J = 9.5, 8.0 Hz, HAr), 7.55 (d, 2H, J 
= 8.0 Hz, HAr), 7.30–7.34 (m, 3H, HAr), 7.14–7.24 (m, 3H, HAr), 7.02 (d, 1H, J = 8.0 
Hz, HAr), 6.82 (d, 1H, J = 8.0 Hz, HAr), 6.51 (d, 1H, J = 16.0 Hz, CH), 5.83 (d, 1H, J 
= 16.0 Hz, CH), 5.52 (s, 1H, OH), 2.19 (s, 3H, CH3), 1.52–1.57 (m, 1H, CH), 0.69–
0.73 (m, 1H, CH), 0.59–0.63 (m, 1H, CH), 0.47-0.54 (m, 2H, CH). 13C NMR (d6-
acetone, 125 MHz): δ 143.3 (CAr), 136.8 (CAr), 136.2 (CAr), 132.0 (CAr), 130.5 (CAr), 
129.8 (CArH), 129.4 (CH), 128.8 (CArH), 128.7 (CArH), 128.1 (CArH), 127.7 (CArH), 
127.5 (CArH), 126.9 (CH), 123.2 (CArH), 119.2 (CArH), 78.9 (C), 22.4 (CH), 21.6 (CH), 










1583, 1558, 1494, 1449, 1402, 1334, 1159, 1091, 975, 929, 751, 661, 566, 545. MS 
(ESI) m/z calcd. (C25H25NO3S + Na+): 442.1447, found: 442.1446 (M + Na+). 
N-(2-(1-Cyclopentyl-1-hydroxy-3-phenylallyl)phenyl)-4-methylbenzenesulfonamide 
169l 
Yellow oil (0.92 g, 69% yield). 1H NMR (d6-acetone, 500 MHz): δ 
11.41 (s, 1H, NH), 8.03 (dd, 1H, J = 8.0, 1.5 Hz, HAr), 7.63 (d, 1H, J 
= 8.5 Hz, HAr), 7.58 (d, 2H, J = 8.0 Hz, HAr), 7.52–7.46 (m, 1H, HAr), 7.25 (dd, 6H, J 
= 6.0, 3.0 Hz, HAr), 7.16 (dq, 1H, J = 6.0, 3.0 Hz, HAr), 7.13–7.07 (m, 1H, HAr), 3.53 
(dd, 1H, J = 17.0, 9.5 Hz, CH), 3.39 (dd, 1H, J = 17.0, 4.0 Hz), 3.09 (td, 1H, J = 10.0, 
4.0 Hz, CH), 2.32 (s, 3H, CH3), 2.16-2.32 (m, 1H, CH), 1.91-1.92 (m, 1H, CH), 1.65-
1.67 (m, 1H, CH), 1.55-1.58 (m ,2H, CH), 1.44-1.53 (m, 1H, CH), 1.25-1.31 (m, 2H, 
CH), 1.04-1.08 (m, 1H, CH). 13C NMR (d6-acetone, 125 MHz): δ 144.8 (CAr), 144.0 
(CAr), 139.7 (CAr), 136.5 (CAr), 131.8 (CArH), 129.7 (CH), 128.1 (CArH), 128.0 (CArH), 
127.1 (CH), 126.0 (CArH), 122.8 (CArH), 122.7 (CAr), 118.7 (CArH), 46.2 (CH), 45.2 
(C), 31.3 (CH2), 31.2 (CH2), 25.0 (CH2), 24.6 (CH2), 20.5 (CH3). IR (neat, νmax, cm-
1): 3438, 2952, 1700, 1649, 1493, 1451, 1335, 1246, 1159, 1090, 916, 813, 756, 701, 
657, 628, 562, 544. MS (ESI) m/z calcd. (C27H28NO3S - H+): 446.1795, found: 
446.1791 (M – H+). 
N-(2-(1-Hydroxy-1,3-diphenylallyl)phenyl)-4-methylbenzenesulfonamide 169m 
Colourless oil (0.87 g, 64% yield). 1H NMR (CDCl3, 400 MHz): δ 
8.97 (s, 1H, NH), 7.62 (d, 1H, J = 8.0 Hz, HAr), 7.18–7.34 (m, 14H, 
HAr), 7.07 (d, 1H, J = 8.0 Hz, HAr), 6.94 (d, 2H, J = 8.5 Hz, HAr), 6.63 (d, 1H, J = 16.0 
Hz, CH), 6.24 (d, 1H, J = 16.0 Hz, CH), 3.00 (s, 1H, OH), 2.27 (s, 3H, CH3). 13C NMR 
(CDCl3, 100 MHz): δ 143.8 (CAr), 143.3 (CAr), 136.8 (CAr), 136.4 (CAr), 136.1 (CAr), 










128.8 (CArH), 128.7 (CArH), 128.3 (CArH), 128.0 (CArH), 127.5 (CArH), 127.0 (CArH), 
126.8 (CH), 122.7 (CArH), 119.2 (CArH), 81.3 (C), 21.6 (CH3). IR (neat, νmax, cm-1): 
3444, 3207, 3060, 3027, 2923, 1600, 1583, 1493, 1449, 1402, 1331, 1282, 1156, 1091, 
976, 941, 907, 752, 733, 700, 662, 565, 545. MS (ESI) m/z calcd. (C28H25NO3S + 
Na+): 478.1447, found: 478.1445 (M + Na+). 
N-(2-(1-Hydroxy-1-(2-methoxyphenyl)-3-phenylallyl)phenyl)-4-
methylbenzenesulfonamide 169n 
Colourless oil (0.97 g, 66% yield). 1H NMR (CDCl3, 400 MHz): δ 
9.73 (brs, 1H, NH), 7.71 (d, 1H, J = 8.0 Hz, HAr), 7.57 (d, 2H, J = 8.0 
Hz, HAr), 7.28–7.41 (m, 5H, HAr), 7.19 (t, 1H, J = 8.0 Hz, HAr), 6.79–
7.04 (m, 7H, HAr), 6.69 (d, 1H, J = 8.0 Hz, HAr), 6.52 (d, 1H, J = 16.0 Hz, CH), 6.18 
(d, 1H, J = 16.0 Hz, CH), 5.67 (s, 1H, OH), 3.74 (s, 3H, CH3), 2.24 (s, 3H, CH3). 13C 
NMR (CDCl3, 100 MHz): δ 157.1 (CAr), 143.2 (CAr), 137.3 (CAr), 136.9 (CAr), 136.4 
(CAr), 132.4 (CArH), 131.9 (CAr), 131.5 (CAr), 130.9 (CArH), 129.8 (CArH), 129.4 (CH), 
128.9 (CArH), 128.9 (CArH), 128.7 (CArH), 128.6 (CArH), 128.1 (CArH), 127.5 (CArH), 
127.1 (CH), 122.4 (CArH), 121.3 (CArH), 118.5 (CArH), 112.4 (CArH), 81.9 (C), 56.0 
(CH3), 21.6 (CH3). IR (neat, νmax, cm-1): 3473, 3212, 3028, 2926, 2856, 1599, 1583, 
1490, 1455, 1401, 1336, 1284, 1236, 1159, 1092, 910, 753, 661, 565, 545. MS (ESI) 
m/z calcd. (C29H27NO4S + Na+): 508.1553, found: 508.1553 (M + Na+). 
N-(2-(1-Hydroxy-3-phenyl-1-(thiophen-2-yl)allyl)phenyl)-4-methylbenzenesulfonamide 
169o 
Pale yellow oil (1.05 g, 76% yield). 1H NMR (d6-acetone, 500 MHz): 
δ 9.22 (brs, 1H, NH), 7.67 (d, 1H, J = 8.0 Hz, HAr), 7.49 (d, 2H, J = 
8.0 Hz, HHetAr), 7.31–7.33 (m, 6H), 7.14–7.23 (m, 2H), 7.04 (d, 1H, J 











J = 16.0 Hz, CH), 6.33 (d, 1H, J = 16.0 Hz, CH), 2.26 (s, 3H, CH3). 13C NMR (d6-
acetone, 125 MHz): δ 149.1 (CHetAr), 143.4 (CAr), 136.7 (CAr), 136.6 (CAr), 135.9 
(CAr), 132.9 (CArH), 131.7 (CAr), 131.2 (CArH), 129.5 (CH), 129.3 (CArH), 129.0 
(CArH), 128.8 (CArH), 128.4 (CArH), 127.5 (CArH), 127.1 (CArH), 127.0 (CH), 126.5 
(CArH), 126.4 (CArH), 122.9 (CArH), 119.3 (CArH), 79.9 (C), 21.60 (CH3). IR (neat, 
νmax, cm-1): 3426, 3238, 3064, 3029, 2924, 1650, 1600, 1583, 1494, 1452, 1403, 1333, 
1158, 1091, 972, 911, 828, 752, 704, 566, 545. MS (ESI) m/z calcd. (C26H22NO3S2 - 
H+): 460.1047, found: 460.1040 (M – H+). 
General procedure for the TfOH-catalysed allylic amination5 
To a round-bottom flask containing the allylic alcohol substrate (0.2 mmol) open to 
the air was added 2 mL of TfOH (0.01 mol %) from a stock solution. Reaction progress 
was monitored to completion by TLC analysis. The crude mixture was quenched with 
water (2 mL/0.2 mmol of substrate), extracted with EtOAc (3 x 10 mL), and 
concentrated under reduced pressure. Purification by column chromatography on silica 
gel (eluent: 100% toluene, or 10:1 n–hexane–EtOAc) furnished the title compound. 
2-Phenyl-1-tosyl-1,2-dihydroquinoline 171b 4a 
Colourless oil (54 mg, 75% yield). Acquired analytical data matches that 
reported in the literature. 1H NMR (d6-acetone, 400 MHz): δ 7.63 (d, 
1H, J = 8.0 Hz, HAr), 7.33-7.41 (m, 4H, HAr), 7.33–7.22 (m, 6H, HAr), 7.19 (d, 1H, J = 
7.5 Hz, HAr), 7.09 (d, 1H, J = 7.5 Hz, HAr), 6.40 (d, 1H, J = 9.5 Hz, CH), 6.17–6.07 
(m, 2H, CH and =CH), 2.38 (s, 3H, CH3). 13C NMR (d6-acetone, 100 MHz): δ 143.7 
(CAr), 139.3 (CAr), 136.6 (CAr), 133.1 (CAr), 129.2 (CH), 128.9 (CAr), 128.4 (CArH), 
127.9 (CArH), 127.7 (CArH), 127.2 (CArH), 127.1 (CArH), 126.5 (CArH), 126.4 (CArH), 






2-(4-Chlorophenyl)-1-tosyl-1,2-dihydroquinoline 171c 4a  
Colourless crystalline solid (70 mg, 88% yield); m.p. 135–137 °C. 
Acquired analytical data matches that reported in the literature. 1H 
NMR (CDCl3, 400 MHz): δ 7.64 (d, 1H, J = 8.0 Hz, HAr), 7.32 (d, 2H, J = 8.5 Hz, 
HAr), 7.28 (d, 2H, J = 8.5 Hz, HAr), 7.19–7.21 (m, 3H, HAr), 7.08–7.16 (m, 3H, HAr), 
6.97 (dd, 1H, J = 7.5, 1.0 Hz, HAr), 6.30 (d, 1H, J = 9.5 Hz, CH), 5.98 (d, 1H, J = 6.0 
Hz, CH), 5.85 (dd, 1H, J = 9.5, 6.0 Hz. CH), 2.35 (s, 3H, CH3). 13C NMR (CDCl3, 
100 MHz): δ 143.7 (CAr), 137.0 (CAr), 136.1 (CAr), 133.9 (CAr), 132.8 (CArH), 129.3 
(CH), 129.0 (CArH), 128.7 (CArH), 128.6 (CArH), 127.7 (CArH), 127.3 (CArH), 126.8 
(CArH), 126.5 (CArH), 126.2 (CArH), 126.1 (CArH), 126.0 (CH), 56.3 (CH), 21.7 (CH). 
MS (ESI): m/z (C22H18NClO2S + H+) found: 396.1 and 398.1.  
2-(4-Bromophenyl)-1-tosyl-1,2-dihydroquinoline 171d 4a 
Colourless oil (82 mg, 93% yield). Acquired analytical data 
matches that reported in the literature. 1H NMR (CDCl3, 400 
MHz): δ 7.64 (d, 1H, J = 8.0 Hz, HAr), 7.31–7.37 (m, 4H, HAr), 7.20–7.22 (m, 3H, 
HAr), 7.08–7.14 (m, 3H, HAr), 6.97 (dd, 1H, J = 7.5, 1.0 Hz, HAr), 6.30 (d, 1H, J = 9.5 
Hz, CH), 5.97 (d, 1H, J = 6.0 Hz, CH), 5.85 (dd, 1H, J = 9.5, 6.0 Hz, CH), 2.35 (s, 3H, 
CH3). 13C NMR (CDCl3, 100 MHz): δ 143.7 (CAr), 137.6 (CAr), 136.1 (CAr), 132.8 
(CAr), 131.7 (CArH), 129.3 (CH), 128.6 (CArH), 128.6 (CAr), 127.7 (CArH), 127.4 
(CArH), 126.8 (CArH), 126.5 (CH), 126.1 (CArH), 125.9 (CArH), 122.1 (CH), 56.4 (CH), 
21.7 (CH3). MS (ESI): m/z (C22H18NBrO2S + H+) found: 440.0 and 442.0. 
2-(4-Methoxyphenyl)-1-tosyl-1,2-dihydroquinoline 171e 4b 
Colourless oil (56 mg, 71% yield). Acquired analytical data 
matches that reported in the literature. 1H NMR (CDCl3, 500 












3H, HAr), 7.08–7.14 (m, 3H, HAr), 6.97 (d, 1H, J = 7.5 Hz, HAr), 6.76 (d, 2H, J = 9.0 
Hz, HAr), 6.27 (d, 1H, J = 9.5 Hz, CH), 5.97 (d, 1H, J = 6.0 Hz, CH), 5.84 (dd, 1H, J 
= 9.5, 6.0 Hz, CH), 3.73 (d, 3H, CH3), 2.35 (d, 3H, CH3). 13C NMR (CDCl3, 125 
MHz): δ 159.5 (CAr), 143.5 (CAr), 136.4 (CArH), 132.9 (CArH), 130.4 (CH), 129.2 
(CArH), 129.0 (CArH), 128.8 (CArH), 128.4 (CArH), 127.9 (CArH), 127.4 (CArH), 126.9 
(CArH), 126.6 (CArH), 126.3 (CArH), 125.5 (CH), 113.9 (CArH), 56.8 (CH), 55.3 (CH3), 
21.7 (CH3). MS (ESI): m/z (C23H21NO3S + H+) found: 392.1. 
6-Bromo-2-phenyl-1-tosyl-1,2-dihydroquinoline 171f 
Pale yellow oil (56 mg, 64% yield). 1H NMR (CDCl3, 400 MHz): δ 
7.52 (d, 1H, J = 8.5 Hz, HAr), 7.36 (d, 2H, J = 8.5 Hz, HAr), 7.31 (dd, 
3H, J = 8.5, 2.0 Hz, HAr), 7.22–7.24 (m, 3H, HAr), 7.12–7.14 (m, 3H, HAr), 6.23 (d, 
1H, J = 9.5 Hz, CH), 6.02 (d, 1H, J = 6.0 Hz, CH), 5.93 (dd, 1H, J = 9.5, 6.0 Hz, CH), 
2.37 (s, 3H, CH3). 13C NMR (CDCl3, 100 MHz): δ 143.9 (CArBr), 138.0 (CAr), 136.1 
(CAr), 132.1 (CAr), 131.2 (CH), 130.4 (CAr), 129.5 (CArH), 129.4 (CArH), 129.1 (CArH), 
128.7 (CArH), 128.3 (CArH), 128.2 (CArH), 127.5 (CArH), 127.3 (CArH), 124.7 (CH), 
120.0 (CAr), 57.1 (CH), 21.7 (CH). IR (neat, νmax, cm-1): 3062, 2922, 1644, 1598, 
1484, 1343, 1089, 813, 685. MS (ESI) m/z calcd. (C22H18BrNO2S + Na+): 462.0134 
& 464.0119, found: 462.0137 & 464.0124 (M + Na+). 
6-Fluoro-2-phenyl-1-tosyl-1,2-dihydroquinoline 171g 
Colourless oil (61 mg, 81% yield). 1H NMR (CDCl3, 400 MHz): δ 
7.52 (m, 1H, HAr), 7.15–7.23 (m, 7H, HAr), 7.04 (d, 2H, J = 7.5 Hz, 
HAr), 6.82 (d, 1H, J = 8.5 Hz, HAr), 6.60 (d, 1H, J = 8.5 Hz, HAr), 6.14 (d, 1H, J = 9.5 
Hz, CH), 5.94 (d, 1H, J = 5.5 Hz, CH), 5.83–5.85 (m, 1H, CH), 2.29 (s, 3H, CH3). 13C 
NMR (CDCl3, 125 MHz): δ 161.0 (d, J = 246 Hz, CArF), 143.8 (CAr), 137.9 (CAr), 











J = 3 Hz, CAr), 128.6 (CArH), 128.2 (CArH), 128.1 (CArH), 127.6 (CArH), 127.4 (CArH), 
125.0 (CH), 115.1 (d, J = 23 Hz, CArH), 112.7 (d, J = 23 Hz, CArH), 57.1 (CH), 21.7 
(CH). 19F NMR (CDCl3, 282 MHz) δ –115.2. IR (neat, νmax, cm-1): 3062, 3031, 2962, 
2924, 1612, 1598, 1578, 1484, 1451, 1345, 1262, 1165, 1045, 810, 709, 576. MS (ESI) 
m/z calcd. (C22H18FNO2S + Na+): 402.0934, found: 402.0938 (M + Na+). 
1-((2-Nitrophenyl)sulfonyl)-2-phenyl-1,2-dihydroquinoline 171h 
Colourless oil (51 mg, 65% yield). 1H NMR (CDCl3, 400 MHz): δ 7.65 
(d, 1H, J = 8.0 Hz, HAr), 7.59 (td, 1H, J = 8.0, 1.0 Hz, HAr), 7.48 (dd, 1H, 
J = 8.0, 1.0 Hz, HAr), 7.29–7.36 (m, 3H, HAr), 7.17–7.25 (m, 6H, HAr), 7.05 (dd, 1H, J 
= 7.0, 2.0 Hz, HAr), 6.36 (d, 1H, J = 10.0 Hz, CH), 6.17 (m, 1H, CH), 6.10 (d, 1H, J = 
6.0 Hz, CH); 13C NMR (CDCl3, 125 MHz): δ 137.6, (CAr), 133.8 (CArH), 132.0 (CAr), 
131.1 (CAr), 130.7 (CArH), 130.7 (CAr), 129.5 (CH), 129.2 (CArH), 128.7 (CArH), 128.6 
(CArH), 128.3 (CArH), 128.3 (CArH), 127.7 (CArH), 127.5 (CArH), 127.3 (CArH), 126.6 
(CArH), 125.0 (CH), 123.7 (CArH), 57.3 (CH). IR (neat, νmax, cm-1): 3088, 3062, 2960, 
2925, 1679, 1603, 1542, 1371, 1265, 1173, 1060, 1023, 766, 697, 584. MS (ESI) m/z 
calcd. (C21H16N2O4S + Na+): 415.0723, found: 415.0722 (M + Na+). 
4-Methyl-2-phenyl-1-tosyl-1,2-dihydroquinoline 171i 4b 
Colourless oil (60 mg, 80% yield). Acquired analytical data matches that 
reported in the literature. 1H NMR (CDCl3, 400 MHz): δ 7.61 (d, 1H, J 
= 7.5 Hz, HAr), 7.05–7.28 (m, 12H, HAr), 5.90 (d, 1H, J = 6.0 Hz, CH), 5.62 (d, 1H, J 
= 6.0 Hz, CH), 2.34 (s, 3H, CH3), 1.72 (s, 3H, CH3). 13C NMR (CDCl3, 100 MHz): δ 
143.2 (CAr), 138.8 (CAr), 135.9 (CAr), 133.0 (CAr), 131.2 (CArH), 130.8 (CAr), 128.9 
(CH), 128.3 (CArH), 128.18 (CArH), 128.08 (CArH), 127.7 (CArH), 127.5 (CArH), 127.4 
(CArH), 126.6 (CArH), 123.08 (CArH), 122.99 (CH), 56.7 (CH), 21.5 (CH3), 17.9 (CH). 










Colourless crystalline solid (71 mg, 76% yield); Tm = 135–137 °C. 1H 
NMR (CDCl3, 400 MHz): δ 7.68 (d, 1H, J = 8.0 Hz, HAr), 7.34 (d, 2H, 
J = 8.0 Hz, HAr), 7.27–7.31 (m, 4H, HAr), 7.15–7.24 (m, 7H, HAr), 7.11 
(d, 4H, J = 8.0 Hz, HAr), 6.00 (d, 1H, J = 6.0 Hz, CH), 5.76 (d, 1H, J = 6.0 Hz, CH), 
2.44–2.46 (m, 3H, CH), 2.32 (s, 3H, CH3), 2.13–2.15 (m, 1H, CH); 13C NMR (CDCl3, 
100 MHz): δ 143.5 (CAr), 141.7 (CAr), 138.7 (CAr), 136.5 (CAr), 135.2 (CAr), 133.4 
(CAr), 129.9 (C), 129.2 (CArH), 128.74 (CArH), 128.68 (CArH), 128.4 (CArH), 128.3 
(CArH), 128.1 (CArH), 127.9 (CArH), 127.6 (CArH), 126.8 (CArH), 126.3 (CArH), 123.0 
(CArH), 122.7 (CH), 56.8 (CH), 34.5 (CH2), 33.6 (CH2), 21.6 (CH). IR (neat, νmax, 
cm-1): 3060, 3023, 2923, 2851, 1643, 1596, 1490, 1451, 1342, 1163, 1087, 1032, 976, 
808, 682, 570, 544. MS (ESI) m/z calcd. (C30H27NO2S + Na+): 488.1655, found: 
488.1655 (M + Na+). 
4-Cyclopropyl-2-phenyl-1-tosyl-1,2-dihydroquinoline 171k 
Orange solid (59 mg, 73% yield); Tm = 116–118 °C. 1H NMR (CDCl3, 
400 MHz): δ 7.55 (dd, 1H, J = 7.5, 1.5 Hz, HAr), 7.40 (dd, 1H, J = 7.5, 
1.5 Hz, HAr), 7.11–7.21 (m, 10H, HAr), 7.01 (d, 2H, J = 8.0 Hz, HAr), 
5.89 (d, 1H, J = 6.0 Hz, CH), 5.55 (dd, 1H, J = 6.0, 1.5 Hz, CH), 2.28 (s, 3H, CH3), 
1.30–1.32 (m, 1H, CH), 0.65–0.67 (m, 1H, CH), 0.44–0.47 (m, 1H, CH), 0.10–0.14 
(m, 1H, CH), –0.30–0.33 (m, 1H, CH). 13C NMR (CDCl3, 100 MHz): δ 143.5 (CAr), 
138.8 (CAr), 136.8 (CAr), 136.2 (CAr), 132.9 (CAr), 130.9 (C), 129.1 (CArH), 128.5 
(CArH), 128.2 (CArH), 128.1 (CArH), 127.9 (CArH), 127.6 (CArH), 127.5 (CArH), 126.7 
(CArH), 123.7 (CArH), 121.9 (CH), 56.8 (CH), 21.6 (CH3), 11.9 (CH), 6.2 (CH2), 4.3 










1449, 1345, 1163, 1008, 782, 698, 575. MS (ESI) m/z calcd. (C25H23NO2S + Na+): 
424.1342, found: 424.1342 (M + Na+). 
4-Cyclopentyl-2-phenyl-1-tosyl-1,2-dihydroquinoline 171l 
Pale yellow oil (41 mg, 45% yield). 1H NMR (CDCl3, 500 MHz): δ 
7.64 (d, 1H, J = 7.5 Hz, HAr), 7.15–7.22 (m, 6H, HAr), 7.28–7.33 (m, 4H, 
HAr), 7.08 (d, 1H, J = 8.0 Hz, HAr), 5.99 (d, 1H, J = 6.5 Hz, CH), 5.71 
(dd, 1H, J = 6.5, 1.5 Hz, CH), 2.77–2.83 (m, 1H, CH), 2.33 (s, 3H, CH3), 1.80–1.86 
(m, 1H, CH), 1.58–1.64 (m, 2H, CH), 1.48–1.54 (m, 2H, CH), 1.34–1.42 (m, 2H, CH), 
0.33–0.38 (m, 1H, CH). 13C NMR (CDCl3, 125 MHz): δ 143.4 (CAr), 139.3 (CAr), 
138.9 (CAr), 136.6 (CAr), 133.2 (CAr), 130.8 (C), 129.2 (CArH), 128.6 (CArH), 128.4 
(CArH), 127.9 (CArH), 127.8 (CArH), 127.7 (CArH), 127.5 (CArH), 126.5 (CArH), 123.7 
(CArH), 119.7 (CH), 56.9 (CH), 39.8 (CH), 31.9 (CH2), 31.2 (CH2), 25.4 (CH2), 25.0 
(CH2), 21.6 (CH3). IR (neat, νmax, cm-1): 3061, 2955, 2916, 2866, 1598, 1492, 1450, 
1348, 1165, 1053, 809, 755, 704. MS (ESI) m/z calcd. (C27H27NO2S + Na+): 
452.1655, found: 452.1659 (M + Na+). 
2,4-Diphenyl-1-tosyl-1,2-dihydroquinoline 171m 
Colourless crystalline solid (51 mg, 55% yield); Tm = 195–197 °C. 1H 
NMR (CDCl3, 400 MHz): δ 7.71 (d, 1H, J = 8.0 Hz, HAr), 7.38 (t, 4H, 
J = 8.5 Hz, HAr), 7.27–7.30 (m, 4H, HAr), 7.24–7.25 (m, 3H, HAr), 7.03–7.11 (m, 3H, 
HAr), 6.84–6.88 (m, 3H, HAr), 6.18 (d, 1H, J = 6.5 Hz, CH), 5.89 (d, 1H, J = 6.5 Hz, 
CH), 2.31 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz): δ 143.6 (CAr), 138.7 (CAr), 
138.4 (CAr), 138.3 (CAr), 136.0 (CAr), 133.4 (C), 130.3 (CArH), 129.3 (CArH), 128.79 
(CArH), 128.76 (CArH), 128.64 (CArH), 128.60 (CArH), 128.2 (CArH), 128.1 (CArH), 










56.8 (CH), 21.5 (CH3). IR (neat, νmax, cm-1): 3058, 3031, 2917, 2849, 1738, 1594, 
1491, 1329, 1151, 1062, 988, 805, 753. MS (ESI) m/z calcd. (C28H23NO2S + Na+): 
460.1342, found: 460.1333 (M + Na+). 
4-(2-Methoxyphenyl)-2-phenyl-1-tosyl-1,2-dihydroquinoline 171n 
Off-white solid (86 mg, 92% yield); Tm = 203–205 °C. 1H NMR 
(CDCl3, 400 MHz): δ 7.67 (d, 1H, J = 8.0 Hz, HAr), 7.56 (d, 2H, J = 7.0 
Hz, HAr), 7.09–7.48 (m, 10H, HAr), 7.01 (t, 1H, J = 7.5 Hz, HAr), 6.93 
(d, 1H, J = 8.0 Hz, HAr), 6.86 (m, 1H, HAr), 6.67 (d, 1H, J = 8.0 Hz, HAr), 6.15 (d, 1H, 
J = 6.0 Hz, CH), 5.89 (d, 1H, J = 6.0 Hz, CH), 3.71 (brs, 3H, OCH3), 2.38 (s, 3H, 
CH3). 13C NMR (CDCl3, 100 MHz): δ 157.5 (CAr), 143.4 (CAr), 132.8 (CAr), 130.8 
(CArH), 129.3 (CArH), 128.5 (CArH), 128.2 (CArH), 128.1 (CArH), 128.0 (CArH), 127.7 
(CArH), 127.1 (CArH), 126.3 (CAr), 125.8 (CArH), 125.6 (CArH), 120.3 (CArH), 111.1 
(CH), 57.0 (CH3), 55.5 (CH), 21.6 (CH3). IR (neat, νmax, cm-1): 3067, 3027, 2917, 
1580, 1492, 1351, 1254, 1162, 988, 787, 700, 565. MS (ESI) m/z calcd. (C29H25NO3S 
+ Na+): 490.1447, found: 490.1438 (M + Na+). 
2-Phenyl-4-(thiophen-2-yl)-1-tosyl-1,2-dihydroquinoline 171o 
Black solid (54 mg, 61% yield); Tm = 158–160 °C. 1H NMR (CDCl3, 
400 MHz): δ 7.70 (d, 1H, J = 8.0 Hz, HAr), 7.34–7.37 (m, 4H, HAr), 
7.15–7.30 (m, 9H, HAr), 7.06 (d, 2H, J = 8.0 Hz, HAr), 6.99 (dd, 1H, J = 
5.0, 3.5 Hz, HAr), 6.69 (dd, 1H, J = 3.5, 1.0 Hz), 6.14 (d, 1H, J = 6.5 Hz, CH), 6.01 (d, 
1H, J = 6.5 Hz, CH), 2.27 (s, 3H, CH3). 13C NMR (CDCl3, 100 MHz): δ 143.7 (CAr), 
139.6 (CAr), 138.0 (CAr), 135.7 (CAr), 133.4 (CAr), 131.6 (CAr), 129.8 (CAr), 129.4 
(CArH), 128.9 (CArH), 128.9 (CArH), 128.6 (CArH), 128.1 (CArH), 127.7 (CArH), 127.4 











(CH), 56.7 (CH), 21.6 (CH3). IR (neat, νmax, cm-1): 3062, 3029, 2922, 2853, 1623, 
1598, 1449, 1347, 1164, 1089, 1062, 808, 698, 566. MS (ESI) m/z calcd. 
(C26H21NO2S2 + Na+): 466.0906, found: 466.0910 (M + Na+). 
Experimental procedure for the preparation of 2-phenyl-1-tosyl-1,2-dihydroquinoline 
171b mediated by chiral Brønsted acid BA21.  
To a solution of toluene (2 mL) containing 169b (23 mg, 0.06 mmol) 
was added BA21 (2 mg, 0.003 mmol) in one portion at 0 °C. On 
monitoring the reaction mixture to completion by TLC analysis after 2 h, the solvent 
was removed under reduced pressure and the resulting crude mixture was purified by 
column chromatography on silica gel (eluent: 10:1 nHexane-EtOAc) to afford the title 
compound. Colourless oil (19 mg, 89% yield). Enantiomeric excess is 35% as 
determined by chiral HPLC (Daicel Chiralpak IC column, 85:15 n–hexane–iPrOH, 
flow rate = 1.0 mL/min, 254 nm): major isomer: tR = 15.3 min; minor isomer: tR = 13.4 
min. 
Experimental procedure for the preparation of 2-(4-chlorophenyl)-3-tosyl-1a,2,3,7b-
tetrahydrooxireno[2,3-c]quinoline 227 
To a solution of dichloromethane (5 mL) containing 171c was 
added NaHCO3 (5 mg, 0.06 mmol) and m-CPBA (10 mg, 0.06 
mmol) in one portion at 0 °C. On monitoring the reaction mixture to completion by 
TLC analysis after 6 h, the solvent was removed under reduced pressure and the 
resulting crude mixture was purified by column chromatography on silica gel (eluent: 
5:1 n–hexane–EtOAc) to afford the title compound. Colourless oil (22 mg, 85% yield). 
1H NMR (CDCl3, 500 MHz): δ 7.74 (d, 1H, J = 8.0 Hz, HAr), 7.48 (d, 2H, J = 8.0 Hz, 
HAr), 7.30–7.35 (m, 2H, HAr), 7.14–7.25 (m, 7H, HAr), 5.87 (d, 1H, J = 2.0 Hz, CH), 










(CDCl3, 125 MHz): δ 143.7 (CAr), 135.7 (CAr), 135.1 (CAr), 134.5 (CAr), 133.6 
(CArCl), 130.1 (CArH), 129.9 (CArH), 129.2 (CArH), 129.13 (CArH), 129.10 (CArH), 
128.0 (CArH), 127.3 (CArH), 126.4 (CAr), 126.1 (CH), 62.1 (CH), 55.0 (CH), 50.8 (CH), 
21.8 (CH3). IR (neat, νmax, cm-1): 3069, 3032, 2923, 1598, 1491, 1343, 1162, 1091, 
976, 807, 760, 676, 569, 547. MS (ESI) m/z calcd. (C22H18ClNO3S + Na+): 434.0588 
& 436.0564 found: 434.0590 & 436.0579 (M + Na+). 
Experimental procedure for the preparation of 2-phenyl-1-tosyl-1,2,3,4-
tetrahydroquinoline 228 
To a round bottom flask containing Pd/C (0.10 g, 10 wt. %) in methanol 
(5 mL) and previously purged three times with nitrogen gas was added 
171c (0.025 g, 0.06 mmol) dissolved in methanol (5 mL). A hydrogen atmosphere was 
then purged into the stirring solution and the resulting reaction mixture was stirred at 
room temperature for 2 h. Upon completion, the reaction mixture was filtered through 
a pad of Celite and concentrated under reduced pressure. Purification by column 
chromatography on silica gel (eluent: 5:1 n–hexane–EtOAc) gave the title compound. 
Pale yellow oil (21 mg, 95% yield). 1H NMR (CDCl3, 500 MHz): δ 7.87 (d, 1H, J = 
8.0 Hz, HAr), 7.43 (d, 2H, J = 6.0 Hz, HAr), 7.28–7.31 (m, 5H, HAr), 7.18–7.22 (m, 3H, 
HAr), 7.10 (t, 1H, J = 7.5 Hz, HAr), 6.96 (d, 1H, J = 7.5 Hz, HAr), 5.36 (brs, 1H, CH), 
2.39 (s, 3H, CH3), 2.31–2.34 (m, 1H, CH2), 2.18 (brs, 1H, CH2), 1.79–1.88 (m, 2H, 
CH2). 13C NMR (CDCl3, 125 MHz): δ 143.6 (CAr), 142.6 (CAr), 136.4 (CAr), 136.3 
(CAr), 134.1 (CArH), 129.6 (CArH), 128.7 (CArH), 128.1 (CArH), 127.4 (CArH), 127.2 
(CArH), 127.1 (CArH), 126.9 (CArH), 126.3 (CArH), 125.7 (CArH), 59.8 (CH), 32.1 
(CH2), 25.5 (CH2), 21.7 (CH3). IR (neat, νmax, cm-1): 3030, 2950, 2869, 1599, 1487, 
1454, 1346, 1162, 1090, 972, 813, 794, 699, 660, 570. MS (ESI) m/z calcd. 






Chromatographs of 2-phenyl-1-tosyl-1,2-dihydroquinoline 171b 
HPLC resolution data were collected using a Daicel Chiralpak IC column, 85:15 n–
hexane–iPrOH, flow rate = 1.0 mL/min, 254 nm 
 
Figure 6.1: Racemic sample of 2-phenyl-1-tosyl-1,2-dihydroquinoline 171b 
 
Figure 6.2: Chiral trace for 2-phenyl-1-tosyl-1,2-dihydroquinoline 171b 
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6.5 Experimental Data for Chapter 4 
6.5.1 General Procedures 
a–Bromination – to access the a-bromo ketone 245 
 
a–Bromination with NBS: To a solution of the appropriate ketone (30 mmol) in MeCN 
(4.5 mL/mmol) at RT was added NBS (1.15 eq.), and p-TsOH (0.1 eq.). The resulting 
mixture was brought to reflux and allowed to stir for 12 h, or until completion as 
determined by TLC analysis. Upon completion Et2O (3 mL/mmol) was added and the 
solution washed with water (3 x 3 mL/mmol), and saturated NaHCO3 (3 mL/mmol). 
The combined organics were then dried over MgSO4 and the mixture concentrated 
under reduced pressure. The resulting solid residue was then recrystallised with a 
mixture of n-hexane and EtOAc circa. 6:1. 
a–Bromination with Br2: To a solution of the appropriate ketone (30 mmol) in DCM 
(4.5 mL/mmol) in an ice bath was added, dropwise, Br2 (1 eq.). The resulting mixture 
was kept below 3 °C and allowed to stir for 2 h, or until completion as determined by 
TLC analysis. Upon completion, water (3 mL/mmol) was added and the solution 
stirred for a further 4 h. The resulting mixture was extracted with EtOAc/nHexane 3:1 
(3 x 3 mL/mmol), sat. NaHCO3 (3 mL/mmol), and saturated brine (3 mL/mmol). The 
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Amination – to access the NH2.HCl salt 246 
 
To a solution of hexamethylenetetramine (1.1 eq.) in CHCl3 (3 mL/mmol) was added 
the appropriate bromo-ketone (10 mmol). The mixture was then brought to reflux and 
stirred vigorously for 4 h, or until completion as determined by TLC analysis. Upon 
completion the reaction mixture was cooled to RT and filtered. The collected 
precipitate was then suspended in EtOH (2 mL/mmol) and conc. HCl (1 mL/mmol) 
was added dropwise. The solution was then stirred at RT for 12 h. The resulting white 
precipitate was then removed via filtration and the filtrate collected and concentrated 
under reduced pressure. 
t-Butoxycarbonyl group installation to 247 
 
To a solution of the appropriate amino HCl salt (16 mmol), Boc2O (1.5 eq.) in DCM 
(3 mL/mmol) was added Na2CO3 (1.5 eq.) and the resulting mixture brought to reflux 
and stirred for 16 h, or until completion as determined by TLC analysis. Upon 
completion the reaction mixture was cooled to RT and Et2O (3 mL/mmol) was added 
to dilute the suspension. The solution was then washed with water (3 x 3 mL/mmol) 
and sat. brine (3 mL/mmol). The organic layer was then dried over MgSO4 and 
concentrated under reduced pressure and purified by column chromatography on silica 



















Condensation reaction – to access α,β-unsaturated ketone 248 
 
Under nitrogen atmosphere, to an anhydrous toluene (10 mL) solution of the 
appropriate acetamide (6 mmol), aldehyde (1.2 eq.), and propionic acid (0.2 eq.) was 
added piperidine (0.1 eq.). The resulting mixture was then stirred and heated to reflux 
for 16 h. The reaction mixture was then allowed to cool to room temperature. The 
resulting precipitate was filtered, dried in vacuo, and used in the next step without 
further purification. 
Sodium borohydride reduction – to access secondary allylic alcohols 172 
 
The appropriate ketone (1 mmol) was dissolved in EtOH (30 mL/mmol) and cooled to 
0 °C. Sodium borohydride (3 eq.) was added in one portion and the reaction mixture 
was allowed to stir for 2 h. Upon completion, the reaction mixture was quenched by 
the addition of water (1 mL/mmol) and the solvent was removed under reduced 
pressure. The crude mixture was dissolved in DCM (10 mL/mmol), washed with water 
(10 mL), brine (10 mL), dried over MgSO4, and concentrated under reduced pressure. 
The crude mixture was purified by column chromatography on silica gel (eluent: 40% 




























Grignard addition – to access tertiary allylic alcohols 172 
 
The appropriate ketone (1 mmol) was dissolved in THF (60 mL/mmol) and a solution 
of alkyl or aryl magnesium bromide (4.5 eq.) was added at -78 °C and subsequently 
allowed to return to room temperature. The reaction mixture was allowed to stir at 
room temperature for 12 h and the progress of the reaction was followed by TLC 
analysis and mass spectrometry. Upon completion, the reaction mixture was quenched 
with saturated NH4Cl (60 mL/mmol). After additional stirring at room temperature for 
10 min, EtOAc (90 mL/mmol) was added and the organic phase was separated. The 
aqueous phase was further extracted with EtOAc (3 x 30 mL/mmol) and the combined 
organic layers were washed with brine (60 mL), dried over anhydrous MgSO4 and 
concentrated under reduced pressure. The crude mixture was purified by column 
chromatography on silica gel (eluent: 40% EtOAc-nHexane) to afford the tertiary 
alcohol substrate. 
Brønsted acid-catalysed cyclisation of b–amino enols 174 and 175 
 
To a 2 mL round bottomed flask was added the appropriate β-amino enol (0.1 mmol) 
and a 1 mL solution of TfOH in EtOH (0.005 mmol/mL) in one portion. The reaction 
mixture was brought to reflux and allowed to stir for 0.25-1 h whilst the progress of 
the reaction was followed by TLC analysis. Upon completion, the reaction mixture 
was quenched with water (20 mL/mmol) and the product extracted with EtOAc (3 x 5 
RMgX




































mL). The combined organics were then washed with saturated brine (100 mL/mmol), 
dried over MgSO4 and subsequently concentrated under reduced pressure. The 
resulting residue was then purified using column chromatography (15% EtOAc–n–
hexane) to afford the oxazol-2(3H)-one 174 or oxazolidin-2-one 175.  
6.5.2 Compound Data 
t-Butyl (3-hydroxy-1,3-bis(4-methoxyphenyl)prop-1-en-2-yl)carbamate 172a 
 White solid (3.1 g, 77% yield); Tm = 94–96 °C. 1H NMR 
(CDCl3, 400 MHz): δ 7.34 (d, 2H, J = 8.5 Hz, HAr), 7.28 (d, 
2H, J = 8.5 Hz, HAr), 6.92-6.86 (m, 4H, HAr), 6.21 (brs, 1H, 
NH), 6.12 (s, 1H, C=CH), 5.41 (s, 1H. OCH), 5.25 (brs, 1H, OH), 3.76 (s, 3H, OCH3), 
3.75 (s, 3H, OCH3), 1.34 (brs, 9H, CCH3). 13C NMR (CDCl3, 100 MHz): δ 158.8 
(CAr), 158.7 (CAr), 154.3 (HNCOO), 135.4 (CAr), 133.4 (CArH), 129.8 (CArH), 127.6 
(CArH), 127.4 (CArH), 118.9 (=CH), 114.0 (CArH), 113.4 (CArH), 80.8 (C), 75.6 (CH), 
55.2 (OCH3), 28.0 (C(CH3)3). IR (neat, νmax, cm-1): 3007, 2967, 1694, 1606, 1507, 
1288, 1248, 1170, 1024, 890, 811, 771, 681. MS (ESI) m/z calcd. (C22H27NO5 + Na+) 
calcd.: 408.1787, found: 408.1783 (M + Na+). 
t-Butyl (3-hydroxy-3-(4-methoxyphenyl)-1-phenylprop-1-en-2-yl)carbamate 172b 
White solid (98 mg, 88% yield); Tm = 85–98 °C. 1H NMR 
(CDCl3, 400 MHz): δ 7.33-7.38 (m, 6H, HAr), 7.23-7.27 (m, 1H, 
HAr), 6.88 (d, 2H, J = 8.5 Hz, HAr), 6.25 (brs, 1H, NH), 6.09 (s, 1H, C=CH), 5.51 (d, 
1H, J = 7.5 Hz, OCH), 5.18 (brs, 1H, NH), 3.81 (s, 3H, OCH3), 1.34 (brs, 9H, CCH3). 
13C NMR (CDCl3, 100 MHz): δ 159.0 (CAr), 154.3 (HNCOO), 135.3 (CAr), 133.5 
(CAr), 128.9 (CArH), 128.7 (CArH), 127.6 (CArH), 127.5 (CArH), 113.6 (=CH), 81.3 (C), 










1524, 1230, 1151, 1015, 885, 803, 733, 680. MS (ESI) m/z calcd. (C21H25NO4 + Na+) 
calcd.: 378.1681, found: 378.1675 (M + Na+). 
t-Butyl (3-hydroxy-3-(4-methoxyphenyl)-1-(4-(trifluoromethyl)phenyl)prop-1-en-2-
yl)carbamate 172c 
 White solid (108 mg, 87% yield); Tm = 88–90 °C. 1H NMR 
(CDCl3, 400 MHz): δ 7.56 (d, 2H, J = 8.0 Hz, HAr), 7.44 (d, 
2H, J = 8.0 Hz, HAr), 7.34 (d, 2H, J = 8.5 Hz, HAr), 6.86 (d, 
2H, J = 8.5 Hz, HAr), 6.05-6.30, (m, 2H), 5.47 (s, 1H, CH), 3.78 (s, 3H, OCH3), 1.31 
(s, 9H, CCH3). 13C NMR (CDCl3, 100 MHz): δ 159.2 (CAr), 153.6 (HNCOO), 139.3 
(CAr), 138.8 (CAr), 132.9 (CArH), 128.7 (CArH), 127.7 (CArH), 125.5 (CArH), 124.2 (q, 
J = 272.5 Hz, CF3), 113.5 (=CH), 81.4 (C), 75.2 (OCH), 55.3 (OCH3), 28.0 (C(CH3)3). 
IR (neat, νmax, cm-1): 3445, 3260, 2988, 2936, 1702, 1612, 1507, 1323, 1242, 1158, 
1109, 1067, 1014, 827, 752. MS (ESI) m/z calcd. (C22H24F3NO4 - H+): 422.1579, 
found: 422.1581 (M - H+). 
t-Butyl (3-hydroxy-3-(4-methoxyphenyl)-1-(4-nitrophenyl)prop-1-en-2-yl)carbamate 
172d 
 Yellow solid (121 mg, 74% yield); Tm = 126–130 °C. 1H 
NMR (CDCl3, 400 MHz): δ 8.15 (d, 2H, J = 8.5 Hz, HAr), 
7.48 (d, 2H, J = 8.5 Hz, HAr), 7.34 (d, 2H, J = 8.5 Hz, HAr), 
6.88 (d, 2H, J = 8.5 Hz, HAr), 6.09-6.30 (m, 2H), 5.48 (d, 1H, J = 4.0 Hz, OCH), 3.79 
(s, 3H, CH3), 1.31 (brs, 9H, CCH3). 13C NMR (CDCl3, 100 MHz): δ 159.4 (CAr), 
153.1 (HNCOO), 146.3 (CAr), 142.8 (CAr), 140.1 (CAr), 132.5 (CArH), 129.1 (CArH), 
127.7 (CArH), 123.9 (CArH), 113.9 (=CH), 81.7 (C), 75.2 (OCH), 55.4 (OCH3), 28.1 















White solid (106 mg, 87% yield). Tm = 92–94 °C. 1H NMR 
(CDCl3, 500 MHz): ∂ 7.47 (d, 2H, J = 8.0 Hz, HAr), 7.35 (d, 
2H, J = 8.5 Hz, HAr), 7.21 (d, 2H, J = 8.5 Hz, HAr), 6.88 (d, 
2H, J = 8.0 Hz, HAr), 5.96-5.18 (m, 2H), 5.48 (s, 1H, OCH), 4.42 (brs, 1H, OH), 3.80 
(s, 3H, OCH3), 1.34 (brs, 9H, CCH3). 13C NMR (CDCl3, 125 MHz): ∂ 159.2 (CAr), 
153.9 (HNCOO), 134.3 (CAr), 133.1 (CAr), 131.9 (CAr), 130.3 (CArH), 127.7 (CArH), 
121.2 (CArH), 113.7 (CArH), 81.5 (=CH), 75.4 (C), 55.4 (OCH), 28.2 (OCH3). IR 
(neat, nmax/cm-1): 3456, 3251, 2926, 1715, 1509, 1345, 1261, 1171, 1111, 1055, 1019, 
759. MS (ESI) m/z calcd. (C21H24NO4Br + Na+): 456.0786 & 458.0766, found: 
456.0780 & 458.0759 (M + Na+). 
t-Butyl (3-hydroxy-3-(4-methoxyphenyl)-1-(naphthalen-2-yl)prop-1-en-2-yl)carbamate 
172f 
 Yellow solid (95 mg, 86% yield); Tm = 120–124 °C. 1H 
NMR (CDCl3, 400 MHz): δ 7.77–7.81 (m, 4H, HAr), 7.46–
7.52 (m, 3H, HAr), 7.42 (d, 2H, J = 8.5 Hz, HAr), 6.90 (d, 2H, J = 8.5 Hz, HAr), 6.37 
(brs, 1H, NH), 6.32 (s, 1H, C=CH), 5.55 (s, 1H, OCH), 3.79 (s, 3H, OCH3), 1.36 (brs, 
9H, CCH3). 13C NMR (CDCl3, 100 MHz): δ 158.9 (CAr), 154.1 (HNCOO), 137.4 
(CArH), 133.4 (CArH), 133.4 (CArH), 132.9 (CArH), 128.1 (CArH), 127.9 (CArH), 127.6 
(CArH), 126.4 (CArH), 118.7 (CArH), 113.5 (=CH), 81.0 (C), 75.4 (OCH), 55.2 (OCH3), 










815, 747, 671. MS (ESI) m/z calcd. (C25H27NO4 - OH+): 388.1913, found: 388.1903 
(M - OH+). 
t-Butyl (1-(benzofuran-2-yl)-3-hydroxy-3-(4-methoxyphenyl)prop-1-en-2-yl)carbamate 
172g 
 Brown solid (86 mg, 91% yield); Tm = 108–112 °C. 1H NMR 
(CDCl3, 400 MHz): δ 8.26 (brs, 1H, NH), 7.49-7.51 (m, 1H, 
HAr), 7.44-7.46 (m, 1H, HAr), 7.40 (d, 2H, J = 8.5 Hz, HAr), 
7.27 (dt, 1H, J = 7.5, 1.5 Hz, HAr), 7.22 (dt, 1H, J = 7.5, 1.5 Hz, HAr), 6.90 (d, 2H, 
HAr), 6.51 (d, 1H, J = 0.5 Hz, C=CH), 5.72 (d, 1H, J = 7.0 Hz, HAr), 5.70 (s, 1H, OCH), 
5.26 (brs, 1H, OH), 3.81 (s, 3H, OCH3), 1.47 (s, 9H, CCH3). 13C NMR (CDCl3, 100 
MHz): δ 158.9 (CAr), 154.2 (CAr), 153.5 (HNCOO), 153.4 (CAr), 140.1 (CAr), 133.2 
(CAr), 128.2 (CArH), 127.7 (CArH), 124.4 (CArH), 123.3 (CArH), 120.8 (CArH), 113.5 
(CArH), 110.8(CArH), 105.4(CArH), 101.6 (=CH), 81.6 (C), 73.7 (OCH), 55.3 (OCH3), 
28.2 (C(CH3)3). IR (neat, νmax, cm-1): 3491, 3396, 2977, 2933, 2837, 1715, 1490, 
1446, 1242, 1149, 1021, 821, 731. MS (ESI) m/z calcd. (C23H25NO5 + Na+): 
418.1630, found: 418.1597 (M + Na+). 
t-Butyl (1-(furan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)prop-1-en-2-yl)carbamate 172h 
 Yellow oil (131 mg, 84% yield). 1H NMR (CDCl3, 400 MHz): 
δ 7.77 (brs, 1H), 7.39 (d, 1H, J = 2.0 Hz, HAr), 7.33 (d, 2H, J = 
8.5 Hz, HAr), 6.82–6.86 (m, 2H), 6.37 (dd, 1H, J = 3.5, 2.0 Hz), 6.17 (d, 1H, J = 3.5 
Hz), 5.56 (brs, 1H), 5.60 (d, 1H, J = 7.0 Hz), 5.32 (brs, 1H), 3.76 (s, 3H), 1.40 (s, 9H, 
CCH3). 13C NMR (CDCl3, 100 MHz): δ 158.8 (CAr), 153.6 (HNCOO), 151.6 (CAr), 
141.5 (CArH), 136.8 (CArH), 133.5 (CArH), 127.6 (CArH), 113.4 (CHetArH), 111.4 









(neat, νmax, cm-1): 2933, 2837, 1685, 1604, 1508, 1366, 1245, 1155, 1020, 830, 767. 
MS (ESI) m/z calcd. (C19H23NO5 + Na+): 368.1452, found: 368.1474 (M + Na+). 
t-Butyl (1-hydroxy-1-(4-methoxyphenyl)-4-methylpent-2-en-2-yl)carbamate 172i 
 White solid (146 mg, 92% yield); Tm = 126–128 °C. 1H NMR 
(CDCl3, 400 MHz): δ 7.26 (d, 2H, J = 9.0 Hz, HAr), 6.83 (d, 2H, 
J = 9.0 H, HAr z), 5.75 (brs, 1H), 5.20-5.23 (m, 2H), 4.91 (brs, 1H), 3.77 (s, 3H), 2.45-
2.57 (m, 1H), 1.36 (s, 9H, CCH3), 1.00 (t, 6H, J = 6.0 Hz). 13C NMR (CDCl3, 100 
MHz): δ 158.7 (CAr), 154.9 (HNCCOO), 133.9 (CAr), 133.6 (CArH), 127.3 (CArH), 
113.4 (C), 80.4 (=CH), 75.8 (OCH), 55.2 (OCH3), 28.1 (C(CH3)3), 26.2 (CH), 22.4 
(CH), 22.4 (CH). IR (neat, νmax, cm-1): 3248, 2986, 2867, 1693, 1526, 1287, 1245, 
1163, 1021, 774, 681. MS (ESI) m/z calcd. (C18H27NO4 + Na+): 344.1838, found: 
344.1819 (M + Na+). 
t-Butyl (1-hydroxy-1-(4-methoxyphenyl)-4-methylhex-2-en-2-yl)carbamate 172j 
 White solid (101 mg, 88% yield); Tm = 90–94 °C. 1H NMR 
(CDCl3, 400 MHz): δ 7.28 (d, 2H, J = 8.5 Hz, HAr), 6.84 (d, 
2H, J = 8.5 Hz, HAr), 5.67-5.85 (m, 1H), 5.24-5.26 (m, 1H), 5.19 (d, 1H, J = 9.5 Hz, 
=CH), 5.06 (brs, 1H), 3.77 (s, 3H, OCH3), 2.22-2.32 (m, 1H), 1.37 (s, 9H, CCH3), 0.99 
(dd, 3H, J = 8.0, 6.5 Hz, CH), 0.87 (td, 3H, J = 7.5, 2.0 Hz, CH). 13C NMR (CDCl3, 
100 MHz): δ 158.6 (CAr), 155.0 (HNCOO), 134.8 (CAr), 134.0 (CArH), 127.3 (CArH), 
127.2, 113.4, 80.4 (=CH), 75.9 (OCH), 55.1 (OCH3), 33.1, 29.7, 28.1 (C(CH3)3), 20.0, 
11.9. IR (neat, νmax, cm-1): 3257, 2965, 2926, 1693, 1509, 1289, 1245, 1162, 1020, 
806, 772, 684. MS (ESI) m/z calcd. (C19H29NO4 + Na+): 358.1994, found: 358.1976 










t-Butyl (1-cyclohexyl-3-hydroxy-3-(4-methoxyphenyl)prop-1-en-2-yl)carbamate 172k 
 White solid (72 mg, 76% yield); Tm = 129–131 °C. 1H NMR 
(CDCl3, 400 MHz): δ 7.26 (d, 2H, J = 9.0 Hz, HAr), 6.83 (d, 2H, 
J = 9.0 Hz, HAr), 5.67 (brs, 1H), 5.20-5.23 (m, 2H), 4.83 (brs, 1H), 3.78 (s, 3H, OCH3), 
2.12-2.17 (m, 1H), 1.63-1.72 (m, 5H), 1.37 (s, 9H, CCH3), 1.05-1.26 (m, 5H). 13C 
NMR (CDCl3, 100 MHz): δ 158.8 (CAr), 155.0 (HNCOO), 134.1 (CAr), 134.1 (CArH), 
127.3 (CArH), 113.5, 80.6 (=CH), 76.0 (OCH3), 55.3 (C), 36.0, 32.6, 32.5 , 28.2 
(C(CH3)3), 26.0 (CH), 25.8 (OCH3), 25.8 (CH). IR (neat, νmax, cm-1): 3249, 2981, 
2925, 2847, 1694, 1527, 1509, 1286, 1243, 1160, 1021, 870, 685. MS (ESI) m/z calcd. 
(C21H31NO4 + H+): 362.2331, found: 362.2311 (M + H+). 
 t-Butyl (3-hydroxy-1-phenyl-3-(p-tolyl)prop-1-en-2-yl)carbamate 172l 
 White solid (136 mg, 89% yield); Tm = 110–115 °C. 1H NMR 
(CDCl3, 400 MHz): ∂ 7.33-7.37 (m, 6H, HAr), 7.23-7.25 (m, 1H, 
HAr), 7.14 (d, 2H, J = 8.0 Hz, HAr), 6.23 (brs, 1H), 6.11 (brs, 1H), 5.52 (d, 1H, J = 7.0 
Hz), 2.34 (s, 3H), 1.34 (brs, 9H, CCH3). 13C NMR (CDCl3, 125 MHz): ∂ 154.3 
(HNCOO), 138.4 (CAr), 137.0 (CAr), 135.3 (CArH), 128.9 (CArH), 128.7 (CArH), 127.5 
(CArH), 126.3 (CArH), 81.3, 75.9, 28.2 (C(CH3)3), 21.3 (CArMe). IR (neat, νmax, cm-
1): 3345, 3265, 2992, 1702, 1648, 1555, 1295, 1249, 1158, 1010, 781, 651. MS (ESI) 
m/z calcd. (C21H25NO3 + Na+): 362.1732, found: 362.1739 (M + Na+). 
t-Butyl (3-hydroxy-1,3-diphenylprop-1-en-2-yl)carbamate 172m 
 White solid (190 mg, 85% yield); Tm = 106–110 °C. 1H NMR (CDCl3, 
400 MHz): δ 7.60-7.58 (m, 2H, HAr), 7.48-7.44 (m, 5H, HAr), 7.40-7.34 
(m, 2H, HAr), 6.54 (brs, 1H, NH), 6.31 (s, 1H, C=CH), 5.43-5.80 (m, 2H), 1.45 (brs, 













(CArH), 128.5 (CArH), 128.0 (CArH), 127.3 (CArH), 127.2 (CArH), 126.2 (CArH), 118.8 
(C=CH), 81.0 (C), 75.8 (OCH), 27.9 (C(CH3)3). IR (neat, νmax, cm-1): 3335, 3239, 
2986, 1694, 1642, 1523, 1274, 1252, 1163, 1022, 773, 679. MS (ESI) m/z calcd. 
(C20H23NO3 + Na+): 348.1576, found: 348.1573 (M + Na+). 
t-Butyl (1-cyclohexyl-3-hydroxy-3-phenylprop-1-en-2-yl)carbamate 172n 
 White solid (151 mg, 89% yield); Tm = 146–150 °C. 1H NMR (CDCl3, 
400 MHz): δ 7.34–7.36 (m, 2H, HAr), 7.27–7.31 (m, 2H, HAr), 7.20–
7.23 (m, 1H, HAr), 5.69 (brs, 1H, NH), 5.22–5.27 (m, 2H), 5.05 (brs, 1H, OH), 2.13–
2.20 (m, 1H, CH), 1.63-1.73 (m, 5H, CH), 1.35 (brs, 9H, CCH3), 1.06–1.30 (m, 5H, 
CH). 13C NMR (CDCl3, 100 MHz): δ 155.0 (HNCOO), 141.8 (CAr), 133.9 (CAr), 
128.0 (CArH), 127.0 (CArH), 126.1 (CArH), 80.7 (=CH)), 76.5 (OCH), 35.9 (CH), 32.6 
(CH), 32.4 (CH), 28.1 (C(CH3)3), 26.0 (CH), 25.8 (CH), 25.7 (CH). IR (neat, νmax, 
cm-1): 3256, 2925, 2849, 1694, 1526, 1447, 1288, 1164, 1010, 891, 694. MS (ESI) 
m/z calcd. (C20H29NO3 + Na+): 354.2045, found: 354.2043 (M + Na+). 
t-Butyl (3-hydroxy-3,3-bis(4-methoxyphenyl)-1-(4-(trifluoromethyl)phenyl)prop-1-en-2-
yl)carbamate 172o 
 White solid (162 mg, 69% yield); Tm = 114–116 °C. 1H 
NMR (CDCl3, 400 MHz): δ 7.52 (d, 2H, J = 8.0 Hz, HAr), 
7.43 (d, 2H, J = 8.0 Hz, HAr), 7.33 (d, 4H, J = 9.0 Hz, HAr), 
6.86 (d, 4H, J = 9.0 Hz, HAr), 6.24 (brs, 1H), 5.88 (brs, 1H), 3.80 (s, 6H, OCH3), 1.18 
(brs, 9H, CCH3). 13C NMR (CDCl3, 100 MHz): δ 159.1 (CAr), 152.7 (HNCOO), 140.1 
(CAr), 136.4 (CAr), 129.0 (C), 128.5 (CArH), 127.1 (CArH), 126.4 (q, J = 270.5 Hz), 
125.2 (CArH), 121.2 (CArH), 113.5 (=CH), 82.1 (C), 80.9 (C), 55.5 (OCH3), 27.9 












1247, 1161, 1122, 1108, 1065, 828. MS (ESI) m/z calcd. (C29H30F3NO5 + Na+): 
552.1974, found: 552.1959 (M + Na+). 
t-Butyl (1-cyclopropyl-3-hydroxy-3,3-bis(4-methoxyphenyl)prop-1-en-2-yl)carbamate 
172p 
 White solid (81 mg, 61% yield); Tm = 140–142 °C. 1H NMR 
(CDCl3, 400 MHz): δ 7.20 (d, 4H, J = 9.0 Hz, HAr), 6.74 (d, 4H, 
J = 9.0 Hz, HAr), 5.84 (brs, 1H), 4.35 (d, 1H, J = 9.0 Hz, =CH), 
3.70 (s, 6H, OCH3), 1.37-1.46 (m, 1H, CH), 1.27 (s, 9H, CCH3), 0.67-0.71 (m, 2H, 
CH), 0.19-0.23 (m, 2H, CH). 13C NMR (CDCl3, 100 MHz): δ 158.7 (CArH), 154.6 
(HNCOO), 137.1 (CAr), 136.6 (C), 131.9 (CArH), 128.8 (CArH), 113.2 (=CH), 81.6 (C), 
80.2 (C), 55.3 (OCH3), 28.2 (C(CH3)3), 10.3 (CH2), 7.1 (CH). IR (neat, νmax, cm-1): 
3300, 3002, 2963, 2908, 2833, 1685, 1609, 1508, 1284, 1245, 1170, 1035, 826, 812. 
MS (ESI) m/z calcd. (C25H31NO5 + Na+): 448.2081, found: 448.2100 (M + Na+). 
t-Butyl (1-cyclohexyl-3-hydroxy-3,3-bis(4-methoxyphenyl)prop-1-en-2-yl)carbamate 
172q 
 White solid (147 mg, 92% yield); Tm = 144–148 °C. 1H NMR 
(CDCl3, 400 MHz): δ 7.79 (d, 4H, J = 9.0 Hz, HAr), 7.33 (d, 4H, 
J = 9.0 Hz, HAr), 6.25 (brs, 1H), 5.45 (d, 1H, J = 9.0 Hz, =CH), 
5.01 (brs, 1H), 4.28 (s, 6H, OCH3), 2.71-2.79 (m, 1H, CH), 2.16-2.23 (m, 5H, CH), 
1.87 (s, 9H, CCH3), 1,61-1.78 (m, 3H, CH), 1.44-1.53 (m, 2H, CH). 13C NMR (CDCl3, 
100 MHz): δ 158.6 (CAr), 155.1 (HNCOO), 153.2 (CAr), 150.2 (C), 136.9 (CArH), 
135.4 (CArH), 134.6 (CArH), 128.8 (CArH), 113.2 (=CH), 81.8 (C), 80.2 (C), 55.2 
(OCH3), 37.1 (CH), 32.2 (CH), 28.1 (C(CH3)3), 26.0 (CH), 25.8 (CH). IR (neat, νmax, 
cm-1): 2924, 2847, 1683, 1606, 1528, 1505, 1246, 1167, 1020, 829, 766, 671. MS 











t-Butyl (1-cyclohexyl-3-hydroxy-3,3-diphenylprop-1-en-2-yl)carbamate 172r 
White solid (189 mg, 99% yield). Tm = 139–142 °C. 1H NMR (CDCl3, 
400 MHz): ∂ 7.45 (d, 4H, J = 7.5 Hz, HAr), 7.28 (t, 4H, J = 7.5 Hz, HAr), 
7.22 (t, 2H, J = 7.5 Hz, HAr), 6.99 (brs, 1h), 5.91 (brs, 1H), 4.84 (d, 1H, J = 9.5 Hz, 
=CH), 2.36 (dtt, 1H, J = 21.0, 11.0, 3.5 Hz, CH), 1.71-1.74 (m, 2H), 1.58-1.65 (m, 
3H), 1.30 (s, 9H, CCH3), 1.21-1.26 (m, 2H, CH), 1.08-1.16 (m, 1H, CH), 0.86-0.94 
(m, 2H, CH). 13C NMR (CDCl3, 125 MHz): ∂ 146.7 (HNCOO), 137.4 (CAr), 135.1 
(CArH), 128.7 (CArH), 127.7 (CArH), 83.1 (=CH), 80.0 (C), 37.9 (CH), 33.1 (CH), 28.5 
(C(CH3)3), 26.8 (CH), 26.7 (CH). IR (neat, νmax, cm-1): 3259, 2928, 2855, 1691, 1522, 
1454, 1279, 1178, 1016, 887, 689. MS (ESI) m/z calcd. (C26H33NO3 + Na+): 
430.2358, found: 430.2362 (M + Na+). 
t-Butyl (3-hydroxy-3-methyl-1-phenylbut-1-en-2-yl)carbamate 172s 
White solid (108 mg, 68% yield). Tm = 86–88 °C. 1H NMR (CDCl3, 
400 MHz): ∂ 7.43 (d, 2H, J = 7.5 Hz, HAr), 7.27 (t, 2H, J = 7.5, HAr), 
7.16 (t, 1H, J = 7.5, HAr), 6.47 (d, 1H, J = 3.0 Hz), 4.15 (brs, 1H), 1.41 (s, 6H, CCH3), 
1.30 (brs, 9H, CCH3). 13C NMR (CDCl3, 125 MHz): ∂ 154.4 (HNCOO), 129.4 (C), 
128.9 (CAr), 127.4 (CArH), 120.2 (CArH), 79.5 (C), 73.1 (C), 28.9 (CCH3), 28.9 
(C(CH3)3). IR (neat, νmax, cm-1): 3520, 3351, 2921, 28102, 1752, 1479, 1023, 902, 
699. MS (ESI) m/z calcd. (C16H23NO3 + Na+): 300.1576, found: 300.1580 (M + 
Na+). 
t-Butyl (1-(furan-2-yl)-3-hydroxy-3-methylbut-1-en-2-yl)carbamate 172t 
White solid (114 mg, 61% yield). Tm = 92–95 °C. 1H NMR (CDCl3, 
400 MHz): ∂ 7.47 (m, 1H), 7.03 (brs, 1H), 6.43 (m, H), 6.40 (m, 1H), 


















(CDCl3, 125 MHz): ∂ 154.7 (CHet), 152.7 (HNCOO), 142.2 (C), 140.5 (CHetArH), 
112.1 (CHetArH), 110.3 (CHetArH), 109.7, 79.7 (=CH), 72.9 (C), 28.8 (C), 28.5 
(C(CH3)3). IR (neat, νmax, cm-1): 3509, 3390, 2909, 2810, 1732, 1501, 1438, 1125, 
1039, 846, 755. MS (ESI) m/z calcd. (C14H21NO4 + Na+): 290.3148, found: 290.3160 
(M + Na+). 
t-Butyl (1-(benzofuran-2-yl)-3-hydroxy-3-methylbut-1-en-2-yl)carbamate 172u 
White solid (92 mg, 69% yield). Tm = 98–101 °C. 1H NMR (CDCl3, 
400 MHz): ∂ 7.50 (d, 1H, J = 8.0 Hz, HAr), 7.41 (d, 1H, J = 8.0 Hz, 
HAr), 7.24 (t, 1H, J = 8.0 Hz, HAr), 7.18 (t, 1H, J = 8.0 Hz, HAr), 6.76 
(s, 1H, HHetAr), 6.53 (s, 1H, HHetAr), 6.52 (s, 1H, HHetAr), 4.36 (brs, 1H), 1.44 (s, 6H, 
CCH3), 1.40 (s, 9H, CCH3). 13C NMR (CDCl3, 125 MHz): ∂ 154.3 (CHetAr), 154.2 
(CHetAr), 153.2 (HNCOO), 143.3 (C), 129.0 (CHetAr), 123.9 (CArH), 122.7 (CArH), 120.6 
(CArH), 110.6 (CHetArH), 108.0 (=CH), 105.0 (CHetAr), 78.9 (C), 72.1 (C), 27.9 
(C(CH3)3), 27.6 (CCH3). IR (neat, νmax, cm-1): 3496, 3390, 2899, 2842, 1722, 1515, 
1440, 1158, 1028, 824, 730. MS (ESI) m/z calcd. (C18H23NO4 + Na+): 340.1525, 
found: 340.1533 (M + Na+). 
t–Butyl (3-hydroxy-1,3,3-triphenylprop-1-en-2-yl)carbamate 172v 
White solid (125 mg, 78% yield). Tm = 132–136 °C. 1H NMR (CDCl3, 
400 MHz): ∂ 7.75–7.82 (m, 2H, HAr), 7.65 (t, 2H, J = 8.5 Hz, HAr), 
7.30–7.51, (m, 11H, HAr), 6.29 (brs, 1H), 5.69 (s, 1H, =CH), 5.16 (brs, 1H), 1.75 (s, 
9H, CCH3). 13C NMR (CDCl3, 125 MHz): ∂. IR (neat, νmax, cm-1): 3301, 2915, 2867, 
1709, 1525, 1241, 1169, 1025, 899, 711. MS (ESI) m/z calcd. (C26H27NO3 + Na+): 















White solid (19 mg, 59% yield). Tm = 90–94 °C. 1H NMR 
(d6-acetone, 500 MHz): ∂ 9.47 (s, 1H, NH), 7.47 (d, 2H, J 
= 9.0 Hz, HAr), 7.22 (d, 2H, J = 8.5 Hz, HAr), 6.99 (d, 2H, J 
= 9.0 Hz, HAr), 6.89 (d, 2H, J = 8.5 Hz, HAr), 3.94 (s, 2H, CH), 3.82 (s, 3H, CH), 3.77 
(s, 3H, CH). 13C NMR (d6-acetone, 125 MHz): ∂ 160.3 (CAr), 159.8 (CAr), 155.3 (C), 
130.1 (CAr), 129.8 (CArH), 127.3 (CAr), 125.3 (CArH), 122.2 (C), 120.4 (C), 115.3 
(CArH), 115.1 (CArH), 55.7 (CH3), 55.2 (CH3), 30.8 (CH2). IR (neat, νmax, cm-1): 3183, 
2950, 1735, 1608, 1515, 1241. MS (ESI) m/z calcd. (C18H17NO4 + Na+): 334.1052, 
found: 334.1055 (M + Na+). 
4-Benzyl-5-(4-methoxyphenyl)oxazol-2(3H)-one 174b 
White solid (17.5 mg, 62% yield). Tm = 88–94 °C. 1H NMR (d6-
acetone, 500 MHz): ∂ 9.33 (brs, 1H, NH), 7.43 (d, 2H, J = 9.0 Hz, 
HAr), 7.30-7.34 (m, 2H), 7.23-7.26 (m, 3H), 6.99 (d, 2H, J = 9.0 Hz, HAr), 3.93 (s, 2H, 
CH), 3.82 (s, 3H, CH). 13C NMR (d6-acetone, 125 MHz): ∂ 159.51 (CAr), 156.3 (C), 
136.2 (CAr), 136.1 (CAr), 129.2 (CArH), 128.4 (CArH), 127.4 (C), 126.8 (CArH), 120.7 
(CAr), 118.83 (C), 114.4 (CArH), 55.5 (CH), 30.5 (CH). IR (neat, νmax, cm-1): 3187, 
2955, 1740, 1604, 1510, 1246. MS (ESI) m/z calcd. (C17H15NO3 + Na+): 304.0950, 
found: 304.0942 (M + Na+). 
5-(4-Methoxyphenyl)-4-(4-(trifluoromethyl)benzyl)oxazol-2(3H)-one 174c 
White solid (34 mg, 98% yield). Tm = 88–90 °C. 1H NMR 
(CDCl3, 400 MHz): ∂ 8.31 (brs, 1H, NH), 7.61 (d, 2H J = 
8.0 Hz, HAr), 7.42 (d, 2H, J = 9.0 Hz) , HAr, 7.38 (d, 2H, J = 

















NMR (CDCl3, 125 MHz): ∂ 159.8 (CAr), 155.6 (C), 140.0 (CAr), 136.9 (CAr), 128.8 
(CArH), 128.67 (q, J = 237.0 Hz, CArH), 126.9 (C), 126.3 (q, J = 4.0 Hz, C), 120.3 (C), 
117.2 (CArH), 114.6 (CArH), 55.5 (CH3), 30.4 (CH2). 19F NMR (CDCl3, 470 MHz): ∂ 
-62.59. IR (neat, νmax, cm-1): 3178, 2927, 1741, 1611, 1513, 1252. MS (ESI) m/z 
calcd. (C18H14F3NO3 + Na+): 372.0823, found: 372.0819 (M + Na+). 
5-(4-Methoxyphenyl)-4-(4-nitrobenzyl)oxazol-2(3H)-one 174d 
Whites solid (20 mg, 60% yield). Tm = 118–123 °C. 1H 
NMR (d6-DMSO, 400 MHz): ∂ 10.83 (s, 1H, NH), 8.20 (d, 
2H, J = 8.5 Hz, HAr), 7.54 (d, 2H, J = 8.5 Hz) , HAr, 7.38 (d, 
2H, J = 9.0 Hz, HAr), 6.98 (d, 2H, J = 9.0 Hz, HAr), 4.08 (s, 2H, CH2), 3.76 (s, 3H, 
CH). 13C NMR (d6-DMSO, 125 MHz): ∂ 158.8 (CAr), 154.2 (CAr), 146.5 (C), 145.1 
(CAr), 134.8 (C), 129.3 (CArH), 126.0 (CArH), 123.8 (CArH), 120.3 (CAr), 117.8 (C), 
114.5 (CArH), 55.2 (CH), 29.3 (CH). IR (neat, νmax, cm-1): 3174, 2961, 1733, 1607, 
1511, 1251. MS (ESI) m/z calcd. (C17H14N2O5 + Na+): 349.0800, found: 349.0781 
(M + Na+). 
4-(4-Bromobenzyl)-5-(4-methoxyphenyl)oxazol-2(3H)-one 174e 
Colourless oil (17 mg, 47% yield). 1H NMR (CDCl3, 400 
MHz): ∂ 8.47 (brs, 1H, NH), 7.47 (d, 2H, J = 8.5 Hz, HAr), 
7.42 (d, 2H, J = 9.0 Hz, HAr), 7.12 (d, 2H, J = 8.5 Hz, HAr), 
6.94 (d, 2H, J = 9.0 Hz, HAr), 3.89 (s, 2H, CH), 3.83 (s, 3H, CH). 13C NMR (CDCl3, 
125 MHz): ∂ 160.9 (CAr), 156.0 (CAr), 151.3 (C), 141.4 (CAr), 135.5 (CArH), 129.3 
(CArH), 128.4 (CArH), 114.5 (C), 111.7 (CAr), 106.7 (C), 90.2  (CArH), 82.2 (CH), 55.5 













(C17H14BrNO3 + Na+): 382.0055 & 384.0044, found: 382.0050 & 384.0031 (M + 
Na+). 
4-(4-Bromobenzylidene)-5-(4-methoxyphenyl)oxazolidin-2-one 175e’ 
Colourless oil (7.5 mg, 21% yield). 1H NMR (CDCl3, 500 
MHz): ∂ 7.88 (brs, 1H, NH), 7.46 (d, 2H, J = 8.5 Hz, HAr), 
7.36 (d, 2H, J = 8.5 Hz, HAr), 7.05 (d, 2H, J = 8.5 Hz, HAr), 
6.96 (d, 2H,  J = 8.5 Hz, HAr), 6.06 (d, 1H, J = 1.5 Hz, =CH), 5.18 (d, 1H, J = 1.5 Hz, 
CH), 3.84 (s, 3H, CH). 13C NMR (CDCl3, 125 MHz): ∂ 160.9 (CAr), 156.7 (CAr), 
137.2 (C), 134.0 (CAr), 132.3 (CArH), 129.4 (CArH), 128.7 (CArH), 128.5 (C), 120.5 
(C), 114.6 (=CH), 100.0 (CH), 82.9 (CH), 55.5 (CH). IR (neat, νmax, cm-1): 3255, 
2960, 1760, 1611, 1514, 1248. MS (ESI) m/z calcd. (C17H14BrNO3 + Na+): 382.0055 
& 384.0044, found: 382.0050 & 384.0031 (M + Na+). 
5-(4-Methoxyphenyl)-4-(naphthalen-2-ylmethyl)oxazol-2(3H)-one 174f 
Yellow solid (33 mg, 99% yield). Tm = 120–124 °C. 1H 
NMR (d6-DMSO, 400 MHz): ∂ 10.87 (s, 1H, NH), 7.87-
7.90 (m, 3H, HAr), 7.76 (s, 1H, HAr), 7.47-7.50 (m, 2H, HAr), 
7.42 (d, 2H, HAr), 6.98 (d, 2H, HAr), 4.09 (s, 2H, CH), 3.75 (s, 3H, CH). 13C NMR 
(d6-DMSO, 125 MHz): ∂ 158.7 (CAr), 154.5 (C), 134.7 (CAr), 133.1 (CAr), 131.9 (CAr), 
128.3 (CArH), 127.5 (CArH), 126.6 (CArH), 126.3 (CArH), 126.0 (CArH), 125.7 (CArH), 
120.7 (C), 119.0 (CAr), 114.5 (C), 55.1 (CH), 29.6 (CH). IR (neat, νmax, cm-1): 3188, 
2960, 1738, 1609, 1509, 1248. MS (ESI) m/z calcd. (C21H17NO3 + Na+): 354.1106, 















Brown solid (22 mg, 68% yield). Tm = 108–112 °C. 1H NMR 
(d6-DMSO, 400 MHz): ∂ 10.84 (s, 1H, NH), 7.55 (dd, 1H, J 
= 8.0, 1.0 Hz, HAr), 7.49 (dd, 1H, J = 8.0, 1.0 Hz, HAr), 7.38 
(d, 2H, J = 9.0 Hz, HAr), 7.22 (td, 1H, J = 7.5, 1.5 Hz, HAr), 7.17 (td, 1H, J = 7.5, 1.5 
Hz, HAr), 7.01 (d, 2H, J = 9.0 Hz, HAr), 6.69 (s, 1H, HHetAr), 6.30 (d, 1H, J = 2.0 Hz, 
=CH), 5.21 (d, 1H, J = 2.0 Hz, CH), 3.78 (s, 3H, CH3). 13C NMR (d6-DMSO, 125 
MHz): ∂ 160.1 (CAr), 156.5 (C), 153.8 (CAr), 152.8 (CAr), 140.2 (CAr), 129.3 (CArH), 
129.0 (C), 128.8 (CArH), 123.5 (CArH), 122.9 (CArH), 114.4 (CArH), 111.2 (CArH), 
101.6 (CArH), 88.5 (=CH), 80.6 (CH), 55.3 (CH). IR (neat, νmax, cm-1): 3281, 2961, 
1766, 1611, 1514, 1248. MS (ESI) m/z calcd. (C15H13NO4 + Na+): 294.0742, found: 
294.0739 (M + Na+). 
4-(Furan-2-ylmethylene)-5-(4-methoxyphenyl)oxazolidin-2-one 174h 
Yellow oil (14 mg, 51% yield). 1H NMR (CDCl3, 500 MHz): ∂ 
8.23 (brs, 1H, NH), 7.41 (m, 1H, HAr), 7.34 (d, 2H, J = 8.5 Hz, 
HAr), 6.94 (d, 2H, J = 8.5 Hz), 6.38 (dd, 1H, J = 3.0, 2.0 Hz, 
=CH), 6.06 (d, 1H, J = 1.5 Hz, HHetAr), 6.03 (d, 1H, J = 3.0 Hz, CH), 5.11 (d, 1H, J = 
1.5 Hz, CH), 3.83 (s, 3H, CH). 13C NMR (CDCl3, 125 MHz): ∂ 160.9 (CAr), 156.0 
(C), 151.3 (CAr), 141.4 (CArH), 135.5 (CAr), 129.3 (CArH), 128.4 (C), 114.5 (CArH), 
111.7 (CArH), 106.7 (CArH), 90.2 (=CH), 82.2 (CH), 55.5 (CH). IR (neat, νmax, cm-1): 
3281, 2961, 1766, 1611, 1514, 1248. MS (ESI) m/z calcd. (C15H13NO4 + Na+): 














White solid (19 mg, 94% yield). Tm = 126–128 °C. 1H NMR (d6-
DMSO, 400 MHz): ∂ 10.687 (s, 1H, NH), 7.37 (d, 2H, J = 9.0 
Hz, HAr), 6.98 (d, 2H, J = 9.0 Hz, HAr), 3.76 (s, 3H, CH), 2.39 (d, 2H, J = 7.0 Hz, CH), 
1.93 (hept, 1H, J = 7.0 Hz, CH), 0.90 (d, 6H, J = 7.0 Hz, CH). 13C NMR (d6-DMSO, 
125 MHz): ∂ 158.4 (CAr), 154.5 (C), 133.9 (CAr), 126.0 (CArH), 121.06 (C), 120.3 (C), 
114.4 (CArH), 55.2 (CH), 32.5 (CH), 27.1 (CH), 22.0 (CH). IR (neat, νmax, cm-1): 
3184, 2958, 1744, 1605, 1512, 1249. MS (ESI) m/z calcd. (C14H17NO3 + Na+): 
270.1106, found: 270.1101 (M + Na+). 
5-(4-Methoxyphenyl)-4-(2-methylbutylidene)oxazolidin-2-one 174j 
White solid (22.5 mg, 86% yield). Tm = 90–94 °C. 1H NMR 
(d6-DMSO, 400 MHz): ∂ 10.65 (s, 1H, NH), 7.35 (d, 2H, J 
= 9.0 Hz, HAr), 6.96 (d, 2H, J = 9.0 Hz, HAr), 3.74 (s, 3H, CH), 2.48 (dd, 1H, J = 14.5, 
6.5 Hz, CH), 2.30 (dd, 1H, J = 14.5, 6.5 Hz, CH), 1.69 (oct, 1H, J = 7.5 Hz, CH), 1.39-
1.29 (m, 1H, CH), 1.18-1.07 (m, 1H, CH), 0.84-0.80 (m, 6H, CH). 13C NMR (CDCl3, 
125 MHz): ∂ 158.4 (CAr), 154.5 (C), 133.9 (CAr), 126.0 (CArH), 121.1 (C), 120.3 (C), 
114.3 (CArH), 55.1 (CH), 33.2 (CH), 30.7 (CH), 28.6 (CH), 18.6 (CH), 11.1 (CH). IR 
(neat, νmax, cm-1): 3203, 2960, 1741, 1603, 1513, 1251. MS (ESI) m/z calcd. 
(C15H19NO3 + Na+): 284.1263, found: 284.1257 (M + Na+). 
4-(Cyclohexylmethyl)-5-(4-methoxyphenyl)oxazol-2(3H)-one 174k 
White solid (28 mg, 97% yield). Tm = 129–131 °C. 1H NMR (d6-
DMSO, 400 MHz): ∂ 10.64 (s, 1H, CH), 7.37 (d, 2H, J = 9.0 Hz, , 
HAr), 6.98 (d, 2H, J = 9.0 Hz, HAr), 3.77 (s, 3H, CH), 2.40 (d, 2H, J = 7.5 Hz, CH), 


















(d6-DMSO, 125 MHz): ∂ 158.4 (CAr), 154.4 (C), 133.9 (CAr), 125.9 (CArH), 121.1 
(C), 119.9 (C), 114.3 (CArH), 55.1 (CH), 36.4 (CH), 32.4 (CH), 31.1 (CH), 25.8 (CH), 
25.6 (CH). IR (neat, νmax, cm-1): 3183, 2921, 1744, 1607, 1513, 1251. MS (ESI) m/z 
calcd. (C17H21NO3 + Na+): 310.1419, found: 310.1414 (M + Na+). 
4-Benzyl-5-(p-tolyl)oxazol-2(3H)-one 174l and 4-(4-Methylbenzyl)-5-phenyloxazol-
2(3H)-one 174l’ 
 White solid (17 mg, 65%. Ratio = 10:1). Tm 
= 92–96 °C. 1H NMR (d6-acetone, 500 
MHz): ∂ 9.56-9.60 (m, 2H, NH), 7.55 (d, 2H, HAr) 7.43 (d, 2H, J = 8.0 Hz, HAr), 7.30-
7.35 (m, 4H, HAr), 7.24 (d, 2H, J = 8.0 Hz, HAr), 7.16 (d, 2H, HAr), 7.14 (d, 2H, HAr), 
4.05 (s, 2H, CH), 4.02 (s, 2H, CH), 2.35 (s, 3H, CH), 2.29 (s, 3H, CH). 13C NMR (d6-
acetone, 125 MHz): ∂ 155.3 (C), 138.4 (CAr), 138.0, 137.3, 136.2, 130.4, 129.7, 129.1, 
127.8, 126.9, 125.6, 121.0 (C), 30.8 (CH), 21.3 (CH). IR (neat, νmax, cm-1): 3180, 
2951, 1742, 1603, 1514, 1245. MS (ESI) m/z calcd. (C17H15NO2 + Na+): 288.1000, 
found: 288.0982 (M + Na+). 
4-Benzyl-5-phenyloxazol-2(3H)-one 174m9 
White solid (10.5 mg, 42% yield). Tm = 106–110 °C. 1H NMR (CDCl3, 
400 MHz): ∂ 9.05 (brs, 1H, NH), 7.45 (d, 2H, J = 9.0 Hz, HAr), 7.18–7.35 
(m, 8H, HAr), 3.91 (s, 2H, CH2). 13C NMR (CDCl3, 125 MHz): 156.0 (C), 136.1 (CAr), 
135.8 (CAr), 129.3 (CArH), 129.0 (CArH), 128.4 (CArH), 128.1 (CArH), 128.1 (C), 127.6 
(CArH), 125.1 (CArH), 120.3 (C), 30.6 (CH). IR (neat, νmax, cm-1): 3275, 2950, 1759, 
1581, 1499, 1229. MS (ESI) m/z calcd. (C16H13NO2 + Na+): 274.0844, found: 



















White solid (15 mg, 58% yield). Tm = 146–150 °C. 1H NMR (d6-DMSO, 
400 MHz): ∂ 10.78 (s, 1H, NH), 7.39-7.46 (m, 4H, HAr), 7.25-7.29 (m, 1H, 
HAr), 2.46 (d, 2H, J = 7.0 Hz, CH), 1.58-1.68 (m, 6H, CH), 1.09-1.22 (m, 3H, CH), 
0.92-1.00 (m, 2H, CH). 13C NMR (d6-DMSO, 125 MHz): ∂ 154.3 (C), 133.7 (CAr), 
128.9 (CArH), 128.5 (C), 127.0 (C), 124.1 (CArH), 121.9 (CArH), 36.4 (CH), 32.3 (CH), 
31.2 (CH), 25.8 (CH), 25.6 (CH). IR (neat, νmax, cm-1): 3192, 2942, 1744, 1600, 1515, 
1233. MS (ESI) m/z calcd. (C16H19NO2 + Na+): 280.1313, found: 280.1319 (M + 
Na+). 
5,5-Bis(4-methoxyphenyl)-4-(4-(trifluoromethyl)benzylidene)oxazolidin-2-one 175o 
White solid (32 mg, 70% yield). Tm = 114–116 °C. 1H NMR 
(d6-acetone, 500 MHz): ∂ 9.70 (brs, 1H, NH), 7.64 (d, 2H, 
J = 8.5 Hz, HAr), 7.60 (d, 2H, J = 8.5 Hz, HAr), 7.39 (d, 4H, 
J = 9.0 Hz, HAr), 6.99 (d, 4H, J = 9.0 Hz, HAr), 5.55 (s, 1H, =CH), 3.83 (s, 6H, CH). 
13C NMR (d6-acetone, 125 MHz): ∂ 161.1 (CAr), 155.9 (C), 143.6 (CAr), 140.4 (CAr), 
133.9 (C), 129.8 (CArH), 129.1 (CArH), 128.4 (CArH), 126.4 (q, CAr), 114.7 (CArH), 
102.5 (=CH), 55.8 (CH). 19F NMR (d6-acetone, 470 MHz): ∂ –62.92. IR (neat, νmax, 
cm-1): 3253, 2969, 2838, 1760, 1611, 1583, 1510, 1323, 831. MS (ESI) m/z calcd. 
(C25H20F3NO4 + H+): 456.1423, found: 456.1417 (M + H+). 
4-(Cyclopropylmethylene)-5,5-bis(4-methoxyphenyl)oxazolidin-2-one 175p 
White solid (35 mg, 99% yield). Tm = 140–142 °C. 1H NMR (d6-
acetone, 500 MHz): ∂ 8.70 (brs, 1H, NH), 7.18 (d, 2H, J = 8.5 Hz, 
HAr), 7.14 (d, 2H, J = 8.5 Hz, HAr), 6.91 (d, 2H, J = 8.5 Hz, HAr), 



















3H, CH), 0.95-1.02 (m, 1H, CH), 0.34-0.40 (m, 1H, CH), 0.24-0.29 (m, 1H, CH), 0.16-
0.21 (m, 1H, CH), -0.30–0.25 (m, 1H, CH). 13C NMR (d6-acetone, 125 MHz): ∂ 
159.8 (CAr), 159.5 (CAr), 157.2 (C), 135.3 (CAr), 133.9 (CAr), 133.6 (CAr), 132.0 (CArH), 
131.1 (CArH), 115.0 (CArH), 113.5 (C), 82.6 (=CH), 55.6 (CH), 15.2 (CH), 3.4 (CH2), 
1.7 (CH2). IR (neat, νmax, cm-1): 3256, 3004, 2954, 2837, 1753, 1665, 1508, 1282, 
1027. MS (ESI) m/z calcd. (C21H21NO4 + Na+): 374.1368, found: 374.1363 (M + 
Na+). 
4-(Cyclohexylmethylene)-5,5-bis(4-methoxyphenyl)oxazolidin-2-one 175q 
White solid (39 mg, 99% yield). Tm = 144–148 °C. 1H NMR (d6-
acetone, 500 MHz): ∂ 9.13 (brs, 1H, NH), 7.29 (d, 4H, J = 9.0 Hz, 
HAr), 6.94 (d, 4H, J = 9.0 Hz, HAr), 4.25 (d, 1H, J = 9.5 Hz, =CH), 
3.81 (s, 6H, CH), 2.34-2.40 (m, 1H, CH), 1.59-1.71 (m, 5H, CH), 1.25-1.34 (m, 2H, 
CH), 1.05-1.20 (m, 3H, CH). 13C NMR (d6-acetone, 125 MHz): ∂ 160.7  (CAr), 156.0 
(C), 138.9 (CAr), 134.7 (CAr), 129.5 (CArH), 114.3 (CArH), 109.7 (=CH), 90.4 (C), 55.7 
(CH), 36.8 (CH), 34.0 (CH), 26.7 (CH), 26.6 (CH). IR (neat, νmax, cm-1): 3185, 3083, 
2912, 1743, 1704, 1510, 1257. MS (ESI) m/z calcd. (C24H27NO4 + Na+): 416.1838, 
found: 416.1832 (M + Na+). 
4-(Cyclohexylmethylene)-5,5-diphenyloxazolidin-2-one 175r 
White solid (29 mg, 87% yield). Tm = 140–144 °C. 1H NMR (d6-acetone, 
500 MHz): ∂ 9.19 (brs, 1H, NH), 7.37-7.43 (m, 10H, HAr), 4.34 (d, 1H, J 
= 9.5 Hz, =CH), 2.39 (qt, 1H, J = 10 Hz, 3.5 Hz, CH), 1.65-1.72 (m, 4H, CH), 1,26-
1.34 (m, 3H, CH), 1.07-1.21 (m, 3H, CH). 13C NMR (d6-acetone, 125 MHz): ∂ 155.9 
(C), 142.7 (CAr), 138.2 (CAr), 135.6 (C), 129.4 (CArH), 129.3 (CArH), 128.1 (CArH), 














cm-1): 3258, 3081, 1745, 1505, 1201. MS (ESI) m/z calcd. (C22H23NO2 + Na+): 
356.1626, found: 356.1618 (M + Na+). 
4-Benzylidene-5,5-dimethyloxazolidin-2-one 175s10 
 Colourless oil (14 mg, 91% yield). 1H NMR (d6-acetone, 500 MHz): ∂ 
9.18 (brs, 1H, NH), 7.35 (d, 2H, J = 7.5 Hz, HAr), 7.31 (t, 2H, J = 7.5 Hz, 
HAr), 7.15 (t, 1H, J = 7.5 Hz, HAr), 5.50 (s, 1H, =CH), 1.60 (s, 6H, CH3). 13C NMR 
(d6-acetone, 125 MHz): ∂ 156.3 (C), 143.5 (CAr), 136.8 (CArH), 129.5 (CArH), 128.3 
(CArH), 126.7 (=CH), 97.5 (C), 85.0 (CH), 28.3 (CH). IR (neat, νmax, cm-1): 3257, 
2985, 1754, 1494, 1193, 1016. MS (ESI) m/z calcd. (C12H13NO2 + Na+): 226.0844, 
found: 226.0838 (M + Na+). 
4-(Furan-2-ylmethylene)-5,5-dimethyloxazolidin-2-one 175t 
 Pale yellow oil (9 mg, 47% yield). 1H NMR (d6-acetone, 500 MHz): 
∂ 9.08 (brs, 1H, NH), 7.49 (d, 1H, J = 2.0 Hz, HHetAr), 6.42-6.43 (dd, 1H, 
J = 3.0, 2.0 Hz, HHetAr), 6.21 (d, 1H, J = 3.0 Hz, HHetAr), 5.49 (s, 1H, 
=CH), 1.57 (s, 6H, CH3). 13C NMR (d6-acetone, 125 MHz): ∂ 155.7 (C), 152.6 (CAr), 
142.7 (CAr), 142.0 (CArH), 112.2 (CArH), 106.5 (CArH), 87.3 (=CH), 84.6 (C), 28.0 
(CH). IR (neat, νmax, cm-1): 3269, 2949, 1762, 1691, 1518, 1255. MS (ESI) m/z calcd. 
(C14H13NO3 + Na+): 216.0637, found: 216.0630 (M + Na+). 
4-(Benzofuran-2-ylmethylene)-5,5-dimethyloxazolidin-2-one 175u 
Colourless oil (12.5 mg, 52% yield). 1H NMR (d6-acetone, 500 
MHz): ∂ 9.53 (brs, 1H, NH), 7.54 (d, 1H, J = 8.0 Hz, HAr), 7.51 (d, 
1H, J = 8.0 Hz, HAr), 7.17-7.23 (m, 2H, HAr), 6.59 (s, 1H, HHetAr), 
5.65 (s, 1H, =CH), 1.63 (s, 6H, CH3). 13C NMR (d6-acetone, 125 MHz): ∂ 155.7 (C), 




















(CAr), 112.0 (CArH), 102.6 (CArH), 86.9 (CAr), 84.8 (C), 27.9 (CH). IR (neat, νmax, cm-
1): 3273, 2948, 1760, 1688, 1511, 1249. MS (ESI) m/z calcd. (C14H13NO3 + Na+): 
266.0793, found: 266.0790 (M + Na+). 
4-Benzylidene-5,5-diphenyloxazolidin-2-one175v 
White solid (25 mg, 38% yield). Tm = 129–132 °C. 1H NMR (d6-acetone, 
500 MHz): ∂ 9.21 (brs, 1H, NH), 7.47–7.59 (m, 5H, HAr) 7.32–7.41 (m, 
10H, HAr), 5.52 (s, 1H, =CH). 13C NMR (d6-acetone, 125 MHz): ∂ 154.8 (C), 142.6 
(CAr), 143.1 (CAr), 138.9 (CAr), 137.2 (CArH), 135.9 (C), 128.9 (CArH), 128.9 (CArH), 
128.5 (CArH), 127.9 (CArH), 127.2 (CArH), 111.2 (=CH). IR (neat, νmax, cm-1): 3265, 
3092, 1741, 1498, 1190, 945, 759. MS (ESI) m/z calcd. (C22H17NO2 + Na+): 
350.1157, found: 350.1149  (M + Na+). 
4-(Diphenylmethylene)-5-phenyloxazolidin-2-one175v’ 
White solid (18.5 mg, 28% yield). Tm = 125–129 °C. 1H NMR (d6-
acetone, 500 MHz): ∂ 9.14 (brs, 1H, NH), 7.56–7.70 (m, 5H, HAr) 7.39–
7.52 (m, 10H, HAr), 6.81 (s, 1H, CH). 13C NMR (d6-acetone, 125 MHz): ∂ 155.6 (C), 
143.4 (CAr), 144.2 (CAr), 139.8 (CAr), 137.5 (CArH), 136.2 (C), 130.0 (CArH), 129.5 
(CArH), 129.0 (CArH), 128.5 (CArH), 127.5 (CArH), 112.6 (CH). IR (neat, νmax, cm-1): 
3268, 3089, 1742, 1501, 1195, 947, 756. MS (ESI) m/z calcd. (C22H17NO2 + Na+): 
350.1157, found: 350.1149  (M + Na+). 
t-Butyl (1-cyclohexyl-3-phenyl-1H-inden-2-yl)carbamate 243r 
White solid (13 mg, 19% yield). Tm = 89–93 °C. 1H NMR (d6-
acetone, 500 MHz): ∂ 7.57–7.65 (m, 3H, HAr), 7.37–7.54 (m, 5H, 
HAr), 7.31–7.49 (m, 4H, HAr), 7.23–7.28 (m, 2H, HAr), 6.29 (brs, 1H), 3.35 (s, 1H, CH), 


















(CAr), 140.0 (CAr), 135.2 (CAr), 129.5 (CArH), 129.1 (CArH), 128.8 (CArH), 128.5 (CArH), 
127.8 (CArH), 127.4 (CArH), 127.0 (CArH), 126.8 (CArH), 126.5 (CArH), 119.2 (C), 113.2 
(C), 85.9 (C), 46.9 (CH), 29.2 (CH). IR (neat, νmax, cm-1): 2962, 2928, 1704, 1611, 
1469, 1232, 1162, 1041, 808, 769. MS (ESI) m/z calcd. (C26H25NO2 + Na+): 
406.1783, found: 406.1771 (M + Na+). 
t-Butyl (1,3-diphenyl-1H-inden-2-yl)carbamate 243v 
Colourless oil (18 mg, 54% yield). 1H NMR (d6-acetone, 500 MHz): 
∂ 7.37–7.54 (m, 5H, HAr), 7.20–7.35 (m, 3H, HAr), 7.17 (t, 1H, J = 8.5 
Hz, HAr), 6.98 (brs, 1H), 3.20 (d, 1H, J = 7.0 Hz, CH), 2.30 (dtt, 1H, 
J = 21.0, 7.0, 3.5 Hz, CH), 1.68–1.71 (m, 2H), 1.55-1.63 (m, 3H), 1.26 (s, 9H, CCH3), 
1.17–1.24 (m, 2H, CH), 1.04–1.11 (m, 1H, CH), 0.80–0.89 (m, 2H, CH). 13C NMR 
(d6-acetone, 125 MHz): ∂ 149.7 (C), 141.6 (CAr), 141.3 (CAr), 138.8 (CAr), 130.2 
(CArH), 129.9 (CArH), 127.9 (CArH), 127.6 (CArH), 126.8 (CArH), 126.1 (CArH), 117.3 (C), 
115.8 (C), 84.1 (C), 47.8 (CH), 32.5 (CH), 31.8 (CH), 28.9 (CH), 27.1 (CH), 26.8 
(CH). IR (neat, νmax, cm-1): 2951, 2935, 2889, 2765, 1736, 1628, 1441, 1255, 1179, 
1067, 911, 819, 721. MS (ESI) m/z calcd. (C26H31NO2 + Na+): 412.2252, found: 
412.2265 (M + Na+). 
4-Benzyl-5-(4-methoxyphenyl)-3-tosyloxazol-2(3H)-one N–Ts–174b 
4-Benzyl-5-(4-methoxyphenyl)oxazol-2(3H)-one (281 mg) was 
dissolved in DMF (2 mL) at 0 ºC, followed by addition of NaH 
(44 mg, 1.1 eq.). The resulting mixture was stirred at 0 ºC for 1 h. p-TsCl (228 mg, 1.2 
eq.) was added to the reaction suspension and stirred at RT for 17 h. Upon completion, 
the reaction was quenched with water (20 mL). The organic layer was separated and 
dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting 










compound as white solid (290 mg, 67% yield). 1H NMR (CDCl3, 400 MHz): ∂ 7.32 
(d, 2H, J = 9.0 Hz, HAr), 7.21-7.24 (m, 5H, HAr), 7.14-7.16 (m, 2H, HAr), 7.00 (d, 2H, 
J = 8.5 Hz), 6.80 (d, 2H, J = 9.0 Hz), 4.21 (s, 2H, CH), 3.69 (s, 3H, CH), 2.26 (s, 3H, 
CH). 13C NMR (CDCl3, 125 MHz): d 160.5 (CAr), 150.6 (C), 145.9 (CAr), 137.1 (CAr), 
133.9 (CAr), 129.5 (CArH), 128.9 (CArH), 128.6 (CArH), 128.3 (CArH), 128.0 (CArH), 
127.0 (CArH), 119.4 (CArH), 114.5 (C), 55.4 (CH), 30.0 (CH), 21.7 (CH). IR (neat, 
νmax, cm-1): 2926, 1782, 1671, 1574, 1494, 1300, 1174, 1026, 665, 567, 543. MS (ESI) 
m/z calcd. (C24H21NO5S + Na+): 458.1038, found: 458.1056 (M + Na+). Tm = 112–
116 °C. 
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